

(19) **DANMARK**



Patent- og
Varemærkestyrelsen

(12)

Oversættelse af europæisk patentskrift

(10) **DK/EP 2697207 T3**

-
- (51) Int.Cl.: **C 07 D 413/08 (2006.01)** **A 61 K 31/421 (2006.01)** **A 61 P 3/06 (2006.01)**
A 61 P 9/10 (2006.01) **C 07 D 263/22 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2017-03-27**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2016-12-14**
- (86) Europæisk ansøgning nr.: **12770951.7**
- (86) Europæisk indleveringsdag: **2012-04-12**
- (87) Den europæiske ansøgnings publiceringsdag: **2014-02-19**
- (86) International ansøgning nr.: **KR2012002739**
- (87) Internationalt publikationsnr.: **WO2012141487**
- (30) Prioritet: **2011-04-12 KR 20110033943**
- (84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**
- (73) Patenthaver: **Chong Kun Dang Pharmaceutical Corp., 8, Chungjeong-ro , Seodaemun-gu, Seoul 120-756, Sydkorea**
- (72) Opfinder: **LEE, Seohee, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea**
OH, Jung Taek, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea
LEE, Jaekwang, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea
LEE, Jaewon, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea
BAE, Suyeal, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea
HA, Nina, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea
LEE, Sera, 464-3 Jung-dong, Giheung-gu, Yongin-si, Gyeonggi-do 446-916, Sydkorea
- (74) Fuldmægtig i Danmark: **PATRADE A/S, Fredens Torv 3A, 8000 Århus C, Danmark**
- (54) Benævnelse: **3-(2-ARYL-CYKLOALKENYLMETHYL)-OXAZOLIDIN-2-ON-DERIVATER**
SOM CHOLESTEROL-ESTER-TRANSFER-PROTEIN-(CETP)-INHIBITORER
- (56) Fremdragne publikationer:
WO-A1-2010/039474
WO-A2-2007/081569
US-A1- 2008 242 711
JULIANNE HUNT ET AL: "Cholesteryl Ester Transfer Protein (CETP) Inhibitors", CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 9, no. 5, 1 April 2009 (2009-04-01), pages 419-427, XP055143193, ISSN: 1568-0266, DOI: 10.2174/156802609788340823
RAJESH KRISHNA ET AL.: 'Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects' BRITISH JOURNAL OF CLINICAL PHARMACOLOGY vol. 68, no. 4, 2009, pages 535 - 545, XP055126351
DANIEL BLOOMFIELD ET AL.: 'Efficacy and safety of the cholesteryl ester transfer protein inhibitor

Fortsættes ...

anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients' AMERICAN HEART JOURNAL vol. 157, no. 2, 2009, pages 352 - 360, 360/EL-360/E2, XP025997680

DESCRIPTION

Technical Field

[0001] The present invention relates to novel cycloalkenyl aryl derivatives, and more particularly to cycloalkenyl aryl derivatives having CETP inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, the use thereof for preparing pharmaceutical compositions, pharmaceutical compositions containing the same, these compositions for use in methods of treating disease, and methods for preparing novel cycloalkenyl aryl derivatives.

Background Art


[0002] Hyperlipidemia refers to high blood cholesterol levels and is asymptomatic. However, hyperlipidemia is a very significant condition, because it causes angina pectoris, myocardial infarction and arteriosclerosis. Statins, drugs that are commonly used to treat hyperlipidemia, exhibit therapeutic effects mainly by lowering LDL-C, but their effects on the prevention of cardiovascular diseases are still very insufficient. A recent study reported that elevated concentration of high-density lipoprotein (HDL-C) is very effective in preventing cardiovascular diseases as effective as lower low-density lipoprotein cholesterol (LDL-C) (Goldbourt et al, Arterioscler Thromb Vase Biol, 1997, 17, 107-113). Among drugs that are used to increase HDL-C, the most effective drug is Niacin. However, this drug needs to be taken in relatively large doses and causes side effects such as facial flushing (Taylor et al, Circulation, 2004, 110, 3512-3517).

[0003] Meanwhile, cholesterol ester transfer protein (CETP) is a protein that participates in reverse cholesterol transport (the reverse transport of cholesterol from peripheral tissue to the liver). When CETP is inhibited, HDL-C can be effectively increased, thus preventing cardiovascular diseases. Accordingly, the development of compounds capable of inhibiting CETP activity is very important (Barter et al., Arterioscler Thromb Vase Biol. 2003, 23, 160-167).

[0004] CETP inhibitors known to date can be divided according to structure into Torcetrapib (WO 02/088085) and Anacetrapib (WO 2006/014357), which are 3,5-bis-trifluoromethylbenzene derivatives, and Dalcetrapib (WO 98/35937) which is a benzothiol derivative.

[0005] However, among these CETP inhibitors, Torcetrapib causes an increase in blood pressure and an increase in mortality, and thus clinical trials thereof were terminated. It was reported that such side effects occur because Torcetrapib increases the levels of hormones, such as aldosterone and cortisol, associated with a significant elevation in blood pressure, and increases the thickness of the vascular wall to cause inflammation, thus increasing mortality (Ferrest et al. British Journal of Pharmacology, (2008) 154, 1465-1473). The other CETP inhibitor Dalcetrapib has not been reported to cause such side effects, but is known to have insufficient rise in HDL-C (Hisashi Shinkai. Expert Opinion on Therapeutic Patents, 2009, 19(9), 1229-1237). Among such CETP inhibitors, Anacetrapib and Dalcetrapib are in clinical trials for the purpose of treating hyperlipidemia and cardiovascular diseases by increasing HDL-C and decreasing LDL-C (Niesor et al, Journal of Lipid Research, 2010, 51, 3443-3453).

[0006] WO 2007/081569 A2 relates to compounds having the structure of general formula



which are considered CETP inhibitors and useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis, wherein substituent B is a cyclic group other than phenyl and has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure, and the 5-membered ring of the structure has a second cyclic substituent in addition to B.

Disclosure

Technical Problem

[0007] It is an object of the present invention to provide novel cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, thereof, or solvates thereof and preparation Methods thereof.


[0008] Another object of the present invention is to provide novel cycloalkenyl aryl derivatives, which have less side effects and can effectively inhibit CETP. isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof.

[0009] Still another object of the present invention is to provide methods for preparing novel cycloalkenyl aryl derivatives.

Technical Solution

[0010] To achieve the above objects, the present invention provides cycloalkenyl aryl derivatives of the following formula 1, racemates, racemic mixtures, enantiomers, diastomeric mixtures, diastomers, atropisomers and mixtures of atropisomers thereof, pharmaceutically acceptable salts thereof hydrates thereof, or solvates thereof, and preparation methods thereof.


[Formula 1]



wherein

B¹ and B² are each independently N or C, with the proviso that both B¹ and B² cannot be N at the same time, and if one of B¹ and B² is N, R² or R⁵ is absent;

R¹ and R² are each independently H, -F, -OH, -NH₂, -C(=O)H, -CH₂OH, -OC₁₋₆ alkyl, -SC₁₋₆ alkyl, -CH₂OC₁₋₆ alkyl, -NH(C₁₋₆ alkyl), -NH(C=O)(C₁₋₆ alkyl), -N(C₁₋₆alkyl)₂, or




or


R¹ and R² together with the carbon atoms to which they are bonded may form a 5- or 6-membered heterocyclic aromatic or non-aromatic ring compound having 1 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(=O), wherein the heterocyclic aromatic or non-aromatic ring compound may optionally be substituted with R⁸;


R³ is -H, -F, -OH, -C₁₋₆ alkyl, or -OC₁₋₆ alkyl;

R⁴ is -H, halogen, -CN, -NO₂, -C₁₋₆ alkyl, -C₂₋₆ alkenyl, -C₃₋₆ cycloalkyl,



-OR⁷, -CH₂OR⁷, -CH₂NR⁷R⁸, -SR⁷, -C(=O)R⁷, -CO₂R⁷, -CHR⁷CO₂R⁸, -C(=O)NR⁷R⁸,





Ar or Het; or

R³ and R⁴ together with the carbon atoms to which they are bonded may form a 5- or 6-membered cycloalkyl or heterocyclic ring compound having 0 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(=O), wherein the cycloalkyl or heterocyclic ring compound may optionally be substituted with R⁸;


Ar is a C6 monocyclic aromatic compound, which is unsubstituted or optionally substituted with one or more selected from the group consisting of halogen, -OH, -NH₂, -C₁-C₆ alkyl and -OC₁-C₆ alkyl;

Het is a 5- or 6-membered heterocyclic ring compound containing 0 to 2 double bonds and having 1 to 4 hetero atoms selected independently from the group consisting of N, O, S, C(=O) and C(=S), and may be unsubstituted or may optionally be substituted with R⁸. R⁵ is -H, -F, -OH, -CF₃, -C₁-C₆alkyl, or -OC₁-C₆ alkyl;


R⁶ is -H or -C₁-C₆ alkyl;

R⁷ is -H, halogen, -C(O)(C₁-C₃ alkyl), -C₁-C₆ alkyl, -OC₁-C₆ alkyl, -C₃-C₆ cycloalkyl, or -OC(=O)(C₁-C₃ alkyl);

R⁸ is-H, halogen, -OH, -CN, -NH₂, -NH(C₁-C₃ alkyl), -C(=O)NH₂, -CO₂H,



-C₃-C₆ cycloalkyl, -Ph or



R⁹ is -H, -CN, -C₁-C₆ alkyl, -OC₁-C₆ alkyl, or -C(=O)(C₁-C₃ alkyl); R¹⁰ is -NH(C₁-C₃ alkyl), -N(C₁-C₃ alkyl)₂, or -S(C₁-C₃ alkyl);

Z is $-\text{CH}_2-$,



R^a is-H, -Cl or -CF₃;

p is an integer ranging from 0 to 2;

A¹ and A² are each independently -(CR¹¹R¹²)-, wherein R¹¹ and R¹² are each independently -

H, -F, or -C₁-C₆ alkyl, or R¹¹ and R¹² together form a 3- or 4-membered spirocyclic non-aromatic ring compound;

A³ is -(CH₃)_n;

X is S or O;

m is an integer ranging from 0 to 3;

n is an integer ranging from 0 to 2;

q is an integer ranging from 1 to 3;


wherein said -C₁-C₃ alkyl, -C₃-C₆ cycloalkyl C₁-C₆ alkyl or -C₂-C₆ alkenyl is unsubstituted or substituted with one or more selected from the group consisting of halogen, -OH, -CF₃, -CN, -CO₂H, -C(=O)CH₃, -OC(=O)CH₃, -C₁-C₃alkyl, -OC₁-C₃alkyl, and -Ph.

[0011] Preferably, the present invention provides cycloalkenyl aryl derivatives according to the above definition, racemates, racemic mixtures, enantiomers, diastomeric mixtures, diastomers, atropisomers and mixtures of atropisomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof:


wherein

B¹ and B² are each independently N or C, with the proviso that both B¹ and B² cannot be N at the same time, and if any one of B¹ and B² is N, R² or R⁵ is absent;

R¹ is -F, -OH, -NH₂, -C(-O)H, -CH₂OH, -OCH₃, -OCF₃, -SCH₃, -CH₂OCH₃, -NHCH₃,



-N(CH₃)₂, or




R² is -H; or


R¹ and R³ together with the carbon atoms to which they are bonded may form a 5- or 6-membered heterocyclic aromatic or non-aromatic ring compound having 1 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(=O), wherein the heterocyclic aromatic or non-aromatic ring compound may optionally be substituted with R⁸;


R³ is -H, -F, -OH, -CH₃, -CF₃, -CH₂CH₃, or -OCH₃;

R⁴ is -H, -F, -Cl, -CN, -NO₂, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -C(CH₃)₃, -CF₃, -CH(CF₃)₂, -CH(CH₃)(CF₃), -C(OCH₃)(CF₃)₂, -CH(OH)CH₃, -C(OH)(CH₃)₂, -C(OH)(CF₃)₂, -C(=CF₂)CF₃, -cyclopropyl,



-OCH₃, -OCH₂CH₃, -OCH(CH₃)₂, -OC(CH₃)₃, -OCF₃, -OCH₂CF₃, -CH₂OH, -CH₂OCH₃, -CH₂NR⁷R⁸, -SCH₃, -C(=O)R⁷, -CO₂R⁷, -CHR⁷CO₂R⁸, -C(=O)NR⁷R⁸,






Ar or Het; or

R³ and R⁴ together with the carbon atoms to which they are bonded may form a 5- or 6-membered cycloalkyl or heterocyclic ring compound having 0 to 3 hetero atoms selected independently from the group consisting of N, O, S, and C(=O), wherein the cycloalkyl or heterocyclic ring compound may optionally be substituted with R⁸;

Ar is a C6 monocyclic aromatic compound, which is unsubstituted or optionally substituted with one or more selected from the group consisting of -F, -Cl, -OH, -NH₂, -CH₃ and -OCH₃; Het is selected from





R⁵ is -H;

R⁶ is -H or -CH₃;

R⁷ is -H, halogen, -C(=O)(C₁-C₃ alkyl), -C₁-C₆ alkyl, -OC₁-C₆ alkyl, -C₃-C₆ cycloalkyl, or -OC(=O)(C₁-C₃ alkyl);

R⁸ is -H, halogen, -OH, -CN, -NH₂, -NH(C₁-C₃ alkyl), -C(=O)NH₂, -CO₂H,





R⁹ is -H, -CN, -C₁-C₆ alkyl, -OC₁-C₆ alkyl, or -C(=O)(C₁-C₃ alkyl);

R¹⁰ is -NH(C₁-C₃ alkyl), -N(C₁-C₃ alkyl)₂, or -S(C₁-C₃ alkyl);

Z is -CH₂-



R^a is -H, -Cl or -CF₃;

p is 2;

A¹ is -CH₂- or -C(CH₃)₂-;

A² is -(CR¹¹R¹²)-, wherein R¹¹ and R¹² are each independently -H, -F, -CH₃, -CF₃, -CH₂CH₃, -CH(CH₃)₂, or or R¹¹ and R¹² together form a 3- or 4-membered spirocyclic non-aromatic ring compounds:

A³ is -(CH₂)_n-;

X is S or O;

m is an integer ranging from 0 to 3;

n is an integer ranging from 0 to 2;

q is an integer ranging from 1 to 3;

wherein said -C₁-C₃ alkyl, -C₃-C₆ cycloalkyl, -C₁-C₆ alkyl or -C₂-C₆ alkenyl is unsubstituted or substituted with one or more selected from the group consisting of -F, -Cl, -Br, -OH, CF₃, -CN, -CO₂H, -C(=O)CH₃, -OC(=O)CH₃, -C₁-C₃ alkyl, -OC₁-C₃ alkyl, and -Ph.

[0012] Specific examples of preferred compounds of formula 1 according to the present invention include:

15	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
16	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
17	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
18	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
19	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
25	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
26	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
27	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

28	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
29	(4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-one
31	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclopent-enyl)methyl)-4-methyloxazolidin-2-one
32	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-one
34	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoic acid
36	methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoate
37	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoic acid
41	methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoate
42	(4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-one
43	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-ethyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
44	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
46	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
47	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
48	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)-methyl)-4-methyl)-4-methyloxazolidin-2-one
49	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3'-chloro-4,6'-dimethoxybiphenyl-3-yl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
50	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)(cyclohex-1-enyl)(methyl)-4-methyloxazolidin-2-one
51	(4S,5R)-3-((2-(1H-indol-4-yl)-5,5-dimethylcyclohex-1-enyl)(methyl)-5-(3,5-bis(trifluoromethyl)(phenyl)-4-methyloxazolidin-2-one
52	(4S,5R)-5-(3,5-bis(trifluoromethyl)(phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
56	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(dimethylamino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
57	2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-5-methoxybenzaldehyde
58	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(hydroxymethyl)-4-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
59	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-methoxy-2-methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
60	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(quinolin-8-yl)cyclohex-1-enyl)methyl)oxazolidin-2-one
61	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(trimethyl-1H-indazol-4-yl)cyclohex-1-enyl)methyl)oxazolidin-2-one
62	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl(methyl)-4-methyloxazolidin-2-one
63	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl(methyl)-4-methyloxazolidin-2-one

64	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
65	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-(isopropylphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
66	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-morpholinophenyl)cyclohex-1-enyl)-methyloxazolidin-2-one
67	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-methylbenzamide
68	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl(cyclohex-1-enyl)-N-ethyl-4-methoxybenzamide
69	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-(2,2,2-trifluoroethyl)benzamide
70	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxybenzamide
71	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamide
72	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl(cyclohex-1-enyl)-4-methoxyphenyl)isobutyramide
	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
79	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzaldehyde
80	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
81	(4S,5R)-3-((2-(5-acetyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
82	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
83	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(2-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)oxazolidin-2-one
84	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-fluoro-5-(trifluoromethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
85	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)ethyl acetate
86	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide
87	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxy-N-methylbenzamide
96	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
97	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
101	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-tert-butyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
103	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
104	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
107	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
108	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

109	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
110	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamide
111	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)isobutyramide
112	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide
113	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide
114	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(methoxymethyl)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
115	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
116	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)acetamide
117	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
118	N-acetyl-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamide
120	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoro-N-methylacetamide
121	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopyrrolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
122	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopipendin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
123	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-difluoro-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
124	methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamate
128	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethanesulfonamide
130	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-N-methylpropanamide
132	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
133	methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetate
134	2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetic acid
136	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanesulfonamide
137	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoromethanesulfonamide
138	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylcyclopropanesulfonamide
140	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylthiourea
141	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoro-N-methylmethanesulfonamide
142	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxoimidazolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

143	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxooxazolidin-3-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
144	(4S,5R)-3-((2-(2-amino-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
145	N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)-N-methylacetamide
146	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,1-dimethylurea
147	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylthio)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
148	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-dimethyl-2-(2-(methylthio)-5-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
149	(Z)-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,1-dimethylguanidine
151	(E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-3-methylguanidine
153	(E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,3,3-trimethylguanidine
156	(Z)-methyl N-3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl-N'-methylcarbamiimidothioate
157	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,3,3-trimethylurea
159	methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate
160	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,1,1-trifluoropropan-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
161	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(1,1,1-trifluoropropan-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
162	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoroacetamide
163	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-bromoacetamide
166	N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)acetamide
167	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-(methylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
168	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(dimethylamino)-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
170	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
171	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(perfluoroprop-1-en-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
172	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoropropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
173	tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(isopropyl)carbamate
174	tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(ethyl)carbamate
177	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-ethylacetamide
178	(4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoro-1-(methoxyimino)ethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

179	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-(2-hydroxy-2-methylpropyl)acetamide
180	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,3-difluoroazetidine-1-carbonyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
181	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
182	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
183	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
184	(4S,5R)-3-((2-(5-acetyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
185	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
187	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-hydroxyazetidine-1-carbonyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
188	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
189	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarbonitrile
190	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarboxamide
191	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
192	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(cyclopropanecarbonyl)-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
193	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
194	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
195	(4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
196	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamide
197	methyl 5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoate
204	5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoic acid
206	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitro-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
207	(4S,5R)-3-((2-(5-amino-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
209	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoro-N-methylmethanesulfonamide
210	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylacetamide
212	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluoromethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
213	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(4-(trifluoromethyl)thiazol-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
215	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-methylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-N-methylacetamide

216	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)acetamide
217	(4S,5R)-3-((2-(5-amino-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
218	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
222	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
223	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
224	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylisobutyramide
225	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylpropionamide
226	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylmethanesulfonamide
227	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-2,2,2-trifluoro-N-methylacetamide
228	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoromethanesulfonamide
229	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2,4-dimethoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
230	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2,4-dimethoxyphenyl)-N-methylacetamide
232	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-hydroxy-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
233	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-methoxy-5-(methylamino)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
234	N-(5-(2-(((4S,5R)-3-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamide
235	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
237	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-cyclopropyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
240	1-((5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate
241	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
243	1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate
244	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamide
246	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-4-methyl-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
247	(4S,5R)-3-((2-(5-amino-2-methoxy-4-methylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
248	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)acetamide
249	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamide
250	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoromethanesulfonamide

251	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoro-N-methylmethanesulfonamide
259	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylethanethioamide
271	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-thiooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide
272	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate
273	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoic acid
274	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one
275	tert-butyl 6-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-5-methoxyindoline-1-carboxylate
276	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
277	(4S,5R)-3-(2-(1-acetyl-5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
278	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(2,2,2-trifluoromethyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
280	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(methylsulfonyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
285	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoate
286	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid
291	(R)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide
292	(S)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide
293	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one
294	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxy-5-nitrophenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one
295	(4S,5R)-3-((6-(5-amino-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
296	(R)-N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide
297	(S)-N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide
298	(R)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-N-methyl-2-phenylpropanamide
299	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanamide
300	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanenitrile
301	(4S,5R)-3-(2-(5-(2-(2H-tetrazol-5-yl)ethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
302	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

303	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one
304	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3',5'-difluoro-4-methoxy-4'-(methoxymethoxy)biphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
305	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3',5'-difluoro-4-methoxy-4'-(methoxybiphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
306	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanamide
307	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanenitrile
308	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoate
309	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoic acid
310	methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoate
311	4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoic acid
312	ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylate
313	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylic acid
314	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxamide
315	methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoate
316	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
317	methyl 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetate
318	2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetic acid
319	2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)-N-methylacetamide
320	2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoic acid
321	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamide
323	methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylate
324	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylic acid
325	3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoic acid
326	methyl 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate
327	7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
328	methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoate
329	3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanamide

330	ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutanecarboxylate
331	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutanecarboxylic acid
332	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzonitrile
333	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
334	(4R,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
335	(4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
336	(4R,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
337	7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxamide
338	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
339	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1-methyl-1H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
340	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
341	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
342	tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)acetate
343	tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetate
344	(R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoate
345	(R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)-3-methylbutanoate
346	(R)-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoic acid
347	methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylate
348	2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetic acid
349	methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoate
350	3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoic acid
353	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
354	tert-butyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate
355	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
356	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
357	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,2,4-oxadiazole-5-carboxylate

358	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
359	methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate
360	(S)-methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)pyrrolidine-2-carboxylate
361	(R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzylamino)-3-methylbutanoate
362	4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclohex-3-enecarboxylic acid
363	(R)-methyl 2-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)(methyl)amino)-3-methylbutanoate
364	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(((R)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
366	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
367	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(((S)-3-fluoropyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0013] Specific examples of more preferred compounds of formula 1 according to the present invention include:

15	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
17	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
18	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
19	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
25	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
26	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
27	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
28	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione
36	methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoate
44	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
48	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
79	3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzaldehyde
80	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
82	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
86	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide
97	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

101	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-tert-butyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
103	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
104	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
107	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
108	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
109	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
110	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamide
112	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide
115	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
117	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
123	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-difluoro-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
124	methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamate
128	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethanesulfonamide
130	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-N-methylpropanamide
132	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
137	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoromethanesulfonamide
181	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
182	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
184	(4S,5R)-3-((2-(5-acetyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
185	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
188	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
189	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarbonitrile
190	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarboxamide
191	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
192	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(cyclopropanecarbonyl)-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

193	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
194	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
195	(4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one
196	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamide
209	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoro-N-methylmethanesulfonamide
210	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylacetamide
212	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluoromethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-ethyloxazolidin-2-one
215	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-N-methylacetamide
222	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
223	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
227	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-2,2,2-trifluoro-N-methylacetamide
234	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamide
237	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-cyclopropyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
241	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
243	1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate
244	N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamide
249	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4A-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamide
251	N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoro-N-methylmethanesulfonamide
272	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate
273	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoic acid
274	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one
285	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoate
286	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid
300	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanenitrile
302	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
303	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one


308	methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoate
313	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylic acid
316	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
317	methyl 2(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetate
321	3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamide
323	methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylate
324	1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylic acid
329	3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanamide
338	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
340	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
341	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
350	3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoic acid
353	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
366	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one
367	(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(((S)-3-fluoropyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

Preparation of compounds


Methods for preparing compounds

[0014] The compounds of formula I according to the present invention can be prepared according to the methods described in various literatures (WO 2006/014357 A1). Methods for preparing the compounds of formula I will now be described in detail with reference to reaction schemes.

[Reaction Scheme 1]



wherein A¹, A², A³, B¹, B², R¹, R², R³, R⁴, R⁵, R⁶, R^a, p and X are as defined above; Y is a leaving group, preferably a halide group (e.g., chloride or bromide); and Q may represent -B(OH)₂ or



[0015] As shown in reaction scheme 1 above, the starting material compound II is allowed to react with phosphorus tribromide (PBr₃) or phosphorus oxychloride (POCl₃) in dimethylformamide (DMF), which is a Vilsmeier reaction, so as to introduce halogen into compound II.

[0016] In the reaction for preparing compound II, methylene chloride may be used as a solvent, and the reaction temperature is 0-70 °C, and preferably 0-45 °C.


[0017] Compound V can be prepared by subjecting compound III and compound IV to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) or an Ullmann reaction (Martin G. Banwell et al. Org. Lett. 2004, 6, 2741). In addition, compound IV used in the synthesis process can be prepared according to the method described in the literature (WO 2006/014357 A1, Erin F. DiMauro et al., J. Med. Chem. 2006, 49, 5671).

[0018] In the reaction for preparing compound V, dimethoxyethane (DME), dimethylsulfoxide (DMSO), water or the like is used as a solvent, and the reaction temperature is 80-150 °C, and preferably 80-100 °C. The resulting compounds V and III may be subjected to reductive amination with amino alcohol compound VI, prepared according to the method described in the literature (WO 2006/014357 A1, Jingjun Yin et al., J. Org. Chem. 2006, 840), thereby synthesizing compounds VII and VIII, respectively.

[0019] The resulting compounds VII and VIII can be converted to the desired compounds I and IX, respectively, by reaction with thiophosgen or triphosgen. In addition, the resulting compound IX may also be converted to the desired compound I by a Suzuki reaction with the compound IV.

[0020] As described above, the compounds of formula I are generally prepared according to the method shown in reaction scheme 1. In addition, compounds of examples of the present invention may also be prepared according to the following reaction schemes 2, 3, 4 and 5.


[Reaction Scheme 2]



Compound 15. X= S, R₂= 2-methoxy-5-isopropylbenzene
 Compound 16. X= S, R₂= 2-methoxybenzene
 Compound 17. X= S, R₂= 2-methoxy-4-fluoro-5-isopropylbenzene
 Compound 18. X= O, R₂= 2-methoxybenzene
 Compound 36. X= O, R₂= 2-methoxy-5-methylbenzoate
 Compound 41. X= O, R₂= 2-methoxy-4-fluoro-5-methylbenzoate
 Compound 51. X= O, R₂= 4-indole
 Compound 56. X= O, R₂= 2-methoxy-5-dimethylbenzenamine
 Compound 97. X= O, R₂= 2-fluoro-5-trifluoromethylbenzene
 Compound 115. X= O, R₂= 2-methoxy-5-*t*-butylbenzene
 Compound 117. X= O, R₂= 2-methoxy-5-trifluoromethoxybenzene

[0021] Reaction scheme 2 above shows a general process for preparing compounds 15, 16, 17, 18, 36, 41, 51, 56, 97, 115 and 117 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 2. As shown in reaction scheme 2, dimethylformamide (DMF) and phosphorus tribromide (PBr₃) are added dropwise to the starting material dimethylcyclohexanone to obtain compound 2 which is then subjected to a Suzuki reaction with commercially available boronic acid derivatives in the presence of a palladium catalyst, thus synthesizing compound 3. The obtained compound 3 is converted to compound 5 by reaction with compound 4, prepared according to the method described in the literature (2006/014357 A1, Jingjun Yin et al., J. Org. Chem. 2006, 840). The obtained compound 5 can be converted into the desired compound 6 by reaction with thiophosgen or triphosgen.

[Reaction Scheme 3]




Compound 57. R₂= 4-methoxy-2-benzaldehyde
 Compound 60. R₂= 8-quinoline
 Compound 61. R₂= 1-methyl-4-indazole
 Compound 79. R₂= 2-methoxy-5-benzaldehyde


[0022] Reaction scheme 3 above shows a general process for synthesizing compounds 57, 60, 61 and 79 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 3 above. The starting material compound 7 is allowed to react with compound 4, acetic acid and sodium cyanoborohydride to synthesize

compound 8 which is then allowed to react with triphosgen, thereby preparing compound 9. The obtained compound 9 can be subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) with various boronic acids, thereby preparing desired compounds.

[Reaction Scheme 4]




[0023] Reaction scheme 4 above shows a general process for synthesizing compounds 133 and 134 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 4 above. As shown in reaction scheme 4, the starting material compound 10 is allowed to react with iodine (I_2) and silver sulfate to synthesize compound 11 which is then allowed to react with bis(pinacolato)diboron in the presence of a palladium catalyst, thus preparing compound 12. Compound 9 and boronic acid may be added dropwise to the obtained compound 12, and then subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093), thereby preparing compound 133. The obtained compound 133 can be converted into compound 134 by hydrolysis with lithium hydroxide (LiOH).




[0024] Reaction scheme 5 above shows a general process for synthesizing compounds 110, 112, 128, 136, 137, 138, 141, 163 and 177 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 5 above. As shown in reaction scheme 5 above, the starting material boronic acid compound 13 is subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093) with compound 2 to prepare compound 14 which is then nitrated with nitric acid, thus synthesizing compound 15. The obtained compound 15 may be subjected to the reactions shown in reaction scheme 2, thus synthesizing compound 16 and compound 52. The obtained compound 52 may be treated with a nickel metal to reduce the nitro group thereof, and then allowed to react with various acyl chloride or sulfonyl chloride compounds, thus preparing various compounds. The resulting compounds 110, 136 and 137 maybe allowed to react with iodomethane, thus obtaining compounds 112, 128, 138, 141 and 177.

[Reaction Scheme 6]




[0025] Reaction scheme 6 above shows a general process for synthesizing compounds 286 and 311 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 6 above. As shown in reaction scheme 6, the starting material 4-methoxyphenethyl bromide or 4-methoxybenzyl chloride is subjected to the reaction described in the paper (Akio Baba et al., Tetrahedron 2009, 65, 5462), thus synthesizing compound 19. The obtained compound 19 is allowed to react with iodine (I_2) and silver sulfate to synthesize compound 20 which is then allowed to react with bis(pinacolato)diboron in the presence of a palladium catalyst, thus preparing compound 21. Compound 2 is added dropwise to the obtained compound 21, and then subjected to a Suzuki reaction (Morris, G. A., et al., Tetrahedron Lett., 2001, 42, 2093), thus synthesizing compound 22. The obtained compound 22 is subjected to the reactions shown in reaction scheme 2 (reductive amination and cyclization) to synthesize compounds 285 and 310 which are then hydrolyzed with lithium hydroxide (LiOH), thus preparing the desired compounds 286 and 311.

[Reaction Scheme 7]



[0026] Reaction scheme 7 above shows a general process for synthesizing compounds 349 and 350 of the present invention, and other compounds of the present invention can also be prepared according to reaction scheme 7 above. As shown in reaction scheme 7, key intermediate compound 29 can be synthesized in the following manner with reference to the literature (US 2010/0081673 A1). The starting material 6-hydroxynicotinic acid is allowed to react with bromine (Br_2) to obtain compound 24 which is then esterified, thus synthesizing compound 25. The obtained compound 25 is allowed to be reacted with Meerwein's salt (US 5929094 A1) to synthesize compound 26. The obtained compound 26 is reduced with diisobutylaluminum hydride (DIBAL-H) to obtain compound 27 which is then chlorinated with titanium chloride (TiCl_4), thus synthesizing compound 28. The resulting compound 28 is reacted with the reagents described in the paper (Akio Baba et al., *Tetrahedron* 2009, 65, 5462), thus synthesizing key intermediate compound 29. Then, compound 29 are subjected to the reactions shown in reaction schemes 4 and 6, thereby preparing the desired compounds 349 and 350.

[Reaction Scheme 8]



[0027] Reaction scheme 8 above shows a general process for synthesizing compound 366 of the present invention, and other compounds of the present invention can also be synthesized according to reaction scheme 8 above. As shown in reaction scheme 8, the starting material 2-bromo-3-pyridinol is reacted with iodine (I_2) to synthesize compound 33 which is then methylated, thus synthesizing compound 34. The resulting compound 34 is subjected to a Suzuki reaction (Morris, G. A., et al., *Tetrahedron Lett.*, 2001, 42, 2093) to synthesize compound 35 which is then reacted with intermediate compound 36, thus synthesizing compound 37. Then, various reactions (hydroxylation, oxidation (N-oxide)/reduction (DIBAL-H), and oxidation (Dess-Martin)) are carried out to obtain intermediate compound 41. Then, the reactions shown in reaction scheme 6 are carried out to obtain compound 43. Indium (In) and a saturated ammonium chloride aqueous solution are added dropwise to and reacted with compound 43, thus preparing compound 366.

[0028] The cycloalkenyl aryl derivatives of formula I may contain one or more asymmetric carbon atoms, and may thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers. Such isomers can be resolved using the methods of prior arts. For example, isomers of the cycloalkenyl aryl derivatives of formula I can be resolved by column chromatography or HPLC. Alternatively, any enantiomer of a compound of formula I can be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.

[0029] Some of the compounds of the present invention are observed as mixtures of atropisomers (rotamers) in the NMR spectra. The individual atropisomers as well as mixtures thereof are encompassed with the compounds of the present invention.

[0030] The compounds of formula I according to the present invention can be in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. Preferred examples of acids which can be used to form pharmaceutically acceptable acid addition salts include hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid.

[0031] Hereinafter, the present invention will be described in further detail with reference to examples, preparation examples and experimental examples. It is to be understood, however, that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention.

Advantageous Effects

[0032] The present invention can provide novel cycloalkenyl aryl derivatives, racemates, racemic mixtures, enantiomers, diastereomeric mixtures, diastereomers, atropisomers and mixtures of atropisomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof, and preparation methods thereof.

[0033] In addition, the present invention can provide novel cycloalkenyl aryl derivatives, which have less side effects and can effectively inhibit CETP, racemates, racemic mixtures, enantiomers, diastereomeric mixtures, diastereomers, atropisomers and mixtures of atropisomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof and preparation methods thereof.

Best Mode

[Examples]

[0034] Hereinafter, the present invention will be described in further detail with reference to examples. It is to be understood, however, that these examples are illustrative purposes only and are not construed to limit the scope of the present invention.

Compound 15

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione

[0035] As shown in reaction scheme 2, intermediate 5 was synthesized. Thiophosgene (5 mL) and triethylamine (66 μ L, 0.44 mmol) was added dropwise to the obtained intermediate 5 (53 mg, 0.095 mmol), and then the reaction mixture was refluxed with stirring overnight at 100°C. After the completion of the reaction, the reaction mixture was diluted with methylene chloride (CH_2Cl_2), washed with saturated sodium hydrogen carbonate solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO_2 , 5% Hex/EA), thus obtaining Compound 15 (10 mg, 18%).

[0036] ^1H NMR (400 MHz, CDCl_3): 1:1.5 atropisomer mixture; δ 7.77 (s, 1H), 7.65 (s, 2H), 6.98-6.95 (m, 1H), 6.72-6.62 (m, 2H), 5.63-5.60 (m, 1H), 4.50 (bd, 1H), 4.14-4.11 (m, 0.6H), 4.01-3.97 (m, 0.4H), 3.66 (s, 1H), 3.61 (s, 2H), 2.75-2.67 (m, 1H), 2.46-2.42 (bm, 1H), 2.18-2.16 (bm, 1H), 2.01-1.77 (m, 3H), 1.45-1.36 (m, 2H), 1.11-1.04 (m, 6H), 0.94-0.92 (m, 6H), 0.31 (d, 1.2H, $J = 6.6$), 0.19 (d, 1.8H, $J = 6.6$). MS (ESI) m/z 600 ($\text{M}^+ + \text{H}$).

Compound 16

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-

methyloxazolidine-2-thione

[0037] Compound 16 (21 mg, 39%) as yellow solid was obtained according to the same method as the synthesis of compound 15.

[0038] ¹H NMR (400 MHz, CDCl₃); 1:1.7 atropisomer mixture; δ 7.77 (s, 1H), 7.65 (s, 2H), 7.15 (m, 1H), 6.89-6.71 (m, 3H), 5.62 (d, 1H, *J* = 8.3), 4.52 (s, 0.5H), 4.48 (s, 0.5H), 4.16-3.97 (m, 1H), 3.70 (bd, 0.7H), 3.69-3.64 (bd, 3H), 3.58 (bd, 0.4H), 2.19-2.14 (bm, 1H), 2.01-1.76 (m, 3H), 1.42-1.34 (m, 2H), 0.93 (m, 6H), 0.34 (d, 1.1H, *J* = 6.6), 0.21 (d, 1.9H, *J* = 6.6).

Compound 17**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl-4-methyloxazolidine-2-thione**

[0039] Compound 17 (38 mg, 70%) as yellow solid was obtained according to the same method as the synthesis of compound 15.

[0040] ¹H NMR (400 MHz, CDCl₃); 1:1.5 atropisomer mixture; δ 7.78 (s, 1H), 7.65 (s, 2H), 6.89-6.67 (m, 1H), 6.43 (m, 1H), 5.63 (d, 1H, *J* = 8.4), 4.52-4.46 (m, 1H), 4.11-4.07 (m, 0.5H), 4.01-3.97 (m, 0.4H), 3.66 (bd, 0.6H), 3.65 (s, 1H), 3.59 (s, 2H), 3.56 (bd, 0.4H), 3.05-2.99 (m, 1H), 2.20-2.00 (bm, 1H), 1.91-1.77 (m, 2H), 1.42-1.37 (m, 2H), 1.12 (d, 3H, *J* = 6.9), 1.08 (d, 1.5H, *J* = 6.9), 1.02 (d, 1.3H, *J* = 6.9), 0.93 (m, 6H), 0.34 (d, 1.2H, *J* = 6.6), 0.24 (d, 1.8H, *J* = 6.6). MS (ESI) *m/z* 618 (*M*⁺ + H).

Compound 18**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0041] As shown in reaction scheme 2, intermediate 5 was synthesized. The obtained intermediate 5 (43 mg, 0.083 mmol) was dissolved in methylene chloride (3 mL). Triphosgene (13 mg, 0.04 mmol) and diisopropylethylamine (0.09 mL, 0.49 mmol) were added dropwise to the obtained reaction mixture, and then stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 18 (36 mg, 80%) as colorless oil.

[0042] ¹H NMR (400 MHz, CDCl₃); 1:1.5 atropisomer mixture; δ 7.74 (s, 1H), 7.62 (s, 2H), 7.14-7.09 (m, 1H), 6.89-6.71 (m, 3H), 5.50-5.46 (m, 1H), 3.92-3.79 (m, 2H), 3.66 (s, 1.3H), 3.63 (s, 1.8H), 3.48 (bd, 0.6H), 3.33 (bd, 0.4H), 2.20-2.00 (m, 1H), 2.00-1.81 (m, 3H), 1.41-1.35 (m, 2H), 0.94 (d, 3H, *J* = 6), 0.91 (s, 3H), 0.31 (d, 1.2H, *J* = 6.6), 0.19 (d, 1.8H, *J* = 6.5). MS (ESI) *m/z* 542 (*M*⁺ + H).

Compound 19**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl-4-methyloxazolidin-2-one**

[0043] Compound 19 (37 mg, 100%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0044] ^1H NMR (400 MHz, CDCl_3); 1:1.2 atropisomer mixture; δ 7.75 (s, 1H), 7.62 (s, 2H), 6.68 (dd, 1H, $J = 8.7, 10.9$), 6.42 (dd, 1H, $J = 12, 17$), 5.50 (t, 1H, $J = 6.8$), 3.91-3.77 (m, 2H), 3.62 (s, 1.4H), 3.59 (s, 1.7H), 3.44 (bd, 0.6H), 3.31 (bd, 0.4H), 3.09-2.97 (m, 1H), 2.39-2.34 (bm, 0.5H), 2.12-2.01 (bm, 1H), 1.95-1.90 (bm, 0.6H), 1.82-1.80 (m, 2H), 1.43-1.32 (m, 2H), 1.11-1.01 (m, 6H), 0.94 (s, 3H), 0.90 (d, 3H, $J = 6.6$), 0.31 (d, 1.4H, $J = 6.5$), 0.22 (d, 1.6H, $J = 6.5$). MS (ESI) m/z 602.0 ($\text{M}^+ + \text{H}$).

Compound 25

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0045] Compound 25 (33 mg, 87%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0046] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.83 (s, 1H), 7.71 (s, 2H), 6.79-6.73 (m, 1H), 6.55-6.47 (m, 1H), 5.62-5.56 (m, 1H), 3.98-3.85 (m, 2H), 3.70 (s, 1.4H), 3.67 (d, 1.6H, $J = 3.9$), 3.59-3.35 (m, 1H), 3.13-3.07 (m, 1H), 2.25-2.02 (m, 2H), 1.82-1.71 (m, 3H), 1.35-1.28 (m, 1H), 1.19-1.09 (m, 6H), 1.04-1.02 (m, 3H), 0.39 (dd, 1.38H, $J = 1.7, 6.5$), 0.34 (d, 0.79H, $J = 6.5$), 0.30 (d, 0.82H, $J = 6.5$).

Compound 26

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidine-2-thione

[0047] Compound 26 (22 mg, 73%) as yellow solid was obtained according to the same method as the synthesis of compound 15.

[0048] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.88 (s, 1H), 7.76 (s, 2H), 6.82-6.78 (m, 1H), 6.59-6.49 (m, 1H), 5.78-5.73 (m, 1H), 4.75-4.25 (m, 1H), 4.40-4.07 (m, 1H), 3.82 (d, 0.3H), 3.75 (s, 1.5H), 3.71-3.58 (m, 0.7H), 3.69 (d, 1.5H, $J = 4.1$), 3.15-3.10 (m, 1H), 2.60-2.05 (bm, 3H), 1.85-1.77 (bm, 3H), 1.43-1.33 (m, 1H), 1.19-1.08 (m, 6H), 1.06 (d, 3H, $J = 4.4$), 0.46 (m, 1.1H), 0.40 (d, 0.7H, $J = 6.6$), 0.34 (d, 0.8H, $J = 6.6$).

Compound 27

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0049] Compound 27 (91 mg, 93%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0050] ^1H NMR (400 MHz, CDCl_3); 1:1.1 atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.80 (dd, 1H, $J = 11.6, 8.7$), 6.54 (dd, 1H, $J = 16.9, 12.2$), 5.61 (d, 1H, $J = 8.1$), 4.01-3.87 (m, 2H), 3.73 (s, 1.4H), 3.70 (s, 1.6H), 3.54 (d, 0.6H, $J = 14.5$), 3.43 (d, 0.4H, $J = 14.9$), 3.17-3.08 (m, 1H), 2.43-1.99 (bm, 4H), 1.81-1.73 (bm, 4H), 1.24-1.18 (m, 5H), 1.14 (d, 1H, $J = 6.9$), 0.42 (d, 1.4H, $J = 6.5$), 0.35 (d, 1.6H, $J = 6.5$). MS (ESI) m/z 574 ($\text{M}^+ + \text{H}$).

Compound 28

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-

methyloxazolidine-2-thione

[0051] Compound 28 (75 mg, 82%) as yellow oil was obtained according to the same method as the synthesis of compound 15.

[0052] ¹H NMR (400 MHz, CDCl₃); 1:1.3 atropisomer mixture; δ 7.87 (s, 1H), 7.76 (s, 2H), 6.81-6.54 (t, 1H, *J* = 8.8), 6.54 (dd, 1H, *J* = 12.2, 21.1), 5.77 (t, 1H, *J* = 8.7), 4.64-4.56 (bm, 1H), 4.22-4.08 (m, 1H), 3.78-3.68 (m, 1H), 3.75 (s, 1.23H), 3.69 (s, 1.64H), 3.7-3.09 (m, 1H), 2.44-2.00 (bm, 4H), 1.79-1.71 (bm, 4H), 1.31-1.12 (m, 6H), 0.46 (d, 1.3H, *J* = 6.6), 0.38 (d, 1.7H, *J* = 6.6). MS (ESI) *m/z* 590 (*M*⁺ + H).

Compound 29**(4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0053] Compound 29 (99 mg, 62%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0054] ¹H NMR (400 MHz, CDCl₃); 1:1.7 atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 6.75 (2d, 1H, *J* = 8.6), 6.52 (2d, 1H, *J* = 12.2), 5.60 (dd, 1H, *J* = 8.1, 12.5), 4.04-3.87 (m, 2H), 3.72 (s, 1H), 3.69 (s, 2H), 3.47 (dd, 1H, *J* = 14.6), 3.15-3.05 (m, 1H), 2.47-2.24 (m, 4H), 1.84-1.80 (m, 2H), 1.72-1.48 (m, 4H), 1.21-1.11 (m, 6H), 0.40 (d, 1.1H, *J* = 6.5), 0.27 (d, 1.9H, *J* = 6.5), MS (ESI) *m/z* 588 (*M*⁺ + H).

Compound 31**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0055] Compound 31 (0.13 g, 81 %) as white solid was obtained according to the same method as the synthesis of compound 18.

[0056] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.71 (s, 2H), 6.88 (d, *J* = 8.7, 1H), 6.57 (d, *J* = 12.2, 1H), 5.46 (d, *J* = 8.0, 1H), 4.20 (d, *J* = 15.0, 1H), 3.76-3.95 (m, 1H), 3.65 (s, 3H), 3.11-3.17 (m, 1H), 2.53-2.80 (m, 4H), 1.21-1.28 (m, 6H), 0.40 (m, 3H). MS (ESI) *m/z* 604 (*M*⁺+45).

Compound 32**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)cyclopent-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0057] Compound 32 (0.22 g, 89%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0058] ¹H NMR (400 MHz, CDCl₃) δ 7.85 (s, 1H), 7.69 (s, 2H), 7.08-7.10 (m, 1H), 6.90-6.91 (m, 1H), 6.81 (d, *J* = 8.4, 1H), 5.36 (d, *J* = 8.1, 1H), 4.23 (d, *J* = 14.8, 1H), 3.87-3.94 (m, 1H), 3.68 (m, 3H), 2.54-2.87 (m, 5H), 1.97-2.05 (m, 2H), 1.20-1.22 (m, 6H), 0.40 (m, 3H). MS (ESI) *m/z* 587 (*M*⁺ + H).

Compound 34

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoic acid

[0059] Compound 36 (20 mg, 0.035 mmol) was dissolved in tetrahydropuran/water (3 mL, volume/volume 1:1). Lithium hydroxide (an excess amount) was added dropwise to the obtained solution, and then the reaction mixture was refluxed with stirring at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, thus obtaining Compound 34 (16 mg, 60%) as white solid.

[0060] ¹H NMR (400 MHz, benzene-*d*₆); 1:1 atropisomer mixture; δ 8.19-8.14 (m, 1H), 8.03-8.01 (m, 1H), 7.63 (s, 1H), 7.41-7.15 (m, 2H), 6.39-6.3 (m, 1H), 4.78-4.76 (d, *J* = 8.0, 0.5H), 4.72-4.70 (d, *J* = 8.0, 0.5H), 4.19-4.16 (d, *J* = 13.6, 0.5H), 4.04-4.00 (d, *J* = 13.6, 0.5H), 3.49-3.31 (m, 2H), 3.14 (s, 1.5H), 3.11 (s, 1.5H), 2.38-1.98 (m, 4H), 1.67-1.56 (m, 5H), (-)0.09-(-)0.11 (d, *J* = 6.5, 1.5H), (-)0.15-(-)0.17 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 558 (*M*⁺ + H).

Compound 36

methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzoate

[0061] Compound 36 (40 mg, 63%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0062] ¹H NMR (400 MHz, benzene-*d*₆); 1:1 atropisomer mixture; δ 8.11-8.05 (m, 1H), 7.96-7.91 (d, *J* = 2.2, 0.5H), 7.95-7.94 (d, *J* = 2.2, 0.5H), 7.62 (s, 1H), 7.38-7.36 (d, *J* = 6.4, 1H), 6.41-6.35 (dd, *J* = 8.6, 8.6, 1H), 4.76-4.74 (d, *J* = 8.0, 0.5H), 4.70-4.68 (d, *J* = 8.0, 0.5H), 4.20-4.16 (d, *J* = 15.6, 0.5H), 4.01-3.98 (d, *J* = 15.6, 0.5H), 3.58 (s, 1.5H), 3.52 (s, 1.5H), 3.43-3.30 (m, 3H), 3.16 (s, 1.5H), 3.12 (s, 1.5H), 2.16-2.07 (m, 3H), 1.67-1.55 (m, 4H), (-)0.12-(-)0.13 (d, *J* = 6.5, 1.5H), (-)0.17-(-)0.19 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 573 (*M*⁺ + H).

Compound 37

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoic acid

[0063] Compound 37 (19 mg, 80%) as white solid was obtained according to the same method as the synthesis of compound 34.

[0064] ¹H NMR (400 MHz, benzene-*d*₆); 1:1 atropisomer mixture; δ 8.19-8.14 (m, 1H), 8.03-8.01 (m, 1H), 7.63 (s, 1H), 7.41-7.15 (d, 2H), 6.39-6.35 (m, 1H), 4.83-4.81 (d, *J* = 8.4, 0.5H), 4.77-4.75 (d, *J* = 8.4, 0.5H), 4.17-4.13 (d, *J* = 15.2, 0.5H), 4.00-3.96 (d, *J* = 15.2, 0.5H), 3.49-3.31 (m, 2H), 3.14 (s, 1.5H), 3.11 (s, 1.5H), 2.42-1.90 (m, 3H), 1.46-1.23 (m, 4H), 1.06-0.83 (m, 6H), (-)0.06-(-)0.08 (d, *J* = 6.5, 1.5H), (-)0.13-(-)0.15 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 586 (*M*⁺ + H).

Compound 41

methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzoate

[0065] Compound 41 (45 mg, 70%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0066] ^1H NMR (400 MHz, benzene- d_6); 1:1 atropisomer mixture; δ 8.11-8.05 (m, 1H), 7.96-7.91 (d, 0.5H), 7.95-7.94 (d, 0.5H), 7.62 (s, 1H), 7.38-7.36 (d, 1H), 6.41-6.35 (dd, J = 8.6, 8.6, 1H), 4.80-4.78 (d, J = 8.0, 0.5H), 4.76-4.74 (d, J = 8.0, 0.5H), 4.16-4.13 (d, J = 15.0, 0.5H), 3.98-3.94 (d, J = 15.0, 0.5H), 3.58 (s, 1.5H), 3.52 (s, 1.5H), 3.43-3.30 (m, 2H), 3.16 (s, 1.5H), 3.12 (s, 1.5H), 2.04-1.93 (m, 3H), 1.42-1.22 (m, 4H), 1.02-0.86 (m, 6H), (-)0.09-(-)0.10 (d, J = 6.5, 1.5H), (-)0.16-(-)0.18 (d, J = 6.5, 1.5H). MS (ESI) m/z 600 (M^+ + H).

Compound 42

(4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)cyclohept-1-enyl)methyl)-4-methyloxazolidin-2-one

[0067] Compound 42 (0.11 g, 75%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0068] ^1H NMR (400 MHz, CDCl_3); 1:1.9 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 7.04 (dd, 1H, J = 8.3, 2.0), 6.81-6.71 (m, 2H), 5.58 (2d, 1H, J = 8.0), 4.05-3.90 (m, 2H), 3.73 (d, 3H, J = 11.3), 3.51 (2d, 1H, J = 14.2), 2.85-2.76 (m, 1H), 2.52-2.27 (m, 4H), 1.85-1.82 (m, 2H), 1.71-1.51 (m, 4H), 1.20-1.14 (m, 6H), 0.38 (d, 1H, J = 6.5), 0.23 (d, 1.9H, J = 6.5). MS (ESI) m/z 574 (M^+ + H).

Compound 43

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-ethyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0069] Compound 43 (0.12 g, 80%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0070] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 2H), 6.76-6.81 (m, 1H), 6.49-6.58 (m, 1H), 3.92-4.14 (m, 2H), 3.69-3.75 (m, 3H), 3.37-3.59 (m, 1H), 3.10-3.15 (m, 1H), 1.82-2.22 (m, 4H), 1.40-1.43 (m, 2H), 0.87-1.00 (m, 6H), 0.40 (m, 3H). MS (ESI) m/z 647 (M^+ + H).

Compound 44

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0071] Compound 44 (2 mg, 4%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0072] ^1H NMR (400 MHz, CDCl_3); 1:1.3 atropisomer mixture; δ 7.81 (s, 1H), 7.68 (s, 2H), 7.03-7.00 (m, 1H), 6.76-6.69 (m, 2H), 5.56 (d, 1H, J = 8.2), 3.96-3.83 (m, 2H), 3.69 (d, 3H, J = 11.1), 3.51 (2d, 1H, J = 14.6, 14.7), 2.61-2.74 (m, 1H), 2.18-2.12 (m, 2H), 1.98-1.82 (m, 2H), 1.50-1.45 (m, 5H), 1.18-1.11 (m, 6H), 0.99-0.94 (m, 6H), 0.37 (d, 1.3H, J = 6.6), 0.28 (d, 1.7H, J = 6.5). MS (ESI) m/z 584 (M^+ + H).

Compound 46

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-

methyloxazolidin-2-one

[0073] Compound 36 (30 mg, 0.052 mmol) was dissolved in anhydrous tetrahydropuran (5 mL). Lithium hydroxide (5 mg, 0.08 mmol) was added dropwise to the obtained solution at - 78°C, and then stirred at room temperature for 5 hours. After the completion of the reaction, the reaction was quenched with 1M HCl (hydrochloride) solution. The reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, thus obtaining Compound 46 (20 mg, 60%) as white solid.

[0074] ¹H NMR (400 MHz, benzene-*d*₆); 1:1 atropisomer mixture; δ 7.62 (s, 1H), 7.40-7.38 (d, *J* = 10.7, 2H), 7.10-6.96 (m, 2H), 6.51-6.45 (m, 1H), 4.73-4.71 (d, *J* = 7.9, 1H), 4.40-4.36 (m, 2H), 4.21-4.15 (m, 1H), 3.49-3.41 (m, 2H), 2.54-2.39 (m, 1H), 2.18-2.05 (m, 3H), 1.73-1.52 (m, 5H), -0.07-(-)0.08 (d, *J* = 6.5, 1.5H), (-)0.16-(-)0.18 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 544 (*M*⁺ + H).

Compound 47**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0075] Compound 46 (6.8 mg, 0.013 mmol) was dissolved in anhydrous tetrahydropuran (2 mL). Sodium hydride (1 mg, 0.03 mmol) was added dropwise to the obtained solution at 0°C, and then stirred at room temperature for 30 minutes. Iodomethane (an excess amount) was added dropwise slowly to the reaction mixture at 0°C, and then stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 47 (5 mg, 97%) as white solid.

[0076] ¹H NMR (400 MHz, benzene-*d*₆); 1:1 atropisomer mixture; δ 7.61 (s, 1H), 7.39-7.38 (m, 2H), 7.13-7.10 (m, 0.5H), 7.06-7.04 (m, 1H), 6.99-6.98 (m, 0.5H), 6.51-6.44 (m, 1H), 4.75-4.68 (dd, *J* = 7.9, 7.9, 1H), 4.22-4.13 (m, 3H), 3.53-3.44 (m, 2H), 3.25 (s, 1.5H), 3.23 (s, 1.5H), 3.19 (s, 1.5H), 3.10 (s, 1.5H), 2.51-2.47 (m, 1H), 2.22-2.09 (m, 3H), 1.71-1.61 (m, 4H), (-)0.07-(-)0.09 (d, *J* = 6.5, 1.5H), (-)0.18-(-)0.20 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 558 (*M*⁺ + H).

Compound 48**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0077] Compound 48 (0.2 g, 79.5%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0078] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.76 (s, 1H), 7.63-7.61 (m, 2H), 7.15-6.64 (m, 1H), 6.49-6.40 (m, 1H), 5.57-5.47 (m, 1H), 3.91-3.77 (m, 2H), 3.63-3.59 (m, 3H), 3.56-3.29 (m, 1H), 3.05-3.00 (m, 1H), 2.35-1.97 (m, 6H), 1.80-1.50 (m, 1H), 1.15-1.00 (m, 6H), 0.34-0.21 (ddd, *J* = 6.5, 3H). MS (ESI) *m/z* 642 (*M*⁺ + H).

Compound 49**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3'-chloro-4,6'-dimethoxybiphenyl-3-yl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0079] Compound 49 (2 mg, 33%) as a colorless oil was obtained according to the same method as the synthesis of compound 18.

[0080] ^1H NMR (400 MHz, CDCl_3); 1:1.5 atropisomer mixture; δ 7.82 (s, 1H), 7.70 (s, 2H), 7.37-7.32 (m, 1H), 7.22-7.11 (m, 3H), 6.90-6.81 (m, 2H), 4.01-3.87 (m, 2H), 3.78-3.70 (m, 6H), 3.68-3.50 (m, 1H), 2.28-2.02 (m, 4H), 1.79-1.72 (m, 4H), 0.41 (d, 1.2H, $J = 6.5$), 0.34 (d, 1.8H, $J = 6.5$). MS (ESI) m/z 654 ($\text{M}^+ + \text{H}$).

Compound 50

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0081] Compound 50 (84 mg, 94%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0082] ^1H NMR (400 MHz, CDCl_3); 1:1.1 atropisomer mixture; δ 7.83 (s, 1H), 7.73 (d, 2H, $J = 4.9$), 7.17-7.13 (m, 1H), 6.95 (t, 1H, $J = 2.4$), 6.76 (dd, 1H, $J = 8.8$, 16.3), 5.59 (2d, 1H, $J = 8.0$), 3.98-3.88 (m, 2H), 3.73 (d, 3H, $J = 11.8$), 3.47 (2d, 1H, $J = 14.7$), 2.38-2.02 (m, 4H), 1.77-1.67 (m, 4H), 0.45 (d, 1.4H, $J = 6.5$), 0.36 (d, 1.6H, $J = 6.5$). MS (ESI) m/z 548 ($\text{M}^+ + \text{H}$).

Compound 51

(4S,5R)-3-((2-(1H-indol-4-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0083] Compound 51 (95 mg, 38%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0084] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture: δ 8.29 (bs, 1H), 7.80 (d, 1H, $J = 7.4$), 7.65 (d, 2H, $J = 17$), 7.26 (d, 1H, $J = 8$), 7.18-7.07 (m, 2H), 6.84 (dd, 1H, $J = 17.7$), 6.36-6.29 (bm, 1H), 5.48 (t, 1H, $J = 8.0$), 4.00-3.43 (m, 3H), 2.65-2.24 (m, 2H), 2.02-1.94 (m, 2H), 1.07 (t, 6H, $J = 13$), 0.25 (2d, 3H, $J = 6.5$).

Compound 52

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0085] As shown in reaction scheme 5, intermediate 16 was reacted with triphosgene, thus obtaining Compound 52 (0.13 g, 62%) as yellow oil.

[0086] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 8.16-8.20 (m, 1H), 7.90-7.92 (m, 1H), 7.87 (s, 1H), 7.74 (d, $J = 8.0$, 1H), 6.95 (t, $J = 9.2$, 1H), 5.67 (d, $J = 8.3$, 0.51H), 5.58 (d, $J = 8.1$, 0.43H), 3.91-4.04 (m, 2H), 3.54 (d, $J = 1.3.9$, 0.45H), 3.32 (d, $J = 15.0$, 0.54H), 2.10-2.27 (m, 2H), 1.89-2.00 (m, 2H), 1.49-1.54 (m, 2H), 1.03-1.10 (m, 6H), 0.42-0.48 (m, 3H). MS (ESI) m/z 633 ($\text{M}+45$).

Compound 56

-(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-dimethylamino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0087] Compound 56 (50 mg, 62%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0088] ^1H NMR (400 MHz, CDCl_3); 1:2 atropisomer mixture: δ 7.85 (s, 1H), 7.73 (m, 2H), 6.81 (d, J = 8.9, 0.35H), 6.74 (d, J = 8.9, 0.65H), 6.60-6.66 (m, 1H), 6.44 (d, J = 3.0, 0.35H), 6.41 (d, J = 3.1, 0.65H), 5.57-5.59 (m, 1H), 3.89-4.08 (m, 2H), 3.67-3.70 (m, 3H), 3.51-3.67 (m, 1H), 2.81-2.86 (m, 6H), 2.06-2.51 (m, 2H) 1.93 (s, 2H), 1.43-1.55 (m, 2H), 1.01-1.05 (m, 6H), 0.47 (d, J = 0.6, 1H), 0.32 (d, J = 6.5, 2H), MS (ESI) m/z 630 (M^+ 45).

Compound 57

2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-5-methoxybenzaldehyde

[0089] As shown in reaction scheme 3, intermediate 9 was synthesized. The obtained intermediate 9 (0.13 g, 0.20 mmol) was subjected to a Suzuki reaction with boronic acid (58 mg, 0.33 mmol), thus obtaining Compound 57 (0.11 g, 75%) as brown oil.

[0090] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture: δ 10.05 (s, 0.49H), 10.00 (s, 0.47H), 7.86 (s, 1H), 7.73 (s, 2H), 7.37-7.42 (m, 1H), 7.70-7.17 (m, 2H), 5.62-5.64 (m, 1H), 3.83-4.03 (m, 2H), 3.86 (d, J = 3.0, 3H), 2.15-2.39 (m, 4H), 1.72-1.88 (m, 4H), 3.82 (d, J = 3.4, 3H), 2.03-2.38 (m, 4H), 1.75 (d, J = 3.8, 4H), 0.37-0.42 (m, 3H), MS (ESI) m/z 542 (M^+ + H).

Compound 58

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-hydroxymethyl)-4-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0091] Compound 57 (94 mg, 0.17 mmol) was dissolved in methanol (2 mL). Sodium borohydride (10 mg, 0.19 mmol) was added dropwise slowly to the obtained solution at room temperature, and then stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with sodium sulfate anhydrous, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 58 (85 mg, 90%) as colorless oil.

[0092] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture: δ 7.87 (s, 1H), 7.74 (d, J = 12.0, 2H), 6.75-7.08 (m, 3H), 5.47-5.68 (m, 1H), 4.53-4.57 (m, 2H), 3.87-4.03 (m, 2H), 3.82 (d, J = 5.4, 3H), 3.62 (d, J = 15.1, 0.37H), 3.31 (d, J = 14.7, 0.61H), 2.09-2.21 (m, 4H), 1.73-1.77 (m, 4H), 0.46-0.57 (m, 3H). MS (ESI) m/z 544 (M^+ + H).

Compound 59

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-methoxy-2-(methoxymethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0093] Compound 59 (85 mg, 90%) as yellow oil was obtained according to the same method as the synthesis of compound 47.

[0094] ^1H NMR (400 MHz, CDCl_3); 1:1.9 atropisomer mixture: δ 7.86 (s, 1H), 7.75 (d, J = 5.9, 2H), 6.75-7.00 (m, 3H), 5.65 (d, J = 8.0, 0.63H), 5.58 (d, J = 8.0, 0.31H), 4.28 (d, J = 5.6, 0.67H), 4.25 (d, J = 3.9, 1.15H), 3.83-4.00 (m, 2H), 3.80-3.81 (m, 3H), 3.78 (d, J = 12.7, 0.32H), 3.40-3.42 (m, 3H), 3.34 (d, J = 14.7, 4H), 2.05-2.25 (m, 4H), 1.70-1.76 (m, 4H), 0.54 (d, J = 6.5, 0.95H), 0.40

(d, $J = 6.5, 1.9\text{H}$). MS (ESI) m/z 558 ($M^+ + H$).

Compound 60

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(quinolin-8-yl)cyclohex-1-enyl)methyl)oxazolidin-2-one

[0095] Compound 60 (8 mg, 22%) as yellow oil was obtained according to the same method as the synthesis of compound 57.

[0096] ^1H NMR (400 MHz, CDCl_3); 1:2 atropisomer mixture; δ 8.94-8.86 (m, 1H), 8.17-8.10 (m, 1H), 7.90 (bd, 1H, $J = 14$), 7.75-7.72 (m, 1H), 7.67-7.62 (bm, 2H), 7.44-7.31 (m, 3H), 3.52-3.34 (m, 1H), 4.13-3.98 (m, 2H), 3.52-3.34 (m, 1H), 2.85-2.60 (m, 1H), 2.40-2.15 (m, 3H), 1.85-1.62 (m, 4H), 0.46 (d, 1H, $J = 6.6$), (-)0.34 (d, 2H, $J = 6.4$). MS (ESI) m/z 535 ($M^+ + H$).

Compound 61

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(1-methyl-1H-indazol-4-yl)cyclohex-1-enyl)methyl)oxazolidin-2-one

[0097] Compound 61 (16 mg, 46%) as yellow oil was obtained according to the same method as the synthesis of compound 57.

[0098] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.80 (d, 2H, $J = 11$), 7.66 (s, 2H), 7.34-7.25 (m, 2H), 6.82 (d, 1H, $J = 6.7$), 5.53 (d, 1H, $J = 15$), 3.86 (bs, 1H), 3.8-3.4 (bm, 1H), 2.6-2.18 (brm, 2H), 2.15 (s, 2H), 1.76 (bs, 4H), 0.38-0.11 (brm, 3H).

Compound 62

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0099] Hydroxyisobutylamidine (9 mg, 0.08 mol) was dissolved in tetrahydrofuran (0.5 mL). Sodium hydride (8 mg, 0.17 mmol) was added dropwise to the obtained solution at room temperature, and stirred at 50°C for 2 hours. Compound 36 (25 mg, 0.044 mmol) was added dropwise to the solution, and was refluxed with stirring at 90°C overnight. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 62 (17 mg, 63%) as white solid.

[0100] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.03-8.00 (m, 1H), 7.85 (s, 1H), 7.78-7.73 (m, 3H), 6.98 (dd, 1H, $J = 11.9, 8.7$), 5.63 (m, 1H), 4.05-3.97 (m, 2H), 3.87 (d, 3H, $J = 12.4$), 3.48 (m, 1H), 3.17-3.05 (m, 1H), 2.25-2.05 (bm, 4H), 1.83-1.75 (bm, 4H), 1.40-1.25 (m, 6H), 0.44-0.39 (m, 3H). MS (ESI) m/z 624 ($M^+ + H$).

Compound 63

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0101] Compound 19 (21 mg, 0.035 mmol) was dissolved in methylene chloride (1 mL). Boron tribromide (0.07 mL, 0.07 mmol) was added dropwise slowly to the obtained solution at -78°C , and stirred at room temperature for 3 hours. After the completion of

the reaction, the reaction was quenched with saturated sodium carbonate solution. The reaction mixture was extracted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 63 (5 mg, 25%) as colorless oil.

[0102] ^1H NMR (400 MHz, CDCl_3); 1:1.6 atropisomer mixture; δ 7.89 (d, $J = 7.4$, 1H), 7.74 (s, 2H), 6.72-6.75 (m, 1H), 6.57-6.64 (m, 1H), 6.04-6.06 (m, 1H), 5.72 (d, $J = 8.0$, 0.61H), 5.62 (d, $J = 8.3$, 0.37H), 3.98-4.06 (m, 1.65H), 3.75 (d, $J = 14.7$, 0.39H), 3.60 (s, 0.38H), 3.37 (d, $J = 14.8$, 0.61H), 3.10-3.15 (m, 1H), 1.48-2.26 (m, 6H), 0.67 (d, $J = 6.5$, 1.18H), 0.50 (d, $J = 6.6$, 1.94H). MS (ESI) m/z 588 ($\text{M}^+ + \text{H}$).

Compound 64

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0103] Compound 64 (24 mg, 52%) as colorless oil was obtained according to the same method as the synthesis of compound 63.

[0104] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.89 (d, $J = 5.4$, 1H), 7.74 (s, 2H), 6.72-6.78 (m, 1H), 6.56-6.64 (m, 1H), 5.65-5.75 (m, 0.8H), 3.94-4.06 (m, 1.46H), 3.69 (m, 0.73H), 3.37 (d, $J = 14.8$, 0.5H), 3.10-3.13 (m, 1H), 1.29-2.28 (m, 7H), 1.04-1.28 (m, 6H), 0.89 (t, $J = 6.7$, 1H), 0.67 (t, $J = 6.7$, 0.99H), 0.47-0.52 (m, 1.5H). MS (ESI) m/z 574 ($\text{M}^+ + \text{H}$).

Compound 65

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-hydroxy-5-isopropylphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0105] Compound 65 (15 mg, 60%) as colorless oil was obtained according to the same method as the synthesis of compound 63.

[0106] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.89 (s, 1H), 7.75 (d, $J = 9.3$, 2H), 6.57-6.78 (m, 3H), 5.66 - 5.86 (m, 1H), 3.96-4.10 (m, 2H), 3.41-3.73 (m, 1H), 2.10-2.48 (m, 6H), 1.75 (m, 1H), 1.15-1.20 (m, 1H), 0.55-0.69 (m, 3H). MS (ESI) m/z 628 ($\text{M}^+ + \text{H}$).

Compound 66

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-morpholinophenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0107] Compound 50 (40.0 mg, 0.073 mmol), palladium acetate (0.8 mg, 0.0037 mmol), biphenyl ligand (2.2 mg, 0.007 mmol), sodium tert-butoxide (10.5 mg, 0.11 mmol) and morpholine (10.9 mg, 0.13 mmol) were dissolved in toluene (1.0 mL). The obtained solution was refluxed in microwave-reactor with stirring at 100°C for 20 minutes. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (4 g silica, 4:1 = hexane : EtOAc), thus obtaining Compound 66 (12.8 mg, 29%) as brown solid.

[0108] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87-7.73 (m, 3H), 6.84-6.60 (m, 3H), 5.62, 5.57 (2d, 1H, $J = 8.0$),

4.05-3.81 (m, 7H), 3.74, 3.70 (2s, 3H), 3.07-2.99 (m, 4H), 2.25-2.03 (m, 4H), 1.84-1.74 (m, 4H), 0.48, 0.34 (2s, 3H). MS(ESI): 599 (M^+).

Compound 67

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-methylbenzamide

[0109] Compound 34 (20 mg, 0.036 mmol), methylamine (13.5 μ L, 0.02 mmol) and 1-hydroxybenzotriazole (5.6 mg, 0.04 mmol) were dissolved in methylene chloride (0.5 mL). 1-Ethyl-3-(3-dimethylpropyl)carbodiimide (7.9 mg, 0.04 mmol) was added dropwise to the obtained solution at 0°C, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was neutralized with saturated sodium hydrogen carbonate solution. The reaction mixture was extracted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (silica, 1% ~ 3% DCM/MeOH, thus obtaining Compound 67 (3 mg, 15%) as colorless oil.

[0110] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (d, 1H, J = 5.0), 7.75-7.57 (m, 3H), 7.54-7.48 (m, 1H), 6.89 (dd, 1H, J = 8.6, 6.5), 6.30-6.16 (m, 1H), 5.54 (m, 1H), 4.07-3.93 (m, 2H), 3.85 (d, 3H, J = 16.0), 3.48-3.36 (m, 1H), 2.99 (dd, 3H, J = 15.5, 4.8), 2.40-2.01 (bm, 4H), 1.84-1.75 (bm, 4H), 0.45 (t, 3H, J = 6.9).

Compound 68

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-ethyl-4-methoxybenzamide

[0111] Compound 68 (11 mg, 61%) as yellow solid was obtained according to the same method as the synthesis of compound 67.

[0112] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (d, 1H, J = 4.8), 7.75-7.58 (m, 3H), 7.51 (m, 1H), 6.89 (dd, 1H, J = 8.5, 6.4), 6.27-6.12 (m, 1H), 5.54 (m, 1H), 4.07-4.02 (m, 2H), 3.83 (d, 3H, J = 15.6), 3.52-3.37 (m, 3H), 2.17-2.05 (bm, 4H), 1.82-1.62 (bm, 4H), 1.28-1.20 (m, 2H), 0.47-0.43 (m, 3H).

Compound 69

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-(2,2,2-trifluoroethyl)benzamide

[0113] Compound 69 (23 mg, 100%) as yellow oil was obtained according to the same method as the synthesis of compound 67.

[0114] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87 (d, 1H, J = 6.8), 7.73 (d, 2H, J = 18.8), 7.67 (dd, 1H, J = 8.5, 2.4), 7.58 (dd, 1H, J = 8.3, 2.4), 6.93 (t, 1H, J = 8.8), 6.88-6.55 (m, 1H), 5.65-5.42 (m, 1H), 4.24-3.94 (m, 4H), 3.85 (d, 3H, J = 18.3), 3.39 (dd, 1H, J = 18.0, 15.3), 2.42-2.05 (bm, 4H), 1.83-1.76 (bm, 4H), 0.51-0.46 (m, 3H). MS (ESI) m/z 639 (M^+ + H).

Compound 70

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxybenzamide

[0115] Compound 70 (24 mg, 100%) as yellow solid was obtained according to the same method as the synthesis of compound 67.

[0116] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (d, 1H, $J = 4.0$), 7.74 (d, 2H, $J = 9.4$), 7.71-7.56 (m, 1H), 7.48 (m, 1H), 6.88 (m, 1H), 6.00 (m, 1H), 5.55 (m, 1H), 4.30-4.20 (m, 1H), 4.07-3.93 (m, 2H), 3.83 (d, 3H, $J = 15.6$), 3.43 (q, 1H, $J = 15.0$), 2.30-2.04 (bm, 4H), 1.82-1.74 (bm, 4H), 1.28-1.22 (m, 6H), 0.45 (dd, 3H, $J = 12.9$, 6.5). MS (ESI) m/z 599 ($\text{M}^+ + \text{H}$).

Compound 71

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamide

[0117] As shown in reaction scheme 5, (4S,5R)-3-((2-(5-amino-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-oxooxazolidin-2-one (29 mg, 0.05 mmol) and diisopropylamine (0.01 mL, 0.08 mmol) were dissolved in tetrahydropuran (1 mL). Acetyl chloride (5 μL , 0.08 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 2:1 = Hexane : EtOAc), thus obtaining Compound 71 (21 mg, 68%) as colorless oil.

[0118] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.84 (d, $J = 9.8$, 2H), 7.79 (s, 1H), 6.77-7.33 (m, 3H), 5.62 (d, $J = 7.9$, 0.5H), 5.52 (d, $J = 8.0$, 0.5H), 4.06-4.16 (m, 2H), 3.98 (t, $J = 15.0$, 1H), 3.76 (d, $J = 7.8$, 3H), 3.58 (d, $J = 14.9$, 0.5H), 3.38 (d, $J = 14.8$, 0.5H), 1.71-2.39 (m, 8H), 2.14 (d, $J = 15.9$, 3H), 0.44 (d, $J = 6.5$, 1.5H), 0.32 (d, $J = 6.4$, 1.5H). MS (ESI) m/z 571 ($\text{M}^+ + \text{H}$).

Compound 72

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)isobutyramide

[0119] Compound 72 (24 mg, 79%) as colorless oil was obtained according to the same method as the synthesis of compound 71.

[0120] ^1H NMR (400 MHz, CDCl_3); 1:1.1 atropisomer mixture; δ 7.84 (s, 1H), 7.78 (s, 2H), 7.58 (d, $J = 2.6$, 0.5H), 7.25 - 7.27 (m, 0.5H), 7.22 (s, 0.5H), 7.13 (s, 0.5H), 7.03 (dd, $J = 8.6$, 2.7, 0.5H), 6.80 (t, $J = 8.3$, 1H), 5.63 (d, $J = 8.0$, 0.44H), 5.51 (d, $J = 8.0$, 0.54H), 4.04 - 4.15 (m, 2H), 3.76 (d, $J = 4.1$, 3H), 3.54 (d, $J = 14.8$, 0.6H), 3.41 (d, $J = 14.8$, 0.4H), 2.44 - 2.53 (m, 1H), 1.71 - 2.34 (m, 4H), 1.15 - 1.30 (m, 6H), 0.44 (d, $J = 6.5$, 1.6H), 0.36 (d, $J = 6.4$, 1.4H). (ESI) m/z 599 ($\text{M}^+ + \text{H}$).

Compound 76

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methylxazolidin-2-one

[0121] Compound 76 (14 mg, 52%) as yellow oil was obtained according to the same method as the synthesis of compound 62.

[0122] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.99-7.96 (m, 1H), 7.86 (s, 1H), 7.75-7.72 (m, 3H), 6.97 (dd, 1H, J = 8.7, 11.7), 5.62 (2d, 1H, J = 8.0, 8.0), 4.04-3.97 (m, 2H), 3.86 (d, 3H, J = 12.3), 3.47 (2d, 1H, J = 14.8, 14.9), 2.24-2.05 (m, 5H), 1.76-1.75 (m, 4H), 1.60-1.58 (m, 2H), 1.16-0.97 (m, 2H), 0.42-0.39 (m, 3H).

Compound 79

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxybenzaldehyde

[0123] As shown in reaction scheme 4, a pinacolato compound was synthesized, and then subjected to a Suzuki reaction with Compound 9, thus obtaining Compound 79 (65 mg, 35%) as colorless oil.

[0124] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 9.86 (s, 1H), 9.81 (s, 1H), 7.83(s, 1H), 7.82-7.71 (m, 3H), 7.56-7.53 (dd, 1H), 7.00-6.95 (dd, 1H), 5.64-5.54 (dd, 1H), 4.00-3.92 (m, 1H), 3.87 (s, 1.5H), 3.84 (s, 1.5H), 3.52-3.49 (d, 0.5H), 3.35-3.31 (d, 0.5H), 2.20-2.19 (m, 1H), 1.80-1.72 (m, 5H), 0.40-0.37 (m, 3H). MS (ESI) m/z 406 (M^+ + H).

Compound 80

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0125] Compound 79 (65 mg, 0.117 mmol) was dissolved in tetrahydropuran (3 mL). Methylmagnesium chloride (56 μL , 0.17 mmol) was added dropwise to the obtained solution at 0°C , and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography (silica gel; Hexane/EtOAc = 6:1 ~ 3:1), thus obtaining Compound 80 (88 mg, 98%) as colorless oil.

[0126] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.83 (s, 1H), 7.73-7.69 (m, 2H), 7.21-7.17 (m, 1H), 7.07 (m, 0.5H), 7.00-6.97 (m, 0.5H), 6.85-6.78 (dd, 1H), 5.59-5.56 (m, 0.5H), 5.50-5.44 (dd, 0.5H), 4.83-4.79 (m, 1H), 4.11-3.94 (m, 2H), 3.78-3.77 (d, 1.5H), 3.72 (s, 1.5H), 3.55-3.39 (m, 1H), 2.17-2.20 (m, 4H), 1.71 (brs, 4H), 1.46-1.39 (m, 3H), 0.43-0.33 (m, 3H). MS (ESI) m/z 557 (M^+ + H).

Compound 81

(4S,5R)-3-((2-(5-acetyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0127] Compound 80 (88 mg, 0.158 mmol) was dissolved in methylene chloride (2 mL). Dess-Martin periodinane (0.17 mg, 0.35 mmol) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography (silica gel; hexane/EtOAc = 5:1 ~ 3:1), thus obtaining Compound 81 (45 mg, 90%) as colorless oil.

[0128] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (m, 0.5H), 7.78 (m, 0.5H), 7.75-7.72 (m, 0.5H), 7.64-7.58 (m, 1.5H), 7.43-7.41 (m, 2H), 6.42-6.39 (m, 1H), 4.83-4.17 (m, 1H), 4.17-4.02 (dd, 1H), 3.45-3.24 (m, 2H), 3.23 (s, 1.5H), 3.19 (s, 1.5H), 2.41-1.99 (m, 4H), 2.27 (s, 1.5H), 2.23 (s, 1.5H), 1.69-1.57 (m, 4H), (-)0.07-(-)0.12 (m, 3H). MS (ESI) m/z 556 (M^+ + H).

Compound 82

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0129] Compound 82 (8.2 mg, 36%) as yellow oil was obtained according to the same method as the synthesis of compound 80.

[0130] ¹H NMR (400 MHz, CDCl₃); 1:1 atropisomer mixture; δ 7.62-7.61 (m, 1H), 7.40-7.29 (m, 3H), 7.291-7.18 (m, 1H), 6.53-6.49 (m, 1H), 4.74-4.69 (m, 1H), 4.28-4.19 (m, 1H), 3.56-3.33 (m, 2H), 3.30 (s, 1.5H), 3.26 (s, 1.5H), 2.54-2.10 (m, 4H), 1.74-1.65 (m, 4H), 1.42-1.37 (m, 6H), (-)-0.07-(-) 0.16 (m, 3H). MS (ESI) m/z 572 (M⁺ + H).

Compound 83**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-3-((2-(2-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)oxazolidin-2-one**

[0131] Compound 83 (96 mg, 95%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0132] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.75 (s, 2H), 7.33-7.22 (m, 3H), 7.17-7.14 (m, 1H), 5.64 (dd, *J* = 4.4, 8.0, 1H), 4.04-3.88 (m, 2H), 3.54, 3.42 (2d, *J* = 15.0, 1H), 2.36-2.04 (m, 4H), 1.81-1.73 (m, 4H), 0.49, 0.43 (2d, *J* = 6.5, 3H). MS (ESI) m/z 568 (M⁺ + H).

Compound 84**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-fluoro-5-(trifluoromethyl)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0133] Compound 84 (0.14 g, 79%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0134] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.87 (s, 1H), 7.75 (s, 2H), 7.55-7.54 (m, 1H), 7.40-7.38 (m, 1H), 7.21-7.14 (m, 1H), 5.64 (d, *J* = 7.9, 1H), 4.15-3.92 (m, 2H), 3.51-3.47 (m, 1H), 2.39-2.20 (m, 4H), 1.78 (bs, 4H), 0.46 (d, *J* = 6.5, 3H). MS (ESI) m/z 570 (M⁺ + H).

Compound 85**1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)ethyl acetate**

[0135] Compound 80 (65.0 mg, 0.117 mmol) was dissolved in tetrahydropuran (2 mL). Methylmagnesium chloride (56 μL, 0.16 mmol) was added dropwise to the obtained solution at 0°C, and stirred at room temperature for 5 hours. After the completion of the reaction, ethyl acetate was added dropwise to the reaction mixture. And then, the reaction mixture was washed with water and brine, and concentrated under reduced pressure. The residue was separated by MPLC (15% Hexane/EtOAc), thus obtaining Compound 85 (30 mg, 70%) as white foam.

[0136] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.82 (s, 1H), 7.73 (d, $J = 7.3$, 1H), 7.25-7.17 (m, 1H), 6.99-6.93 (m, 1H), 6.84-6.77 (m, 1H), 5.82-5.71 (m, 1H), 5.60-5.55 (m, 1H), 3.99-3.87 (m, 2H), 3.75 (s, 1.5H), 3.72 (d, $J = 9.4$, 1.5H), 3.58-3.39 (m, 1H), 2.41-1.63 (m, 11H), 1.49-1.42 (m, 3H), 0.40-0.31 (m, 3H). MS (ESI) m/z 540.0 ($\text{M}^+ + \text{H-OAc}$).

Compound 86

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide

[0137] Compound 86 (5 mg, 35%) as colorless oil was obtained according to the same method as the synthesis of compound 47.

[0138] ^1H NMR (400 MHz, CDCl_3); 1:1.1 atropisomer mixture; δ 7.87 (s, 1H), 7.75 (d, $J = 7.2$, 2H), 7.06-6.84 (m, 3H), 5.65-5.60 (m, 1H), 4.06-3.89 (m, 2H), 3.80 (d, $J = 13.7$, 3H), 3.54-3.44 (m, 1H), 3.18 (d, $J = 24.4$, 3H), 2.50-2.42 (m, 1H), 2.27-1.75 (m, 4H), 1.03-0.83 (m, 6H), 0.48 (d, $J = 6.5$, 1.4H), 0.39 (d, $J = 6.4$, 1.6H). MS (ESI) m/z 613 ($\text{M}^+ + \text{H}$).

Compound 87

3-(2-5((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxy-N-methylbenzamide

[0139] Compound 87 (11 mg, 79%) as yellow solid was obtained according to the same method as the synthesis of compound 47.

[0140] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.77 (d, $J = 6.7$, 2H), 7.29-7.25 (m, 1H), 7.12, 7.07 (2d, $J = 2.0$, 1H), 6.86 (dd, $J = 7.1$, 8.4, 1H), 5.63-5.49 (m, 1H), 4.04-3.92 (m, 2H), 3.81 (d, $J = 9.4$, 3H), 3.53, 3.41 (2d, $J = 15.0$, 1H), 2.88-2.85 (m, 3H), 2.25-2.05 (m, 4H), 1.74 (bs, 4H), 1.20-1.15 (m, 6H), 0.44 (dd, $J = 6.5$, 15.2, 3H). MS (ESI) m/z 613 ($\text{M}^+ + \text{H}$).

Compound 96

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0141] Compound 96 (57 mg, 69%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0142] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87 (s, 1H), 7.75-7.73 (m, 2H), 7.52-7.49 (m, 1H), 7.25-7.23 (m, 1H), 6.96-6.90 (m, 1H), 5.67, 5.65, 5.61, 5.49 (4d, $J = 7.8$, 7.9, 8.1, 8.2, 1H), 4.05-3.89 (m, 2H), 4.05-3.89 (m, 2H), 3.84, 3.82, 3.80 (3s, 3H), 3.55, 3.47, 3.38, 3.32 (4d, $J = 15.0$, 14.8, 14.9, 14.9, 1H), 2.29-2.19 (m, 3H), 1.87-1.71 (m, 3H), 1.45-1.26 (m, 1H), 1.08-1.06 (m, 3H), 0.42-0.37 (m, 3H). MS (ESI) m/z 596 ($\text{M}^+ + \text{H}$).

Compound 97

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0143] Compound 97 (77.8 mg, 75%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0144] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.87 (s, 1H), 7.75, 7.73 (2s, 2H), 7.51 (dm, 1H), 7.23 (d, 1H), 6.94 (d, $J = 8.7$, 0.5H), 6.91 (d, $J = 8.7$, 0.5H), 5.65 (d, $J = 8.1$, 0.5H), 5.55 (d, $J = 8.2$, 0.5H), 3.99-3.89 (m, 2H), 3.50 (d, $J = 14.9$, 0.5H), 3.33 (d, $J = 15.0$, 0.5H), 3.84 (s, 1.5H), 3.81 (s, 1.5H), 2.49-2.15 (m, 2H), 1.99-1.88 (m, 2H), 1.55-1.43 (m, 2H), 1.06, 1.02 (2s, 6H₃), 0.40 (d, $J = 6.6$, 1.5H), 0.37 (d, $J = 6.5$, 1.5H). MS (ESI) m/z 610 ($\text{M}^+ + \text{H}$).

Compound 101

(4S,SR)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5-tert-butyl-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0145] Compound 101 (0.31 g, 89%) as yellow solid was obtained according to the same method as the synthesis of compound 18.

[0146] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.90-7.73 (m, 3H), 6.81-6.75 (m, 1H), 6.58-6.49 (m, 1H), 5.65-5.55 (m, 1H), 4.14-3.91 (m, 2H), 3.74-3.69 (m, 3H), 3.65-3.40 (m, 1H), 3.20-3.10 (m, 1H), 2.58-2.12 (m, 4H), 1.91-1.87 (m, 3H), 1.22-1.18 (m, 6H), 0.95 (d, $J = 2.6$, 9H), 0.41-0.28 (m, 3H). MS (ESI) m/z 630 ($\text{M}^+ + \text{H}$).

Compound 103

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0147] Compound 103 (65 mg, 73%) as colorless oil was obtained according to the same method as the synthesis of compound 80.

[0148] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.84 (s, 1H), 7.71 (m, 2H), 7.21-7.06 (m, 1H), 7.05-6.98 (m, 0.5H), 6.97-6.85 (m, 0.5H), 6.83-6.78 (m, 1H), 5.59-5.30 (m, 1H), 4.85-4.78 (m, 1H), 4.04-3.92 (m, 2H), 3.78-3.72 (m, 3H), 3.55-3.49 (m, 1H), 3.41-3.33 (m, 1H), 2.43-1.90 (m, 6H), 1.47-1.41 (m, 6H), 1.04-1.01 (m, 3H), 0.42-0.30 (m, 3H). MS (ESI) m/z 568.0 ($\text{M}-\text{OH}$).

Compound 104

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0149] Compound 104 (6 mg, 53%) as colorless oil was obtained according to the same method as the synthesis of compound 80.

[0150] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.84 (s, 1H), 7.71 (d, $J = 8.3$, 2H), 7.33-7.30 (m, 1H), 7.18-7.17 (m, 0.5H), 7.078-7.072 (m, 0.5H), 6.82 (d, $J = 8.5$, 0.5H), 6.77 (d, $J = 8.5$, 0.5H), 5.57 (d, $J = 8.1$, 0.5H), 5.48 (d, $J = 8.1$, 0.5H), 4.05-3.90 (m, 2H), 3.77 (s, 1.5H), 3.72 (s, 1.5H), 3.53 (d, $J = 14.5$, 0.5H), 3.38 (d, $J = 14.5$, 0.5H), 2.60-1.70 (m, 6H), 1.55-1.151 (m, 6H), 1.04-1.00 (m, 6H), 0.40 (d, $J = 6.6$, 1.5H), 0.30 (d, $J = 6.6$, 1.5H). MS (ESI) m/z 583 (M^+-OH).

Compound 107

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0151] Compound 107 (34 mg, 48%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0152] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 7.06 (dd, *J* = 8.4, 2.2, 1H), 6.82-6.72 (m, 2H), 5.60-5.57 (m, 1H), 4.01-3.89 (m, 2H), 3.73, 3.70 (2s, 3H), 3.58, 3.44 (2d, *J* = 14.6, 1H), 2.86-2.75 (m, 1H), 2.53-1.86 (m, 4H), 1.54-1.42 (m, 2H), 1.20-1.14 (m, 6H), 1.06-1.01 (m, 6H), 0.38, 0.28 (2d, *J* = 6.5, 3H). MS (ESI) *m/z* 584 (*M*⁺ + H).

Compound 108**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0153] Compound 108 (80 mg, 55%) as yellow oil was obtained according to the same method as the synthesis of compound 18.

[0154] ¹H NMR (400 MHz, CDCl₃); 1:1 atropisomer mixture; δ 7.63 (m, 1H), 7.43-7.32 (m, 2H), 7.04-6.95 (m, 1H), 6.85-6.78 (m, 1H), 6.57-6.45 (m, 1H), 4.77-4.72 (m, 1H), 4.24-4.15 (m, 0.5H), 4.03-3.93 (m, 0.5H), 3.68-3.62 (m, 0.5H), 3.51-3.43 (m, 1.5H), 3.35-3.28 (m, 1.5H), 3.27-3.19 (m, 1.5H), 2.84-2.63 (m, 1H), 2.54-2.38 (m, 2H), 2.33-2.10 (m, 2H), 1.99-1.65 (m, 2H), 1.53-1.39 (m, 1H), 1.24-1.11 (m, 6H), (-)0.01-(-)0.27 (m, 3H). MS (ESI) *m/z* 625 (*M*⁺ + H).

Compound 109**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0155] Compound 109 (87 mg, 93%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0156] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.76 (dd, *J* = 8.7, 3.6, 1H), 6.54, 6.50 (2d, *J* = 12.2, 1H), 5.61 (d, *J* = 8.1, 1H), 3.98-3.87 (m, 2H), 3.70 (d, *J* = 11.7, 3H), 3.55, 3.46 (2d, *J* = 14.7, 1H), 3.15-3.07 (m, 1H), 2.21-2.11 (m, 2H), 1.95-1.81 (m, 2H), 1.53-1.46 (m, 2H), 1.20-1.12 (m, 6H), 1.00-0.86 (m, 6H), 0.42, 0.35 (2d, *J* = 6.5, 3H). MS (ESI) *m/z* 602 (*M*⁺ + H).

Compound 110**N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamide**

[0157] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (48.0 mg, 0.078 mmol) and diisopropylamine (30.0 μl, 0.17 mmol) were dissolved in methylene chloride (1.5 mL). Acetyl chloride (12.3 μl, 0.17 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (4 g silica, 4:1 = hexane/EtOAc), thus obtaining Compound 110 (21.6 mg, 42%) as white solid foam.

[0158] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.85, 7.84 (2s, 1H), 7.82, 7.77 (2s, 2H), 7.49 (d, J = 2.7, 0.5H), 7.35 (dd, J = 8.8, 2.7, 0.5H), 7.13 (d, J = 2.7, 0.5H), 7.12, 7.06 (2brs, 1H), 7.02 (dd, J = 8.8, 2.7, 1H), 6.82-6.78 (m, 1H), 5.61, 5.52 (2d, J = 8.0, 1 H), 4.14-3.92 (m, 2H), 3.76, 3.74 (2s, 3H), 3.57, 3.39 (2d, J = 14.8, 1H), 2.49-2.21 (m, 2H), 2.16-2.12 (2s, 3H₃), 1.96-1.92 (brm, 2H), 1.54-1.41 (m, 2H), 1.04, 1.03, 1.02, 1.00 (4s, 0.41, 0.40, 0.35, 0.33 (4s, 3H, CH₃, 6H). MS (ESI) m/z 600 (M^+ + H).

Compound 111

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)isobutyramide

[0159] Compound 111 (38.8 mg, 72%) as yellow solid foam was obtained according to the same method as the synthesis of compound 110.

[0160] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.79, 7.77 (2s, 2H), 7.56 (d, J = 2.7, 0.5H), 7.32 (dd, J = 8.8, 2.7, 0.5H), 7.22 (d, J = 2.7, 0.5H), 7.08 (brs, 0.5H), 7.04 (dd, J = 8.8, 2.7, 0.5H), 7.02 (brs, 0.5H), 6.82-6.78 (m, 1H), 5.62, 5.51 (2s, 3H), 3.54, 3.41 (2d, J = 14.8, 1H), 2.52-2.08 (m, 3H), 1.94-1.92 (br m, 2H), 1.54-1.41 (m, 2H), 1.24-1.18 (m, 6H), 1.04, 1.03, 1.02, 1.00 (4s, 6H), 0.41, 0.40, 0.38, 0.37 (4s, 3H). MS (ESI) m/z 627 (M^+ + H).

Compound 112

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide

[0161] Compound 110 (18 mg, 0.03 mmol) was dissolved in anhydrous tetrahydropuran (1 mL). Sodium hydride (4 mg, 0.09 mmol) was added dropwise to the obtained solution at 0°C, and stirred at room temperature for 30 minutes. Iodomethane (9.4 μL , 0.15 mmol) was added dropwise slowly to the reaction mixture at 0°C, and then stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 112 (14 mg, 76%) as white solid foam.

[0162] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.88 (s, 1H), 7.74 (s, 2H), 7.08-7.05 (m, 1H), 6.90-6.82 (m, 2H), 5.64 (d, J = 7.9, 1H), 4.05-3.91 (m, 2H), 3.81, 3.78 (2s, 3H), 3.53, 3.43 (2d, J = 14.8, 1H), 3.23, 3.17 (2s, 3H), 2.54-2.19 (m, 2H), 1.85, 1.82 (2s, 3H), 1.57-1.43 (m, 2H), 1.07, 1.05, 1.03, 1.02 (4s, 6H), 0.48, 0.46, 0.36, 0.35 (4s, 3H). MS (ESI) m/z 613 (M^+ + H).

Compound 113

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramide

[0163] Compound 113 (28 mg, 86%) as yellow foam was obtained according to the same method as the synthesis of compound 112.

[0164] ^1H NMR (400 MHz, CDCl_3) atropisomer mixture; δ 7.88 (s, 1H), 7.75 (s, 2H), 7.07 (m, 1H), 6.90-6.82 (m, 2H), 5.63 (d, J = 8.1, 1H), 4.06-3.92 (m, 2H), 3.81, 3.78 (2s, 3H), 3.53, 3.43 (2d, J = 14.8, 1H), 3.21, 3.15 (2s, 3H), 2.52-2.15 (m, 3H), 1.99-1.87 (m, 2H), 1.56-1.40 (m, 2H), 1.06-0.94 (m, 12H), 0.47, 0.45, 0.37, 0.35 (4s, 3H). MS (ESI) m/z 641 (M^+ + H).

Compound 114**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(methoxymethyl)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0165] Compound 9 was subjected to a Suzuki reaction with 6-(trifluoromethyl)benzo[c][1,2]oxaborol-1(3H)-ol, and then, the obtained intermediate compound was used as the same method as the synthesis of Compound 47, to obtain Compound 114 (60 mg, 74%) as white solid.

[0166] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 3H), 7.55-7.47 (m, 1H), 7.13 (d, *J* = 7.8, 1H), 5.64, 5.57 (2d, *J* = 8.1, 1H), 4.36-4.26 (m, 2H), 4.01-3.81 (m, 2H), 3.71-3.21 (m, 1H), 3.43 (d, *J* = 4.1, 3H), 2.23-2.18 (m, 2H), 1.99-1.90 (m, 2H), 1.55-1.46 (m, 2H), 1.07-0.87 (m, 6H), 0.55, 0.38 (2d, *J* = 6.5, 3H). MS (ESI) *m/z* 624 (*M*⁺ + H).

Compound 115**(4S,SR)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0167] Compound 115 (9 mg, 39%) as a gray solid was obtained according to the same method as the synthesis of compound 18.

[0168] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1H), 7.71 (s, 2H), 7.22-7.19 (m, 1H), 6.95 (dd, *J* = 12.6, 2.5, 1 H), 6.80-6.72 (m, 1H), 5.60-5.54 (m, 1H), 4.00-3.86 (m, 2H), 3.73 (d, *J* = 9.9, 3H), 3.57, 3.43 (2d, *J* = 14.7, 1H), 2.55-2.04 (m, 2H), 1.93-1.91 (m, 2H), 1.52-1.42 (m, 2H), 1.28-1.23 (m, 9H), 1.04-1.00 (m, 6H), 0.36, 0.26 (2d, *J* = 6.5, 3H). MS (ESI) *m/z* 598 (*M*⁺ + H).

Compound 116**N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)acetamide**

[0169] 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzaldehyde (32 mg, 0.06 mmol), which is a starting material, and 2,2,2-trifluoroethane amine (5.4 μl, 0.067 mmol) were dissolved in methylene chloride (2 mL). The obtained solution was stirred at room temperature overnight. Sodium cyanoborohydride (4 mg, 0.056 mmol) and acetic acid (3.2 μl, 0.06 mmol) were added dropwise to the solution, and stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was neutralized with saturated sodium hydrogen carbonate solution, extracted with methylene chloride, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained intermediate compound (39 mg, 0.06 mmol) was dissolved in methylene chloride (2 mL). Diisopropylethylamine (26 μl, 0.15 mmol) and acetyl chloride (4.6 μl, 0.06 mmol) were added dropwise carefully to the obtained solution, and stirred at room temperature for 2 hours. The reaction was quenched with water. The reaction mixture was extracted with methylene chloride, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (silica, 20 ~ 50% Hexane/EtOAc), thus obtaining Compound 116 (25 mg, 61%) as colorless oil.

[0170] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, *J* = 12.2, 2H), 7.08-6.98 (m, 1H), 6.88-6.75 (m, 2H), 5.62-5.54 (m, 1H), 4.67-4.53 (m, 2H), 4.03-3.90 (m, 4H), 3.78-3.69 (m, 3H), 3.50-3.31 (m, 1H), 2.21-2.15 (m, 2H), 2.04 (s, 3H), 1.92-1.88 (m, 2H), 1.52-1.45 (m, 2H), 1.05-1.00 (m, 6H), 0.43, 0.34 (dt, *J* = 5.9, 6.5, 3H). MS (ESI) *m/z* 695 (*M*⁺ + H).

Compound 117**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0171] Compound 117 (27.8 mg, 67%) as colorless oil was obtained according to the same method as the synthesis of compound 18.

[0172] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (s, 2H), 7.11-7.08 (m, 1H), 6.89-6.81 (m, 2H), 4.01-3.89 (m, 2H), 3.79, 3.77 (2s, 3H), 3.56, 3.39 (2d, $J = 14.8$, 1H), 2.50-2.04 (m, 2H), 1.99-1.89 (m, 2H), 1.54-1.45 (m, 2H), 1.05, 1.05, 1.02, 1.019 (4s, 6H), 0.40, 0.39, 0.37, 0.35 (4s, 3H). MS (ESI) m/z 626 ($\text{M}^+ + \text{H}$).

Compound 118**N-acetyl-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetamide**

[0173] Compound 118 (0.15 g, 79%) as yellow solid was obtained according to the same method as the synthesis of compound 71.

[0174] MS (ESI) m/z 641 ($\text{M}^+ + \text{H}$).

Compound 120**N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoro-N-methylacetamide**

[0175] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (0.16 g, 0.29 mmol), a starting material, was reacted with di-tert-butyl carboxylate. The obtained intermediate compound was subjected to methylation, and then subjected to deprotection using hydrogen chloride, thus obtaining (4S,5R)-5-(bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxooxazolidin-2-one. The obtained compound (40 mg, 0.07 mmol), a starting material, was dissolved in methylene chloride (1.5 mL). Trifluoroacetic anhydride (TFAA) (20 μL , 0.14 mmol) was added dropwise to the obtained solution at room temperature diisopropylamine (37 μL , 0.21 mmol), and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by Prep TLC (silica, 25% hexane/EtOAc), thus obtaining Compound 120 (37 mg, 80%) as yellow oil.

[0176] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 7.12-7.09 (m, 1H), 6.89-6.83 (m, 2H), 5.61 (d, $J = 8.0$, 1H), 4.01-3.84 (m, 2H), 3.81, 3.78 (2s, 3H), 3.54-3.42 (m, 1H), 3.32 (s, 1.8H), 3.27 (s, 1.2H), 2.50-1.90 (m, 4H), 1.53-1.42 (m, 2H), 1.38, 1.29 (2d, $J = 6.5$, 3H), 1.04-0.99 (m, 6H).

Compound 121**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopyrrolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0177] As shown in reaction scheme 4, 3-iodo-4-methoxyaniline, a starting material, was subjected to acylation using acyl chloride and then reacted with sodium methoxide, a base, to synthesize a compound forming a ring. The obtained compound was reacted with bis(pinacolato)diborane to synthesize a pinacolato intermediate compound. The obtained pinacolato compound (0.05 g, 0.16 mmol) was subjected to a Suzuki reaction with Compound 9 (0.09 g, 0.138 mmol), thus obtaining Compound 121 (29 mg, 30%) as brown oil.

[0178] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (d, J = 7.4, 2H), 7.77 (m, 1H), 7.09-7.60 (m, 2H), 6.84 (t, J = 1.0, 1H), 5.62 (d, J = 7.9, 0.5H), 5.52 (d, J = 8.0, 0.5H), 3.70-4.12 (m, 4H), 3.80-3.82 (m, 3H), 2.12-2.60 (m, 6H), 2.05-2.11 (m, 2H), 1.45-2.11 (m, 2H), 1.01-1.04 (m, 6H), 0.31-0.42 (m, 3H). MS (ESI) m/z 626 (M^+ + H).

Compound 122

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopiperidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0179] Compound 122 (18 mg, 21%) as brown oil was obtained according to the same method as the synthesis of compound 121.

[0180] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.83 (s, 1H), 7.81 (s, 2H), 6.82-7.17 (m, 3H), 5.58 (d, J = 8.0, 0.5H), 5.47 (d, J = 7.9, 0.5H), 3.95-4.02 (m, 2H), 3.78 (d, J = 4.6, 3H), 3.44-3.75 (m, 3H), 2.50-2.55 (m, 2H), 2.05-2.15 (m, 2H), 1.91-1.96 (m, 6H), 1.43-1.49 (m, 2H), 0.99-1.03 (m, 6H), 0.37-0.42 (m, 3H). MS (ESI) m/z 640 (M^+ + H).

Compound 123

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(5,5-difluoro-2-(4-fluoro-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0181] Compound 123 (45 mg, 58%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0182] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.81-6.77 (m, 1H), 6.59-6.51 (m, 1H), 5.65-5.62 (m, 1H), 3.99-3.86 (m, 3H), 3.73 (s, 1.5H), 3.70 (s, 1.5H), 3.57 (d, J = 14.8, 1H), 3.46 (d, J = 14.8, 1H), 3.15-3.09 (m, 1H), 2.70-2.47 (m, 6H), 1.32-1.13 (m, 6H), 0.40 (d, J = 6.5, 1.5H), 0.33 (d, J = 6.5, 1.5H).

Compound 124

methyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamate

[0183] Compound 124 (18 mg, 55%) as yellow oil was obtained according to the same method as the synthesis of compound 120.

[0184] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.75 (s, 2H), 7.07-7.03 (m, 1H), 7.00-6.83 (m, 1H), 6.84-6.77 (m, 1H), 5.60-5.51 (m, 1H), 4.00-3.90 (m, 2H), 3.76 (d, J = 5.4, 3H), 3.68-3.57 (m, 3H), 3.55-3.42 (m, 1H), 3.34, 3.25 (2s, 3H), 2.40-2.04 (m, 2H), 1.92-1.88 (m, 2H), 1.52-1.41 (m, 2H), 1.03-1.00 (m, 6H), 0.41, 0.36 (2d, J = 6.0, 3H).

Compound 128

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethanesulfonamide

[0185] Compound 128 (30 mg, 59%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0186] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (d, *J* = 3.8, 1H), 7.76 (d, *J* = 10.2, 2H), 7.02-7.24 (m, 2H), 6.83-6.88 (m, 1H), 5.58 (t, *J* = 9.6, 1H), 3.92-4.02 (m, 2H), 3.82 (d, *J* = 1.0, 3H), 3.38-3.57 (m, 1H), 3.28 (d, *J* = 13.8, 3H), 2.81 (d, *J* = 28.0, 3H), 2.10-2.47 (m, 2H), 1.94-2.02 (m, 2H), 1.44-1.51 (m, 2H), 1.02-1.06 (m, 6H), 1.36-1.48 (m, 3H). MS (ESI) *m/z* 650 (*M*⁺ + H).

Compound 130

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-N-methylpropanamide

[0187] Compound 130 (17 mg, 43%) as yellow oil was obtained according to the same method as the synthesis of compound 120.

[0188] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (d, *J* = 5.0, 2H), 7.07-7.03 (m, 1H), 6.92-6.83 (m, 2H), 5.61 (t, *J* = 8.0, 1H), 4.05-3.91 (m, 2H), 3.82, 3.78 (2s, 3H), 3.51-3.35 (m, 1H), 3.26, 3.19 (2s, 3H), 2.98-2.88 (m, 2H), 2.48-1.97 (m, 2H), 1.93-1.86 (m, 2H), 1.55-1.44 (m, 2H), 1.03-0.97 (m, 6H), 0.47, 0.39 (2d, *J* = 6.0, 3H). MS (ESI) *m/z* 681, 682 (*M*⁺+1, *M*⁺+2).

Compound 132

(4S,5R)-5-(3,5-bis(trifluoromethyl)-phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0189] 2-Fluoro-4-methoxyacetophenone, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was subjected to a Suzuki reaction with Compound 2, thus synthesizing an aldehyde compound. The obtained aldehyde compound was reacted with Compound 4 to synthesize an amino alcohol compound, as an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 132 (24 mg, 68%) as colorless oil.

[0190] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.94-6.96 (m, 1H), 6.57-6.64 (m, 2H), 5.53-5.62 (m, 1H), 3.80-3.99 (m, 2H), 3.77-3.78 (m, 3H), 3.75-3.80 (m, 1H), 1.20-2.50 (m, 6H), 1.45-1.52 (m, 3H), 1.00-1.05 (m, 6H), 0.30-0.43 (m, 3H). MS (ESI) *m/z* 657 (*M*⁺ + H).

Compound 133

Methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetate

[0191] As shown in reaction scheme 4, pinacolato compound was synthesized. The obtained pinacolato compound (0.1 g, 0.33 mmol), Compound 9 (0.17 g, 0.167 mmol), palladium catalyst (10 mg, 0.02 mmol) and sodium carbonate (70 mg, 0.65 mmol) were dissolved in dimethoxyethane/water (5 mL). The obtained solution was refluxed with stirring in microvessel at 120°C for 15 minutes. After the completion of the reaction, the reaction was quenched with saturated ammonium chloride solution. The reaction product was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 1:1 = Hexane/EtOAc), thus obtaining Compound 133 (91 mg, 45%) as brown oil.

[0192] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.76 (d, J = 7.0, 2H), 7.09-7.13 (m, 1H), 6.76-6.93 (m, 2H), 5.61 (d, J = 8.1, 0.5H), 5.55 (d, J = 8.0, 0.5H), 3.90-4.03 (m, 2H), 3.75 (d, J = 7.3, 3H), 3.64 (d, J = 38.0, 3H), 3.41-3.68 (m, 2H), 3.41-3.68 (m, 1H), 2.04-2.53 (m, 2H), 1.89-1.98 (m, 2H), 1.42-1.54 (m, 2H), 1.01-1.04 (m, 6H), 0.33-0.37 (m, 3H). MS (ESI) m/z 615 ($\text{M}^+ + \text{H}$).

Compound 134

2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetic acid

[0193] Compound 133 (0.08 g, 0.13 mmol) was dissolved in dioxan/water (5 mL V/V 2:1). Lithium hydroxide (0.06 g, 1.32 mmol) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 6 hours. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 1:1 = Hexane/EtOAc), thus obtaining Compound 134 (60 mg, 76%) as brown oil.

[0194] ^1H NMR (400 MHz, CDCl_3); 1:1.3 atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, J = 5.4, 2H), 7.09-7.13 (m, 1H), 6.77-6.91 (m, 2H), 5.58 (t, J = 7.7, 1H), 3.92-4.02 (m, 2H), 3.70-3.76 (m, 3H), 3.41-3.60 (m, 2H), 3.41-3.60 (m, 1H), 2.17-2.50 (m, 2H), 1.88-1.97 (m, 2H), 1.41-1.54 (m, 2H), 1.04-1.07 (m, 6H), 0.41 (d, J = 6.5, 1.3H), 0.33 (d, J = 6.5, 1.7H). MS (ESI) m/z 601 ($\text{M}^+ + \text{H}$).

Compound 136

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanesulfonamide

[0195] Compound 136 (37 mg, 63%) as yellow solid was obtained according to the same method as the synthesis of compound 110.

[0196] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.74 (d, J = 6.4, 2H), 7.16, 7.08 (2dd, J = 8.7, 2.7, 1H), 7.04, 6.94 (2d, J = 2.7, 1H), 6.83-6.78 (m, 1H), 6.35-6.28 (m, 1H), 5.59 (dd, J = 4.5, 8.0, 1H), 4.04-3.92 (m, 2H), 3.76, 3.74 (2s, 3H), 3.54, 3.39 (2d, J = 14.0, 1H), 2.46-2.01 (m, 3H), 1.92 (bs, 2H), 1.53-1.43 (m, 2H), 1.12-1.06 (m, 2H), 1.06-1.03 (m, 6H), 1.02-0.82 (m, 2H), 0.43, 0.38 (2d, J = 6.5, 3H).

Compound 137

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoromethanesulfonamide

[0197] Compound 137 (43 mg, 98%) as white solid was obtained according to the same method as the synthesis of compound 110.

[0198] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, J = 4.9, 2H), 7.29-7.25 (m, 1H), 7.21-6.99 (m, 1H), 6.96-6.81 (m, 1H), 5.63-5.51 (m, 1H), 3.98-3.87 (m, 2H), 3.84 (d, J = 5.2, 2H), 3.77 (d, J = 8.3, 1H), 3.56, 3.37 (2d, J = 15.0, 1H), 2.46-1.99 (m, 2H), 1.95-1.91 (m, 2H), 1.55-1.40 (m, 2H), 1.04-0.95 (m, 6H), 0.37-0.33 (m, 3H). MS (ESI) m/z 689 (M^+ + H).

Compound 138

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylcyclopropanesulfonamide

[0199] Compound 138 (21 mg, 66%) as yellow solid was obtained according to the same method as the synthesis of compound 112.

[0200] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.75 (d, J = 4.6, 2H), 7.27-7.20 (m, 1H), 7.10, 7.04 (2d, J = 2.7, 1H), 6.83 (dd, J = 12.1, 8.8, 1H), 5.57 (dd, J = 14.9, 8.0, 1H), 4.01-3.91 (m, 2H), 3.77 (d, J = 7.1, 3H), 3.56, 3.41 (2d, J = 14.6, 1H), 3.30, 3.25 (2s, 3H), 2.47-2.22 (m, 3H), 1.92 (bm, 2H), 1.51-1.44 (m, 2H), 1.11-0.84 (m, 4H), 1.02-1.00 (m, 6H), 0.39 (dd, J = 6.5, 2.4, 3H). MS (ESI) m/z 675 (M^+ + H).

Compound 140

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylthiourea

[0201] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (30 mg, 0.049 mmol) was dissolved in ethanol. Isothiocyanato methane (an excess amount) was added dropwise to the obtained solution, and then refluxed with stirring. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 15% ~ 35% = hexane/EtOAc), thus obtaining Compound 140 (20 mg, 59%) as white solid.

[0202] ^1H NMR (400 MHz, CDCl_3); 1:2 atropisomer mixture; δ 7.86 (s, 1H), 7.75 (s, 1H), 7.72 (s, 1H), 7.08-6.96 (m, 1H), 6.92-6.87 (m, 2H), 5.63 (m, 0.5H), 5.42-5.40 (m, 0.5H), 4.32-4.29 (m, 0.5H), 4.18-4.10 (m, 1H), 3.96-3.92 (m, 0.5H), 3.87 (s, 2H), 3.76 (s, 1H), 3.18-3.10 (m, 3H), 2.45-2.39 (m, 1H), 2.2.08-1.87 (m, 2H), 1.80-1.71 (m, 3H), 1.03-1.00 (m, 6H), 0.62-0.60 (d, J = 6.4, 2H), 0.52-0.51 (d, J = 6.4, 1H). MS(ESI) 630 ($\text{M}+\text{H}$) $^+$.

Compound 141

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluoro-N-methylmethanesulfonamide

[0203] Compound 141 (23 mg, 62%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0204] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (d, J = 4.1, 2H), 7.24-7.17 (m, 1H), 7.03, 6.99 (2d, J = 2.7, 1H), 6.86 (dd, J = 13.4, 8.8, 1H), 5.58, 5.52 (2d, J = 8.0, 1H), 3.97-3.81 (m, 2H), 3.79 (d, J = 7.0, 3H), 3.56 (d, J = 15.0, 0.5H), 3.42 (d, J = 15.3, 3H), 3.36 (d, J = 14.9, 0.5H), 2.46-2.04 (m, 2H), 1.99-1.94 (m, 2H), 1.55-1.42 (m, 2H), 1.02 (d, J = 11.6,

6H), 0.37, 0.32 (2d, $J = 6.5$, 3H). MS (ESI) m/z 703 ($M^+ + H$).

Compound 142

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxoimidazolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0205] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (50 mg, 0.081 mmol) was reacted with 2-bromoethane amine (20 mg, 0.10 mmol) to synthesize an intermediate compound. The obtained intermediate compound (0.1 g, 0.167 mmol), diisopropylethylamine (43 μ L, 0.25 mmol) and triphosgene (25 mg, 0.08 mmol) were dissolved in methylene chloride (3 mL). The obtained solution was stirred at room temperature. After the completion of the reaction, the reaction was quenched with saturated ammonium solution. The reaction mixture was extracted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 10% - 20% = hexane/EtOAc), thus obtaining Compound 142 (61.6 mg, 59%) as white solid.

[0206] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.83 (s, 1H), 7.73 (s, 2H), 7.54-7.53 (m, 0.5H), 7.32-7.25 (m, 0.5H), 7.10-7.07 (m, 0.5H), 6.88-6.83 (m, 1H), 5.59-5.51 (dd, $J = 8.2$, 23.7, 1H), 5.50-5.48 (d, $J = 7.9$, 0.5H), 4.09-3.86 (m, 2H), 3.74-3.67 (m, 3H), 3.57-3.53 (d, $J = 14.7$, 0.5H), 3.41-3.37 (d, $J = 4.7$, 0.5H), 2.45-2.41 (m, 0.5H), 2.24-2.22 (m, 1H), 2.17-2.13 (m, 0.5H), 1.93-1.91 (m, 3H), 1.61 (brs, 2H), 1.51-1.41 (m, 3H), 1.02-1.00 (m, 6H), 0.39-0.35 (m, 3H). MS (ESI) m/z 626 ($M^+ + H$).

Compound 143

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxooxazolidin-3-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0207] Compound 143 (10 mg, 32%) as white solid was obtained according to the same method as the synthesis of compound 142.

[0208] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.83 (s, 1H), 7.77-7.72 (m, 2H), 7.29 (m, 0.5H), 7.17-7.16 (m, 0.5H), 7.14-7.07 (m, 0.5H), 6.97-6.94 (0.5H), 6.80-6.75 (m, 1H), 6.49-6.44 (m, 1H), 5.61-5.59 (d, $J = 7.9$, 0.5H), 5.50-5.48 (d, $J = 7.9$, 0.5H), 4.09-3.86 (m, 2H), 3.74-3.67 (m, 3H), 3.57-3.53 (d, $J = 14.7$, 0.5H), 3.41-3.37 (d, $J = 14.7$, 0.5H), 2.45-2.41 (m, 0.5H), 2.24-2.22 (m, 1H), 2.17-2.13 (m, 0.5H), 1.93-1.91 (m, 3H), 1.61 (brs, 2H), 1.51-1.41 (m, 3H), 1.02-1.00 (m, 6H), 0.39-0.35 (m, 3H). MS (ESI) m/z 627 ($M^+ + H$).

Compound 144

(4S,5R)-3-((2-(2-amino-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0209] Compound 144 (54 mg, 50%) as brown oil was obtained according to the same method as the synthesis of compound 132.

[0210] ^1H NMR (400 MHz, CDCl_3); 1:2 atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.63-6.96 (m, 3H), 5.63 (d, $J = 8.0$, 0.68H), 5.54 (d, $J = 8.1$, 0.32H), 3.71-4.04 (m, 2H), 3.49 (d, $J = 14.6$, 1H), 2.70-2.81 (m, 1H), 2.21-2.31 (m, 2H), 1.90-2.05 (m, 2H), 1.48-1.55 (m, 2H), 1.10-1.31 (m, 6H), 1.04-1.09 (m, 6H), 0.57 (d, $J = 6.5$, 1H), 0.33 (d, $J = 6.5$, 2H). MS (ESI) m/z 569 ($M^+ + H$).

Compound 145

N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)-N-methylacetamide

[0211] According to the same method as the synthesis of compound 110, compound 166 was synthesized and then reacted with iodomethane to obtain Compound 145 (10 mg, 45%) as yellow oil.

[0212] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.90 (s, 1H), 7.79 (d, J = 15.0, 2H), 6.90-7.20 (m, 3H), 5.70-5.73 (m, 1H), 3.94-4.13 (m, 2H), 3.13-3.41 (m, 1H), 2.87-3.24 (m, 3H), 2.82-3.00 (m, 1H), 1.62-2.30 (m, 4H), 1.44-1.49 (m, 2H), 1.17-1.29 (m, 6H), 1.00-1.29 (m, 6H), 0.42-0.72 (m, 3H). MS (ESI) m/z 625 (M^+ + H).

Compound 146

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,1-dimethylurea

[0213] Compound 146 (21 mg, 55%) as colorless oil was obtained according to the same method as the synthesis of compound 110.

[0214] ^1H NMR (400 MHz, CDCl_3) atropisomer mixture; δ 7.82 (s, 1H), 7.79 (d, J = 6.2, 2H), 7.77-7.11 (m, 1H), 7.09-6.92 (m, 1H), 6.76 (t, J = 9.0, 1H), 6.14 (d, J = 14.4, 1H), 5.59, 5.44 (2d, J = 7.9, 1H), 4.05-3.91 (m, 2H), 3.73 (s, 3H), 3.52-3.41 (m, 1H), 3.00 (d, J = 15.4, 6H), 2.42-2.09 (m, 2H), 1.93-1.89 (m, 2H), 1.50-1.41 (m, 2H), 1.01-0.99 (m, 6H), 0.40, 0.36 (2d, J = 6.5, 3H). MS (ESI) m/z 628 (M^+ + H).

Compound 147

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methylthio)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0215] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (50 mg, 0.076 mmol), a starting material, was dissolved in chloroform (1.5 mL). Dimethyl sulfide (10 μL , 0.11 mmol) and tert-butyl nitrile (18 μL , 0.15 mmol) were added dropwise to the obtained solution at room temperature, stirred at room temperature for 30 minutes, and then refluxed with stirring and heating for 3 hours. After the completion of the reaction, the reaction mixture was cooled down to room temperature, diluted with n-hexane, and immediately purified by column chromatography (silica, 20% Hexane/EtOAc), thus obtaining Compound 147 (9 mg, 21 %) as yellow oil.

[0216] (ESI) m/z (586.2 neg. (M^+ - H)).

Compound 148

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((5,5-dimethyl-2-(2-(methylthio)-5-(trifluoromethoxy)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0217] Compound 148 (25 mg, 50%) as yellow solid was obtained according to the same method as the synthesis of compound 57.

[0218] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 7.12-7.10 (m, 2H), 6.85-6.83 (m, 1H), 5.64, 5.61 (2d, *J* = 8.0, 1H), 4.10-4.05 (m, 1H), 3.91-3.83 (m, 1H), 3.54, 3.28 (2d, *J* = 15.0, 1H), 2.60-2.00 (m, 2H), 2.41 (s, 3H), 1.94 (bm, 2H), 1.56-1.46 (m, 2H), 1.08-1.03 (m, 6H), 0.50, 0.37 (2d, *J* = 6.5, 3H).

Compound 151

(E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-3-methylguanidine

[0219] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (70 mg, 0.113 mmol), a starting material, was reacted with diphenyl cyanocarboimide to synthesize an intermediate compound. The obtained intermediate compound (70 mg, 0.1 mmol) and methylamine (13 mg, 0.2 mmol) were dissolved in acetonitrile (3 mL). The obtained solution was refluxed with stirring at 80°C. After the completion of the reaction, the reaction mixture was diluted with methylene chloride, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 25% ~ 35% = Hexane/EtOAc), thus obtaining Compound 151 (30 mg, 47%) as white solid.

[0220] ¹H NMR (400 MHz, CDCl₃); 1:2 atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 1H), 7.67 (s, 1H), 7.09-7.05 (m, 1H), 6.95-6.87 (m, 2H), 5.40-5.38 (m, 1H), 4.36-4.32 (m, 0.5H), 4.22-4.18 (m, 1H), 3.94-3.91 (m, 0.5H), 3.88 (s, 2H), 3.76 (s, 1H), 3.08-3.05 (m, 1H), 2.84-2.80 (m, 3H), 2.50-2.37 (m, 1H), 2.08-1.91 (m, 3H), 1.69 (brs, 2H), 1.56-1.42 (m, 2H), 1.03-0.97 (m, 6H), 0.64-0.62 (d, *J* = 6.6, 2H), 0.57-0.56 (d, *J* = 6.5, 1H). MS (ESI) 638 (M+H)⁺.

Compound 149

(Z)-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,1-dimethylguanidine

[0221] Compound 149 (20 mg, 51 %) as white solid was obtained according to the same method as the synthesis of compound 151.

[0222] ¹H NMR (400 MHz, CDCl₃); 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.74-7.72 (m, 2H), 6.95-6.91 (m, 1H), 6.84-6.75 (m, 1H), 6.70-6.68 (m, 1H), 5.61-5.55 (dd, *J* = 8.1, 17.2, 1H), 4.07-3.92 (m, 2H), 3.88 (s, 1.5H), 3.76 (s, 1.5H), 3.63-3.59 (d, *J* = 14.6, 0.5H), 3.51-3.47 (d, *J* = 14.6, 0.5H), 2.95-2.92 (m, 6H), 2.45-2.22 (m, 2H), 1.92 (s, 2H), 1.65 (brs, 2H), 1.49-1.43 (m, 1H), 1.03-0.94 (m, 6H), 0.52-0.50 (d, *J* = 6.5, 1.5H), 0.42-0.41 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 652 (M⁺ + H).

Compound 153

(E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,3,3-trimethylguanidine

[0223] Compound 153 (5 mg, 25%) as white solid was obtained according to the same method as the synthesis of compound 47.

[0224] ¹H NMR (400 MHz, CDCl₃) 1:1 atropisomer mixture; δ 7.85 (s, 1H), 7.74-7.72 (m, 2H), 6.89-6.79 (m, 2H), 6.67-6.62 (m, 1H), 5.63-5.58 (m, 1H), 4.04-3.89 (m, 2H), 3.76-3.73 (m, 3H), 3.55-3.43 (m, 1H), 3.37-3.31 (m, 3H), 2.81-2.79 (m, 6H), 2.40-2.20 (m, 1H), 1.99 (s, 2H), 1.53-1.49 (m, 4H), 1.04-0.96 (m, 6H), 0.49-0.48 (d, *J* = 6.5, 1.5H), 0.39-0.37 (d, *J* = 6.5, 1.5H). MS (ESI) *m/z* 666 (M⁺ + H).

Compound 156

(Z)-methyl N-3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl-N'-methylcarbamimidothioate

[0225] Compound 156 (16 mg, 64%) as colorless oil was obtained according to the same method as the synthesis of compound 47.

[0226] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, *J* = 9.1, 2H), 7.11-7.08 (m, 1H), 6.90-6.83 (m, 2H), 5.60, 5.53 (2d, *J* = 8.0, 1H), 4.64-4.63 (m, 0.5H), 4.29-4.27 (m, 0.5H), 4.19-3.95 (m, 2H), 3.82, 3.75 (2s, 3H), 3.45, 3.21 (2d, *J* = 15.0, 1H), 3.21, 3.16 (2s, 3H), 2.71 (dd, *J* = 14.7, 4.7, 3H), 2.45-2.0 (m, 2 H), 1.92 (s, 2H), 1.51-1.46 (m, 2H), 1.04-1.00 (m, 6H), 0.53, 0.41 (2 d, *J* = 6.6 Hz, 3H).

Compound 157

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,3,3-trimethylurea

[0227] Compound 157 (8 mg, 44%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0228] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.95-6.91 (m, 1H), 6.79, 6.77 (dd, *J* = 8.8, 1 H), 6.72 (dd, *J* = 13.0, 2.7, 1 H), 5.61 (dd, *J* = 4.4, 8.0, 1H), 4.02-3.89 (m, 2H), 3.74 (d, *J* = 8.9, 3H), 3.53, 3.44 (2d, *J* = 14.0, 1H), 3.13, 3.06 (2s, 3H), 2.65 (d, *J* = 12.3, 6H), 2.50-2.00 (m, 2H), 2.07-2.04 (m, 2H), 1.50-1.45 (m, 2H), 1.04-0.99 (m, 6H), 0.43, 0.33 (2d, *J* = 6.5, 3H). MS (ESI) *m/z* 642 (*M*⁺ + H).

Compound 159

methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate

[0229] Compound 159 (30 mg, 32%) as brown oil was obtained according to the same method as the synthesis of compound 133.

[0230] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1H), 7.73-7.75 (m, 2H), 7.13-7.16 (m, 1H), 6.77-6.96 (m, 2H), 5.31-5.61 (m, 1H), 3.89-4.00 (m, 2H), 3.73-3.75 (m, 3H), 3.53-3.68 (m, 3H), 3.53-3.68 (m, 1H), 3.37-3.68 (m, 1H), 1.94-2.47 (m, 6H), 1.44-1.59 (m, 3H), 1.01-1.25 (m, 6H), 0.27-0.38 (m, 3H). MS (ESI) *m/z* 628 (*M*⁺ + H).

Compound 160

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,1,1-trifluoropropan-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0231] According to the same method as the synthesis of Compound 133, 3-iodo-4-methoxyaniline, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 160 (72 mg, 38%) as brown oil.

[0232] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (m, 2H), 6.67-6.77 (m, 1H), 6.52-6.56 (m, 1H), 6.33-6.36 (m, 1H), 5.57-5.60 (m, 1H), 4.00-4.04 (m, 1H), 3.84-3.99 (m, 2H), 3.69 (d, J = 8.2, 3H), 3.46-3.64 (m, 1H), 3.34 (br s, 1H), 1.43-2.50 (m, 6H), 1.33-1.41 (m, 3H), 0.97-1.04 (m, 6H), 0.32-0.46 (m, 3H), 1.01-1.04 (m, 6H), 0.33-0.37 (m, 3H). MS (ESI) m/z 653 ($\text{M}^+ + \text{H}$).

Compound 161

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(1,1,1-trifluoropropan-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0233] Compound 161 (25 mg, 54%) as yellow oil was obtained according to the same method as the synthesis of compound 112.

[0234] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.69-6.81 (m, 2H), 6.48-6.52 (m, 1H), 5.56-5.60 (m, 1H), 4.10-4.14 (m, 1H), 3.90-4.02 (m, 2H), 3.69-3.72 (m, 3H), 3.43-3.69 (m, 1H), 2.80 (d, J = 15.6, 3H), 2.05-2.48 (m, 2H), 1.93 (s, 2H), 1.47-1.55 (m, 2H), 1.34-1.48 (m, 3H), 1.01-1.05 (m, 6H), 0.31-0.45 (m, 3H). MS (ESI) m/z 666 ($\text{M}^+ + \text{H}$).

Compound 162

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoroacetamide

[0235] Compound 162 (0.21 mg, 92%) as yellow foam was obtained according to the same method as the synthesis of compound 18.

[0236] MS (ESI) m/z 653 ($\text{M}^+ + \text{H}$).

Compound 163

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-bromoacetamide

[0237] Compound 163 (44 mg, 100%) as yellow oil was obtained according to the same method as the synthesis of compound 110.

[0238] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.11, 8.04 (2s, 1H), 7.84 (d, J = 5.5, 1H), 7.79, 7.74 (2s, 1H), 7.43-7.36 (m, 1H), 7.15-7.09 (m, 1H), 6.82 (t, J = 9.1, 1H), 5.60, 5.52 (2d, J = 8.0, 1H), 4.08-3.90 (m, 4H), 3.75 (d, J = 7.3, 3H), 3.57, 3.38 (2d, J = 14.7, 1H), 2.24-2.03 (m, 2H), 1.93 (d, J = 11.2, 2H), 1.51-1.41 (m, 2H), 1.01 (dd, J = 10.0, 4.4, 6H), 0.39, 0.34 (2d, J = 6.5, 3H). MS (ESI) m/z 676.0, 679.0 ($\text{M}^+ - 1$, $\text{M}^+ + 2$).

Compound 166

N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)acetamide

[0239] Compound 166 (25 mg, 44%) as colorless oil was obtained according to the same method as the synthesis of compound 110.

[0240] ^1H NMR (400 MHz, CDCl_3): 1:1.2 atropisomer mixture; δ 7.88 (s, 1H), 7.78 (s, 2H), 6.98-7.25 (m, 3H), 5.64-5.67 (m, 1H), 3.77-4.02 (m, 2H), 3.41-3.49 (m, 1H), 2.86-2.98 (m, 1H), 2.52 (s, 1H), 2.47 (s, 2H), 2.14-2.22 (m, 2H), 1.83-1.99 (m, 2H), 1.41-1.50 (m, 2H), 1.22 - 1.31 (m, 6H), 0.90-1.03 (m, 6H), 0.71 (d, J = 6.4, 1H), 0.57 (d, J = 6.5, 2H). MS (ESI) m/z 611 (M^+ + H).

Compound 167

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-isopropyl-2-(methylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0241] Compound 167 (13 mg, 11%) as colorless oil was obtained according to the same method as the synthesis of compound 47.

[0242] ^1H NMR (400 MHz, CDCl_3): 1:1 atropisomer mixture; δ 7.87 (d, J = 5.2, 1H), 7.72 (d, J = 7.4, 2H), 7.00-7.07 (m, 1H), 6.54-6.70 (m, 2H), 5.63 (d, J = 8.1, 0.5H), 5.49 (d, J = 8.2, 0.5H), 3.98 (d, J = 14.7, 0.5H), 3.83-3.92 (m, 1H), 3.71-3.73 (m, 1H), 3.42 (d, J = 14.6, 0.5H), 2.81 (d, J = 8.4, 3H), 2.72-2.78 (m, 1H), 2.18-2.29 (m, 2H), 1.87-1.98 (m, 2H), 1.47-1.54 (m, 2H), 0.74-1.35 (m, 15H), 0.55 (d, J = 6.5, 1.7H), 0.32 (d, J = 6.5, 1.3H). MS (ESI) m/z 583 (M^+ + H).

Compound 168

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(dimethylamino)-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0243] Compound 144 (34 mg, 0.06 mmol), paraformaldehyde (1 mL) and sodium cyanoborohydride (7 mg, 0.12 mmol) were dissolved in acetonitrile (2 mL). Acetic acid (7.4 μL , 0.12 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 4:1 = Hexane/EtOAc), thus obtaining Compound 168 (30 mg, 85%) as colorless oil.

[0244] ^1H NMR (400 MHz, CDCl_3): 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J = 10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J = 6.6, 0.7H), 0.16 (d, J = 6.5, 2.3H). MS (ESI) m/z 597 (M^+ + H).

Compound 170

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0245] 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxoxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzaldehyde (0.18 g, 0.32 mmol), a starting material, was dissolved in dimethoxyethane (5.0 mL). Cesium fluoride (5 mg, 0.03 mmol) and trimethylsilyl trifluoride (0.05 mL, 0.36 mmol) were added dropwise slowly to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with 1M HCl (hydrochloride) solution. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous

magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 4:1 = Hexane/EtOAc), thus obtaining an intermediate compound (0.14 g, 68%) as colorless oil. The obtained intermediate compound (0.14 g, 0.22 mmol) and Dess-Martin periodinane (0.14 mg, 0.33 mmol) were dissolved in methylene chloride (5.0 mL), and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with methylene chloride. The obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 3:1 = hexane/EtOAc), thus obtaining Compound 170 (0.1 g, 70%), which is an intermediate compound, as colorless oil.

[0246] ^1H NMR (400 MHz, CDCl_3); 1:1.2 atropisomer mixture; δ 8.03 (d, J = 7.6, 1H), 7.87 (s, 1H), 7.73 (d, J = 7.5, 3H), 6.99 (t, J = 9.0, 1H), 5.66 (d, J = 7.6, 0.55H), 5.55 (d, J = 7.9, 0.45H), 3.91-4.03 (m, 2H), 3.90 (d, J = 10.4, 3H), 3.54 (d, J = 15.0, 0.45H), 3.31 (d, J = 14.8, 0.55H), 2.21-2.26 (m, 2H), 1.52-1.53 (m, 2H), 1.48-1.51 (m, 2H), 1.02-1.06 (m, 6H), 0.39-0.43 (m, 3H). MS (ESI) m/z 638 (M^+ + H).

Compound 171

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(perfluoroprop-1-en-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0247] Compound 170 (0.1 g, 0.149 mmol) was dissolved in dimethylformamide (5 mL). Triphenylphosphine (0.08 g, 0.3 mmol) and sodium chlorodifluoroacetate (0.05 g, 0.3 mmol) were added dropwise in sequence to the obtained solution at room temperature, and then refluxed with stirring at 135°C for 6 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with ethyl acetate. The obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (4 g silica, 3:1 = hexane/EtOAc), thus obtaining the intermediate Compound 171 (17 mg, 20%) as colorless oil.

[0248] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.18-7.22 (m, 1H), 6.86-6.96 (m, 2H), 5.55-5.62 (m, 1H), 3.84-3.99 (m, 2H), 3.80 (d, J = 8.6, 3H), 3.58 (d, J = 12.2, 0.5H), 3.39 (d, J = 14.9, 0.5H), 2.08-2.51 (m, 2H), 1.88 (s, 2H), 1.49-1.55 (m, 6H), 1.01-1.05 (m, 6H), 0.31-0.34 (m, 3H). MS (ESI) m/z 672 (M^+ + H).

Compound 172

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoropropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0249] Compound 172 (14 mg, 14%) as yellow oil was obtained according to the same method as the synthesis of compound 171.

[0250] ^1H NMR (400 MHz, CDCl_3); 1:1 atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.24-7.31 (m, 1H), 7.01-7.06 (m, 1H), 6.87-6.92 (m, 1H), 5.55-5.63 (m, 1H), 3.83-4.03 (m, 2H), 3.83-4.03 (m, 1H), 3.80 (d, J = 7.2, 3H), 3.55 (d, J = 14.7, 0.5H), 3.37 (d, J = 14.8, 0.5H), 2.21-2.53 (m, 2H), 1.89-1.99 (m, 2H), 1.44-1.52 (m, 2H), 1.04 (d, J = 13.4, 6H), 0.27-0.33 (m, 3H). MS (ESI) m/z 692 (M^+ + H).

Compound 173

tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(isopropyl)carbamate

[0251] Compound 173 (50 mg, 56%) as colorless oil was obtained according to the same method as the synthesis of compound

112.

[0252] ^1H NMR (400 MHz, CDCl_3); 1:1.2 atropisomer mixture; δ 7.84 (s, 1H), 7.72 (s, 2H), 6.92-6.90 (m, 1H), 6.81-6.74 (m, 1H), 6.68-6.66 (m, 1H), 5.62-5.56 (m, 1H), 4.47 (brs, 1H), 3.99-3.90 (m, 2H), 3.89-3.87 (m, 3H), 3.60-3.48 (m, 1H), 2.54-2.49 (m, 1H), 2.24-2.02 (m, 1H), 1.92 (s, 2H), 1.53-1.42 (m, 2H), 1.33-1.21 (m, 9H), 1.19-1.00 (m, 12H), 0.46 (d, J = 6.6, 1H), 0.27 (d, J = 6.3, 2H). MS (ESI) m/z 699 (M^+ + H).

Compound 174

tert-butyl 3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(ethyl)carbamate

[0253] Compound 174 (45 mg, 52%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0254] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.79 (s, 2H), 6.95 (s, 1H), 6.81 (m, 2H), 5.57 (m, 1H), 3.99-3.85 (m, 2H), 3.75-3.74 (m, 3H), 3.63-3.41 (m, 3H), 2.47-1.86 (m, 4H), 1.58-1.23 (m, 11H), 1.16-0.88 (m, 9H), 0.44-0.22 (m, 4H). MS (ESI) m/z 684 (M^+ + H).

Compound 177

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-ethylacetamide

[0255] Compound 177 (15 mg, 79%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0256] ^1H NMR (400 MHz, CDCl_3); 1:1.3 atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 7.03-7.01 (m, 1H), 6.99-6.77 (m, 2H), 5.62-5.60 (d, J = 8.0, 1H), 4.06-3.87 (m, 2H), 3.79 (s, 1.2H), 3.76 (s, 1.8H), 3.74-3.61 (m, 2H), 3.54-3.34 (m, 1H), 2.51-2.47 (m, 0.5H), 2.29-2.08 (m, 1.5H), 2.06-2.01 (m, 1H), 1.93-1.79 (m, 3H), 1.79 (s, 1.5H), 1.75 (s, 1.5H), 1.55-1.43 (m, 2H), 1.17-0.92 (m, 6H), 0.46-0.44 (d, J = 6.2, 1.3H), 0.34-0.32 (d, J = 6.2, 1.7H). MS (ESI) m/z 627 (M^+ + H).

Compound 178

(4S,5R,Z)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoro-1-(methoxyimino)ethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0257] Compound 170 (0.1 g, 0.157 mmol) and methylamine (26 mg, 0.31 mmol) were dissolved in methanol (5 mL). Pyridine (25 μL , 0.31 mmol) was added dropwise slowly to the obtained solution at room temperature, and stirred at 60°C for 12 hours. After the completion of the reaction, the reaction was quenched with water. The reaction mixture was extracted with methylene chloride. The obtained organic layer was dried with anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 3:1 = hexane/EtOAc), thus obtaining Compound 178 (35 mg, 30%), which is an intermediate compound, as colorless oil.

[0258] ^1H NMR (400 MHz, CDCl_3); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J = 10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J = 6.6, 0.7H), 0.16 (d, J = 6.5, 2.3H). MS (ESI) m/z 685

(M⁺ + H).

Compound 179

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-(2-hydroxy-2-methylpropyl)acetamide

[0259] As the same method as the synthesis of Compound 112, except using isobutylene oxide instead of iodomethane, Compound 179 (10 mg, 50%) as colorless oil was obtained.

[0260] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.88 (s, 1H), 7.82-7.78 (m, 1H), 7.48-7.45 (m, 0.5H), 7.24-7.23 (m, 0.5H), 7.17-7.00 (m, 2H), 6.82-6.79 (m, 1H), 4.99-4.98 (d, J = 5.5, 1H), 3.93-3.41 (m, 7H), 2.38-2.32 (m, 1H), 2.17-2.15 (m, 3H), 1.97-1.83 (m, 3H), 1.50-1.42 (m, 2H), 1.38-1.22 (m, 6H), 1.15-1.05 (m, 3H), 0.89-0.86 (m, 3H), 0.69-0.61 (m, 3H). MS (ESI) 671 (M⁺ + H).

Compound 180

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,3-difluoroazetidine-1-carbonyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0261] Compound 180 (17 mg, 77%) as colorless oil was obtained according to the same method as the synthesis of compound 67.

[0262] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 7.55-7.44 (m, 1H), 7.43-7.33 (m, 1H), 6.88 (dd, J = 8.6, 3.9, 1H), 5.60, 5.53 (2d, J = 8.0, 1H), 4.55-4.47 (m, 4H), 4.01-3.93 (m, 2H), 3.83, 3.80 (2s, 3H), 3.48, 3.35 (2d, J = 14.9, 1H), 2.39-2.01 (m, 4H), 1.80-1.73 (m, 4H), 0.42 (dd, J = 15.7, 6.5, 3H). MS (ESI) m/z 633, 634 (M⁺ + H, M⁺ + 2).

Compound 181

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0263] Compound 181 (37 mg, 72%) as white solid was obtained according to the same method as the synthesis of compound 170.

[0264] ¹H NMR (400 MHz, CDCl₃); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J = 10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J = 6.6, 0.7H), 0.16 (d, J = 6.5, 2.3H). MS (ESI) m/z 708 (M⁺ + H).

Compound 182

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluoro-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0265] Compound 182 (12 mg, 47%) as white solid was obtained according to the same method as the synthesis of compound 47.

[0266] ^1H NMR (400 MHz, CDCl_3); 1:3.2 atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.99-7.02 (m, 1H), 6.80-6.86 (m, 2H), 5.59-5.61 (m, 1H), 3.40-3.82 (m, 3H), 2.75-2.78 (m, 1H), 2.67 (d, J = 10.2, 3H), 2.15-2.25 (m, 2H), 1.88-2.05 (m, 2H), 1.52-1.56 (m, 2H), 1.27-1.33 (m, 6H), 1.12-1.19 (m, 6H), 1.04-1.07 (m, 6H), 0.61 (d, J = 6.6, 0.7H), 0.16 (d, J = 6.5, 2.3H). MS (ESI) m/z 722 ($M^+ + \text{H}$).

Compound 183

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0267] Compound 183 (8 mg, 24%) as yellow oil was obtained according to the same method as the synthesis of compound 120.

[0268] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.88 (s, 1H), 7.78 (s, 2H), 6.76-6.72 (m, 1H), 6.52-6.49 (m, 1H), 6.24 (dd, J = 10.1, 2.9, 1 H), 4.99-4.97 (m, 1H), 3.94-3.83 (m, 1H), 3.67-3.61 (2s, 3H), 3.70-3.53 (m, 2H), 2.79, 2.77 (2s, 3H), 2.39-1.91 (m, 4H), 1.86, 1.81 (2s, 1H), 1.60-1.52 (m, 2H), 1.53, 1.49 (2s, 1H), 1.47-1.25 (m, 6H), 1.04-0.97 (m, 6H), 0.79, 0.55 (2s, 3H).

Compound 184

(4S,5R)-3-((2-(5-acetyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0269] As shown in reaction scheme 4, Compound 12 was synthesized. The obtained Compound 12 (0.24 g, 0.83 mmol) was subjected to a Suzuki reaction with Compound 9 (0.39 g, 0.756 mmol) to obtain Compound 184 (0.11 g, 25%) as brown oil.

[0270] MS (ESI) m/z 602 ($M^+ + \text{H}$).

Compound 185

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0271] (3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxoxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzaldehyde (35 mg, 0.06 mmol), a starting material, was dissolved in tert-butyl alcohol (2 mL). Ethanolamine (4 μL , 0.07 mmol) was added dropwise to the obtained solution at room temperature, and stirred for 30 minutes at room temperature. Potassium carbonate (25 mg, 0.18 mmol) and iodine (31 mg, 0.12 mmol) were added dropwise to the obtained reaction mixture. The obtained reaction mixture was refluxed with stirring at 70°C overnight. After the completion of the reaction, saturated sodium thiosulfate solution was added dropwise to the reaction mixture, to quench the reaction. The reaction mixture was extracted with ethyl acetate. The obtained organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining the intermediate Compound 185 (11 mg, 30%) as white solid.

[0272] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.82-7.77 (m, 1H), 7.74, 7.71 (2s, 2H), 7.61 (dd, J = 13.5, 2.1, 1H), 6.87 (dd, J = 8.6, 11.3, 1H), 5.62, 5.49 (2d, J = 8.1, 1H), 4.42-4.32 (m, 2H), 4.04-3.83 (m, 4H), 3.81, 3.79 (2s, 3H), 3.53, 3.35 (d, J = 14.8, 1H), 2.41-2.04 (m, 2H), 1.91 (bs, 2H), 1.52-1.42 (m, 2H), 1.03-1.00 (m, 6H), 0.35 (dd, J = 8.9, 6.5, 3H). MS (ESI)

m/z 611 ($M^+ + H$).

Compound 187

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3-hydroxyazetidine-1-carbonyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0273] Compound 187 (16 mg, 52%) as white solid was obtained according to the same method as the synthesis of compound 67.

[0274] ^1H NMR (400 MHz, $CDCl_3$); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, $J = 4.0$, 2H), 7.54 (dd, $J = 8.5$, 2.2, 0.5H), 7.47 (dd, $J = 8.5$, 2.1, 0.5H), 7.41 (d, $J = 2.1$, 0.5H), 7.30 (d, $J = 2.2$, 0.5H), 6.86 (dd, $J = 8.6$, 4.0, 1H), 5.61, 5.56 (2d, $J = 8.0$, 1H), 4.69 (bm, 1H), 4.44 (bs, 2H), 4.15-3.93 (m, 3H), 3.82, 3.79 (2s, 3H), 3.52, 3.37 (2d, $J = 14.6$, 1H), 3.13, 3.03 (2d, $J = 5.4$, 1H), 2.47-2.08 (m, 2H), 1.92 (bs, 2H), 1.53-1.44 (m, 2H), 1.04-1.01 (m, 6H), 0.44, 0.37 (2d, $J = 6.5$, 3H). MS (ESI) m/z 642, 663 ($(M+H)^+$, $(M+H)^++21$).

Compound 188

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0275] Compound 188 (14 mg, 40%) as white solid was obtained according to the same method as the synthesis of compound 185.

[0276] ^1H NMR (400 MHz, $CDCl_3$); atropisomer mixture; δ 7.84-7.77 (m, 2H), 7.74, 7.71 (2s, 2H), 7.59 (dd, $J = 12.1$, 2.1, 1H), 6.85 (dd, $J = 8.6$, 12.4, 1H), 5.63, 5.50 (2d, $J = 8.0$, 1H), 4.38-4.30 (m, 1H), 4.12-3.93 (m, 4H), 3.80, 3.78 (2s, 3H), 3.52, 3.36 (2d, $J = 14.8$, 1H), 2.47-2.12 (m, 2H), 1.92 (bs, 2H), 1.87-1.71 (m, 1H), 1.50-1.45 (m, 2H), 1.06-1.01 (m, 7.5H), 0.91-0.89 (m, 3H), 0.80 (d, $J = 6.7$, 1.5H), 0.36 (2d, $J = 6.5$, 3H). MS (ESI) m/z 653 ($M^+ + H$).

Compound 189

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarbonitrile

[0277] According to the same method as the synthesis of Compound 12 in reaction scheme 4, a pinacolato compound was synthesized. And then the synthesis procedure was operated according to the same method as shown in reaction scheme 2, to obtain Compound 189 (0.25 g, 81%) as green foam.

[0278] ^1H NMR (400 MHz, $CDCl_3$); atropisomer mixture; δ 7.85 (s, 1H), 7.74 (d, $J = 5.7$, 2H), 7.16 (dd, $J = 8.5$, 2.5, 0.5H), 7.07 (d, $J = 2.4$, 0.5H), 7.02 (dd, $J = 8.5$, 2.5, 0.5H), 6.90 (d, $J = 2.5$, 0.5H), 6.81 (dd, $J = 8.5$, 11.4, 1H), 5.59 (dd, $J = 8.3$, 10.4, 1H), 4.00-3.94 (m, 2H), 3.76, 3.73 (2s, 3H), 3.50, 3.35 (2d, $J = 14.7$, 1H), 2.50-2.04 (m, 2H), 1.92 (bs, 2H), 1.68-1.56 (m, 2H), 1.50-1.47 (m, 2H), 1.34-1.23 (m, 2H), 1.04-1.00 (m, 6H), 0.43, 0.36 (2d, $J = 6.5$, 3H). MS (ESI) m/z 607 ($M^+ + H$).

Compound 190

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclopropanecarboxamide

[0279] Compound 189 (0.1 g, 0.165 mmol), 30% hydrogen peroxide (0.6 mL) and 7M potassium hydroxide (60 μ L) were dissolved in ethanol (1 mL). The obtained solution was stirred at 85°C for 4 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining intermediate compound (27 mg, 28%). The obtained intermediate compound (26 mg, 0.04 mmol) was dissolved in anhydrous methylene chloride (1 mL). Diisopropylamine (45 μ L, 0.26 mmol) and triphosgene (6 mg, 0.02 mmol) were added dropwise to the obtained solution at 0°C, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 190 (19 mg, 70%) as white solid.

[0280] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.72 (d, J = 7.6, 2H), 7.30-7.27 (m, 1H), 7.07, 7.03 (2d, J = 2.3, 1H), 6.86, 6.81 (2d, J = 8.4, 1H), 5.88 (bs, 0.5H), 5.61, 5.54 (2d, J = 8.3, 1H), 5.52-5.42 (bm, 1.5H), 4.20-3.93 (m, 2H), 3.81 (s, 1.7H), 3.74 (s, 1.3H), 3.44, 3.20 (2d, J = 14.5, 1H), 2.50-2.03 (m, 2H), 1.93 (bs, 2H), 1.59-1.46 (m, 4H), 1.04-1.02 (m, 6H), 1.00-0.94 (m, 2H), 0.53, 0.38 (2d, J = 6.5, 3H). MS (ESI) m/z 625 (M^+ + H).

Compound 191

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroacetyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0281] Compound 191 (33 mg, 55%) as yellow oil was obtained according to the same method as the synthesis of compound 170.

[0282] MS (ESI) m/z 656 (M^+ + H).

Compound 192

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(cyclopropanecarbonyl)-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0283] According to the same method as the synthesis of Compound 133, 2-bromo-4-fluorophenol, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was reacted with Compound 4, to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene to obtain Compound 192 (4 mg, 48%) as brown oil.

[0284] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.76-6.79 (m, 1H), 6.50-6.57 (m, 1H), 5.59-5.62 (m, 1H), 3.90-3.98 (m, 2H), 3.73 (s, 3H), 3.53-3.73 (m, 1H), 3.10-3.16 (m, 1H), 2.02-2.45 (m, 2H), 1.91-1.93 (m, 2H), 1.50-1.54 (m, 2H), 1.01-1.05 (m, 6H), 0.32-0.42 (m, 3H). MS (ESI) m/z 628 (M^+ + H).

Compound 193

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)phenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0285] Compound 193 (1 g, 99%) as yellow solid was obtained according to the same method as the synthesis of compound 18.

[0286] MS (ESI) m/z 560 ($M^+ + H$).

Compound 194

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0287] Compound 194 (0.1 g, 80%) as white solid was obtained according to the same method as the synthesis of compound 52.

[0288] MS (ESI) m/z 627 ($M^+ + H$).

Compound 195

(4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluoromethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0289] Compound 194 (0.1 g, 0.16 mmol) was dissolved in methanol (3 mL). Raney-nickel (3 mL) was added dropwise to the obtained solution at room temperature, and stirred at room temperature under hydrogen balloon. After the completion of the reaction, the reaction mixture was filtered with celite, and concentrated under reduced pressure. The reaction mixture was diluted with ethyl acetate, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (12 g silica, 1:1 = hexane/EtOAc), thus obtaining Compound 195 (35 g, 35%) as yellow solid.

[0290] MS (ESI) m/z 597 ($M^+ + H$).

Compound 196

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluoromethyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamide

[0291] Compound 196 (40 mg, 70%) as yellow oil was obtained according to the same method as the synthesis of compound 110.

[0292] MS (ESI) m/z 640 ($M^+ + H$).

Compound 197

methyl 5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoate

[0293] According to the same method as the synthesis of Compound 133, 2-fluoro-4-methoxybenzoic acid, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 197 (0.21 g, 88%) as yellow oil.

[0294] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 1H), 7.71 (s, 1H), 7.57 (dd, $J = 8.3, 10.2$, 1H), 6.61 (dd, $J = 8.8, 12.6$, 1H), 5.64, 5.55 (2d, $J = 8.1$, 1H), 3.98-3.89 (m, 2H), 3.84, 3.82 (2s, 3H), 3.80, 3.79 (2s, 3H), 3.53, 3.33 (2d, $J = 14.6$, 1H), 2.41-2.01 (m, 2H), 1.92-1.87 (bm, 2H), 1.51-1.42 (m, 2H), 1.02 (dd, 13.0, 2.0, 6H), 0.43, 0.39 (2d, $J = 6.5$, 3H). MS (ESI) m/z 618 ($\text{M}^+ + \text{H}$).

Compound 204

5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxybenzoic acid

[0295] Compound 204 (83 mg, 45%) as white solid was obtained according to the same method as the synthesis of compound 34.

[0296] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (d, $J = 8.2$, 2H), 7.63 (dd, $J = 8.4, 3.9$, 1H), 6.65 (dd, $J = 9.0, 12.6$, 1H), 5.65, 5.56 (2d, $J = 8.0$, 1H), 4.00-3.92 (m, 2H), 3.83 (d, $J = 11.2$, 3H), 3.53, 3.31 (2d, $J = 14.8$, 1H), 2.41-2.04 (m, 2H), 1.97-1.84 (m, 2H), 1.50-1.44 (m, 2H), 1.04-1.00 (m, 6H), 0.43 (t, $J = 6.8$, 3H). MS (ESI) m/z 604 ($\text{M}^+ + \text{H}$).

Compound 206

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-nitro-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0297] As shown in reaction scheme 1, 4-methoxy-1-nitro-2-(trifluoromethyl)benzene, a starting material, was subjected to iodination using iodine. The obtained compound was subjected to Ullmann reaction using Compound 2 (Martin G. Barwell et al. Org. Lett. 2004, 6, 2741), to synthesize a compound, and then according to the same method as the synthesis of compound 52, Compound 206 (0.65 g, 83%) as yellow foam was obtained.

[0298] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (d, $J = 4.9$, 2H), 7.69 (d, $J = 2.4$, 1H), 7.22 (d, $J = 11.4$, 1H), 5.66, 5.77 (2d, $J = 8.2$, 1H), 4.03-3.93 (m, 2H), 3.94, 3.93 (2s, 3H), 3.50, 3.31 (2d, $J = 14.9$, 1H), 2.40-2.03 (m, 2H), 1.95 (bs, 2H), 1.53-1.47 (m, 2H), 1.05-1.01 (m, 6H), 0.50 (t, $J = 6.8$, 3H).

Compound 207

(4S,5R)-3-((2-(5-amino-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0299] Compound 207 (0.33 mg, 56%) as white foam was obtained according to the same method as the synthesis of compound 195.

[0300] MS (ESI) m/z 625 ($\text{M}^+ + \text{H}$).

Compound 209

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)trifluoro-N-methylmethanesulfonamide

[0301] Compound 209 (27 mg, 56%) as yellow solid was obtained according to the same method as the synthesis of compound 112.

[0302] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (d, J = 9.6, 1H), 7.74-7.70 (m, 2H), 7.17-7.13 (m, 1H), 7.06 (d, J = 4.8, 1H), 5.65-5.46 (m, 1H), 4.03-3.53 (m, 6H), 3.41-3.29 (m, 3H), 2.22-2.06 (m, 2H), 2.02-1.87 (m, 2H), 1.52-1.46 (m, 2H), 1.04-0.99 (m, 2H), 1.50-0.47 (m, 1H), 0.38 (d, J = 6.5, 1H), 0.32 (d, J = 6.5, 1H). MS (ESI) m/z 771 (M^+ + H).

Compound 210

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylacetamide

[0303] According to the same method as the synthesis of Compound 112, Compound 210 (31 mg, 84%) as white solid was obtained.

[0304] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 7.16-7.13 (m, 1H), 6.95 (d, J = 6.2, 1H), 5.63 (dd, J = 4.4, 8.0, 1H), 4.03-3.91 (m, 2H), 3.86, 3.83 (2s, 3H), 3.45-3.26 (m, 1H), 3.17-3.05 (m, 3H), 2.46-2.03 (m, 2H), 1.97-1.90 (bm, 2H), 1.76-1.71 (m, 3H), 1.53-1.45 (m, 2H), 1.04-0.96 (m, 6H), 0.50-0.36 (m, 3H). MS (ESI) m/z 681 (M^+ + H).

Compound 212

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(((2-(2-methoxy-5-(methyl(4-(trifluoromethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0305] Compound 212 (58.2 mg, 40.3%) as white solid was obtained according to the same method as the synthesis of compound 112.

[0306] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.73, 7.72 (2s, 2H), 7.22, 7.19 (2dd, J = 2.8, 0.9, 1H), 7.02, 7.00 (2d, J = 2.7, 1H), 6.92, 6.89 (2d, J = 8.8, 1H), 6.84, 6.79 (2t, J = 1.0, 1H), 5.61 (d, J = 8.1, 1H), 4.01 (m, 2H), 3.81, 3.78 (2s, 3H), 3.59, 3.47 (2d, J = 14.6, 15.0, 1H), 3.50, 3.44 (2s, 3H), 2.55-1.86 (brm, 4H), 1.51 (m, 2H), 1.27 (m, 2H), 1.05, 1.03, 1.00 (3s, 6H). MS (ESI) m/z 766 ($\text{M}+\text{K}$) $^+$.

Compound 213

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-(((2-(2-methoxy-5-(4-(trifluoromethyl)thiazol-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0307] As shown in reaction scheme 5, intermediate 17 was synthesized. Intermediate 17 (0.3 g, 0.486 mmol) was dissolved in chloroform/saturated sodium carbonate solution (10 mL, V/V 3:1). Thiophosgene (62.5 μL) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate. The obtained organic layer was washed with water and brine. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was dissolved in methanol (3 mL). Ammonia water (0.5 mL) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was crystallized, thus obtaining the intermediate Compound (0.3 g, 87.2%) as white solid. The obtained intermediate compound (0.16 g, 0.27 mmol) was dissolved in ethanol (3 mL). 3-bromo-1,1,1-trifluoropropane-2-one (44.6 μL) was added dropwise to the obtained solution at room temperature, and then refluxed with stirring

at 90°C for 2 hours. After the completion of the reaction, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ethyl acetate. And then, the obtained organic layer was washed with saturated sodium hydrogen carbonate solution, water and brine. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure, thus obtaining Compound 213 (0.18 g, 93.1%) as colorless oil.

[0308] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.23, 8.06 (2brs, 1H), 7.85, 7.84 (2s, 1H), 7.72 (s, 2H), 7.27-7.15 (m, 1.5H), 6.99-6.84 (m, 2.5H), 5.60 (d, J = 8.1, 1H), 4.01 (m, 2H), 3.80, 3.78 (2s, 3H), 3.68, 3.42 (2d, J = 14.2, 1H), 2.51-1.88 (brm, 6H), 1.50 (m, 2H), 1.04 (m, 6H), 0.42, 0.35 (2d, J = 5.4, 6.5, 3H).

Compound 215

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-N-methylacetamide

[0309] Compound 215 (21 mg, 31 %) as white foam was obtained according to the same method as the synthesis of compound 112.

[0310] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87 (s, 1H), 7.73 (s, 2H), 6.86 (m, 1H), 6.68 (m, 1H), 5.64, 5.62 (2s, 1H), 3.97 (m, 2H), 3.79, 3.76 (2s, 3H), 3.51-3.33 (brm, 2H), 3.19, 3.18, 3.08 (3s, 3H), 2.46-1.62 (brm, 9H), 1.46 (m, 2), 1.00 (m, 6H), 0.49-0.36 (m, 3H). MS (ESI) m/z 631 (M^+ + H).

Compound 216

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)acetamide

[0311] Compound 216 (82 mg, 79%) as white solid foam was obtained according to the same method as the synthesis of compound 110.

[0312] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.79-7.76 (m, 4H), 7.21, 7.18 (2s, 1H), 6.64, 6.61 (2d, J = 7.4, 1H), 5.63, 5.46 (2d, J = 7.9, 1H), 4.12 (m, 1H), 3.94(m, 1H), 3.56, 3.30 (2d, J = 15.0, 1H), 2.19, 2.14 (2s, 3H), 1.93, 1.90 (2s, 2H), 1.45 (m, 2H), 1.01, 1.00, 0.99, 0.98 (4s, 6H), 0.46, 0.32 (2d, J = 6.5, 3H). MS (ESI) m/z 617 (M^+ + H).

Compound 217

(4S,5R)-3-((2-(5-amino-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0313] Compound 217 (0.12 g, 99%) as yellow oil was obtained according to the same method as the synthesis of compound 195.

[0314] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2H), 6.58, 6.54 (2d, J = 12.6, 1 H), 6.44, 6.41 (2d, J = 6.1, 1 H), 5.60, 5.58 (2d, J = 2.9, 1 H), 4.0-3.89 (m, 2H), 3.67, 3.64 (2s, 3H), 3.58, 3.47 (2d, J = 14.6, 1H), 3.37 (brs, 2H), 2.42-1.89 (brm, 6H), 1.45 (m, 2H), 0.99 (m, 6H), 0.48, 0.34 (2d, J = 6.6, 6.5, 3H). MS (ESI) m/z 575 (M^+ + H).

Compound 218

(4S,SR)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0315] Compound 218 (0.3 g, 80%) as white solid was obtained according to the same method as the synthesis of compound 206.

[0316] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.78, 7.77 (2d, *J* = 4.4, 1H), 7.72, 7.71 (2s, 2H), 6.74, 6.71 (2d, *J* = 7.6, 1H), 5.56, 5.59 (2d, *J* = 5.4, 1H), 3.96 (m, 2H), 3.89, 3.86 (2s, 3H), 3.52, 3.30 (2d, *J* = 15.0, 1H), 2.38-1.87 (brm, 6H), 1.48 (m, 2H), 1.09, 1.08, 1.00, 0.99 (4s, 6H), 0.47 (t, *J* = 6.7, 3H). MS (ESI) *m/z* 649 (*M*⁺ + K).

Compound 222**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)-4-methyloxazolidin-2-one**

[0317] According to the same method as the synthesis of Compound 133, 2-fluoro-4-methoxyphenol, a starting material, was subjected to several synthesis processes to obtain an iodobenzene compound. The obtained compound was subjected to Ullmann reaction using Compound 2, thus synthesizing an aldehyde compound. The obtained aldehyde compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an Intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 222 (7 mg, 47%) as yellow solid.

[0318] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.72 (s, 2H), 6.75 (dd, *J* = 15.5, 9.2, 1H), 6.65 (dd, *J* = 12.7, 11.4, 1H), 5.60 (dd, *J* = 8.1, 3.0, 1H), 4.38-1.28 (m, 2H), 3.99-3.88 (m, 2H), 3.74, 3.70 (2s, 3H), 3.52, 3.39 (2d, *J* = 14.6, 1H), 2.45-1.99 (m, 2H), 1.95-1.89 (m, 2H), 1.52-1.41 (m, 2H), 1.03-0.98 (m, 6H), 0.41 (2d, *J* = 6.5, 3H), MS (ESI) *m/z* 658 (*M*⁺ + H).

Compound 223**(4S,SR)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0319] According to the same method as the synthesis of Compound 133, benzo[d][1,3]dioxol-5-ol, a starting material, was subjected to several synthesis processes to obtain a pinacolato compound. The obtained pinacolato compound was subjected to a Suzuki reaction using Compound 2, thus synthesizing an aldehyde compound. The obtained aldehyde compound was reacted with Compound 4 to synthesize an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 223 (4 mg, 49%) as colorless oil.

[0320] ¹H NMR (400 MHz, CDCl₃); 1:1.5 atropisomer mixture; δ 7.86 (s, 1H), 7.74 (s, 2H), 6.45-6.52 (m, 2H), 5.87-5.92 (m, 2H), 5.62 (t, *J* = 7.7, 1H), 3.90-4.03 (m, 2H), 3.70 (d, *J* = 7.6, 3H), 3.65 (d, *J* = 3.8, 0.6H), 3.50 (d, *J* = 14.9, 0.4H), 2.01-2.45 (m, 2H), 1.89-1.91 (m, 2H), 1.44-1.49 (m, 2H), 1.00-1.04 (m, 6H), 0.49 (d, *J* = 6.6, 1.2H), 0.38 (d, *J* = 6.5, 1.8H). MS (ESI) *m/z* 586 (*M*⁺ + H).

Compound 224**N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylisobutyramide**

[0321] Compound 224 (49 mg, 74%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0322] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, *J* = 4.5, 2H), 7.17-7.13 (m, 1H), 6.95 (d, *J* = 10.4, 1H), 5.64-5.62 (m, 1H), 4.04-3.91 (m, 2H), 3.86-3.81 (m, 3H), 3.46-3.30 (m, 1H), 3.15-3.03 (m, 3H), 2.45-2.03 (m, 3H), 1.97-1.90 (m, 2H), 1.51-1.45 (m, 2H), 1.04-0.87 (m, 12H), 0.56-0.37 (m, 3H). MS (ESI) *m/z* 709, 710 (*M*⁺+H, *M*⁺+2).

Compound 225

N-(5-(2-(((4*S*,5*R*)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylpropionamide

[0323] Compound 225 (33 mg, 70%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0324] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, *J* = 4.5, 2H), 7.15 (d, *J* = 13.2, 1H), 6.92 (d, *J* = 7.2, 1H), 5.64 (dd, *J* = 8.0, 3.3, 1H), 4.03-3.91 (m, 2H), 3.85 (2d, *J* = 12.6, 1.3, 3H), 3.45-3.32 (m, 1H), 3.16 (s, 1H), 3.04 (s, 1H), 2.45-2.02 (m, 2H), 1.97-1.86 (m, 4H), 1.53-1.45 (m, 2H), 1.04-0.96 (m, 9H), 0.50-0.37 (m, 3H). MS (ESI) *m/z* 695 (*M*⁺ + H).

Compound 226

N-(5-(2-(((4*S*,5*R*)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-N-methylmethanesulfonamide

[0325] According to the same method as the synthesis of Compound 112, Compound 226 (20 mg, 39%) as white solid was obtained.

[0326] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (m, 1H), 7.75 (d, *J* = 12.1, 2H), 7.45-7.06 (m, 2H), 5.63-5.41 (m, 1H), 4.00-3.70 (m, 2H), 3.88-3.80 (m, 3H), 2.50-3.24 (m, 1H), 3.18-3.02 (m, 3H), 2.98, 2.87 (2s, 3H), 2.40-2.03 (m, 2H), 1.97-1.94 (m, 2H), 1.51-1.42 (m, 2H), 1.03-0.97 (m, 6H), 0.54-0.33 (m, 3H). MS (ESI) *m/z* 717 (*M*⁺ + H).

Compound 227

N-(5-(2-(((4*S*,5*R*)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)-2,2,2-trifluoro-N-methylacetamide

[0327] Compound 227 (8 mg, 73%) as yellow solid was obtained according to the same method as the synthesis of compound 112.

[0328] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.87 (s, 1H), 7.76-7.72 (m, 2H), 7.17-7.13 (m, 1H), 7.02-6.95 (m, 1H), 5.66-5.60 (m, 1H), 4.03-3.81 (m, 2H), 3.88-3.84 (m, 3H), 3.52-3.33 (m, 1H), 3.31-3.19 (m, 3H), 2.45-1.99 (m, 2H), 1.97-1.90 (m, 2H), 1.53-1.42 (m, 2H), 1.05-0.89 (m, 6H), 0.53-0.32 (m, 3H). MS (ESI) *m/z* 735 (*M*⁺).

Compound 228

N-(5-(2-(((4*S*,5*R*)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-

methoxy-2-(trifluoromethyl)phenyl)trifluoromethanesulfonamide

[0329] Compound 228 (61 mg, 73%) as yellow oil was obtained according to the same method as the synthesis of compound 110.

[0330] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (d, *J* = 12.2 Hz), 7.32-7.27 (m, 1H), 7.10 (d, *J* = 9.8, 1H), 5.62, 5.51 (2d, *J* = 8.0, 1H), 4.00-3.88 (m, 2H), 3.84 (d, *J* = 5.6, 3H), 3.57, 3.26 (2d, *J* = 14.9, 1H), 2.40-2.07 (m, 2H), 1.93 (bs, 2H), 1.51-1.44 (m, 2H), 1.03-0.98 (m, 6H), 0.44, 0.33 (2d, *J* = 6.5, 3H). MS (ESI) *m/z* 757, 758 (M⁺, M⁺+H).

Compound 229(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2,4-dimethoxy-5-nitrophenyl)5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0331] Compound 229 (89 mg, 74%) as colorless oil was obtained according to the same method as the synthesis of compound 110.

[0332] ¹H NMR (400 MHz, CDCl₃); 1:1.7 atropisomer mixture; δ 7.87 (s, 1H), 7.69-7.78 (m, 2H), 6.49 (d, *J* = 9.1, 1H), 5.67 (d, *J* = 7.4, 0.7H), 5.55 (d, *J* = 8.2 Hz), 3.95-4.07 (m, 2H), 4.00-3.97 (m, 3H), 3.86-3.90 (m, 3H), 3.58 (d, *J* = 14.8, 0.5H), 3.34 (d, *J* = 14.9, 0.5H), 2.18-2.38 (m, 2H), 1.87, MS (ESI) *m/z* 617 (M⁺ + H).

Compound 230N-(5-(2-(2-(((4S,5R)-5-(3-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2,4-dimethoxyphenyl)-N-methylacetamide

[0333] Compound 230 (4 mg, 85%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0334] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (s, 2H), 6.76-6.81 (m, 1H), 6.44-6.48 (m, 1H), 5.61-5.64 (m, 1H), 3.91-4.04 (m, 2H), 3.74-3.85 (m, 6H), 3.40-3.59 (m, 1H), 3.13 (s, 2H), 3.01 (s, 1H), 2.07-2.49 (m, 2H), 1.95-2.10 (m, 3H), 1.78-1.81 (m, 3H), 1.50-1.59 (m, 2H), 1.01-1.08 (m, 6H), 0.07-0.47 (m, 3H), MS (ESI) *m/z* 643 (M⁺ + H).

Compound 232(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-hydroxy-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0335] Compound 218 (0.12 g, 0.2 mmol) and 2-(methylsulfonyl)ethanol (32 mg) were dissolved in dimethylformamide (3 mL). Sodium hydride (15.3 mg) was added dropwise carefully to the obtained solution at room temperature, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with saturated ammonium chloride solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was crystallized, thus obtaining Compound 232 (91 mg, 77%) as yellow solid.

[0336] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 10.98, 10.96 (2s, 1H), 7.86 (s, 1H), 7.79-7.71 (m, 3H), 6.53, 6.51 (2s,

1H), 5.63 (2d, $J = 8.1$, 1H), 4.02-3.93 (m, 2H), 3.87, 3.86 (2s, 3H), 3.45 (2d, $J = 14.9$, 1H), 2.39-1.86 (m, 4H), 1.52-1.43 (m, 2H), 1.01 (2d, $J = 3.8$, 6H), 0.46 (2d, $J = 6.6$, 3H), MS (ESI) m/z 603 ($M^+ + H$).

Compound 233

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-(2-methoxy-5-(methylamino)-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0337] Compound 233 (46mg, 85%) as yellow oil was obtained according to the same method as the synthesis of compound 120.

[0338] ^1H NMR (400 MHz, CDCl_3): atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.96, 6.89 (2s, 1H), 6.37 (d, $J = 8.0$, 1H), 5.61 (d, $J = 7.2$, 1H), 4.03-3.92 (m, 2H), 3.70 (d, $J = 7.6$, 3H), 3.60-3.49 (m, 1H), 2.84, 2.80 (2s, 3H), 2.49-2.02 (m, 2H), 1.92 (bs, 2H), 1.52-1.46 (m, 2H), 1.04-0.98 (m, 6H), 0.52, 0.36 (2d, $J = 0.3$, 3H). MS (ESI) m/z 639 ($M^+ + H$).

Compound 234

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamide

[0339] Compound 234 (1.4 mg, 74%) as yellow oil was obtained according to the same method as the synthesis of compound 112.

[0340] ^1H NMR (400 MHz, CDCl_3): 1:1 atropisomer mixture; δ 7.86 (s, 1H), 7.63 (s, 2H), 6.77 (m, 2H), 5.62 (m, 1H), 4.04-3.90 (m, 2H), 3.80, 3.77, 3.76 (3s, 3H), 3.56-3.89 (m, 2H), 3.16, 3.15, 3.03 (3s, 3H), 2.51 (m, 2H), 2.50-1.25 (m, 4H), 1.22 (m, 4H), 1.03 (m, 6H), 0.45-0.33 (m, 3H). MS (ESI) m/z 641 ($M^+ + H$).

Compound 235

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(2-hydroxy-2-methylpropyl)(methylamino)-2-methoxy-4-(trifluoromethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0341] Compound 235 (7 mg, 39%) as yellow solid was obtained according to the same method as the synthesis of compound 120.

[0342] MS (ESI) m/z 639 ($M^+ + H$).

Compound 237

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-cyclopropyl-4-fluoro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0343] According to the same method as the synthesis of Compound 133, 3-fluoro-4-bromoanisole, a starting material, was subjected to several synthesis processes to obtain a boronic acid compound. The obtained compound was subjected to a Suzuki reaction with Compound 2. The obtained compound was reacted with Compound 4, to obtain an amino alcohol compound, which

is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 237 (2 mg, 22%) as white solid.

[0344] ^1H NMR (400 MHz, CDCl_3); 1:1.3 atropisomer mixture; δ 7.85 (s, 1H), 7.73-7.72 (m, 2H), 6.57-6.44 (m, 2H), 5.60 (t, J = 8.0, 1H), 3.98-3.88 (m, 2H), 3.71, 3.68 (2s, 3H), 3.50, 3.38 (2d, J = 14.5, 1H), 2.45-1.87 (m, 4H), 1.49-1.40 (m, 2H), 1.02-0.92 (m, 6H), 0.91-0.82 (m, 4H), 0.63-0.59 (m, 1H), 0.40 (d, J = 6.5, 1.3H), 0.32 (d, J = 6.5, 1.7H). MS (ESI) m/z 600 (M^+ + H).

Compound 240

1-((5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluoromethyl)phenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate

[0345] Compound 240 (28 mg, 53%) as white solid was obtained according to the same method as the synthesis of compound 110.

[0346] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85-7.74 (m, 3H), 7.11-7.07 (m, 1H), 6.86-6.78 (m, 1H), 5.65, 5.44 (2d, J = 7.6, 1H), 4.12-3.32 (m, 6H), 3.26 (d, J = 9.4, 3H), 2.45-1.88 (m, 7H), 1.49-1.47 (m, 6H), 1.45-1.39 (m, 2H), 1.02-0.97 (m, 6H), 0.65-0.36 (m, 3H). MS (ESI) m/z 767 (M^+ + H).

Compound 241

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0347] According to the same method as the synthesis of Compound 133, 2-fluoro-4-methoxyphenol, a starting material, was subjected to several synthesis processes to obtain boronic acid compound. The obtained compound was subjected to a Suzuki reaction with Compound 2. And then the obtained compound was reacted with Compound 4, to obtain an amino alcohol compound, which is an intermediate compound. The obtained amino alcohol compound was reacted with triphosgene, thus obtaining Compound 241 (3 mg, 60%) as white solid.

[0348] ^1H NMR (400 MHz, CDCl_3); 1:1.5 atropisomer mixture; δ 7.85 (s, 1H), 7.72 (s, 2H), 6.66-6.58 (m, 2H), 5.61 (dd, J = 8.0, 4.6, 1H), 4.39-4.21 (m, 1H), 4.02-3.88 (m, 2H), 3.70, 3.67 (2s, 3H), 3.56, 3.46 (2d, J = 14.5, 1H), 2.47-1.99 (m, 2H), 1.94-1.88 (m, 2H), 1.51-1.40 (m, 2H), 1.31 (d, J = 6.0, 3H), 1.21-1.17 (m, 3H), 1.03-0.98 (m, 6H), 0.44 (d, J = 6.5, 1.2H), 0.33 (d, J = 6.5, 1.8H). MS (ESI) m/z 618 (M^+ + H).

Compound 243

1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetate

[0349] Compound 243 (32 mg, 50%) as yellow solid was obtained according to the same method as the synthesis of compound 110.

[0350] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.83 (s, 1H), 7.75 (s, 2H), 7.05 (d, J = 8.6, 1H), 6.85-6.78 (m, 2H), 5.62-5.57 (m, 1H), 4.02-3.90 (m, 2H), 3.77, 3.74 (2s, 3H), 3.52 (d, J = 14.7, 0.6H), 3.40 (d, J = 14.7, 0.4H), 3.38-3.00 (bm, 3H), 2.42-2.07 (m, 2H), 2.02-1.87 (m, 2H), 1.70-1.40 (bm, 9H), 1.02-0.98 (m, 6H), 0.44-0.38 (m, 3H), MS (ESI) m/z 699 (M^+ + H).

Compound 244**N-(3-(2-(((4S,5R)-5-(3.5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamide**

[0351] Compound 243 (19 mg, 0.027 mmol) was added to methanol (0.8 mL). The solution of potassium carbonate (4 mg, 0.029 mmol) in water (0.2 mL) was added dropwise to the obtained mixture, and stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure, diluted with methylene chloride, washed with brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by PTLC (silica, 70% Hexane/EtOAc), thus obtaining Compound 244 (11 mg, 65%) as white solid.

[0352] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.87 (s, 1H), 7.74 (d, J = 5.7, 2H), 7.12-7.09 (m, 1H), 6.91-6.84 (m, 2H), 5.61 (dd, J = 8.0, 2.1, 1H), 4.36 (bs, 1H), 4.06-3.93 (m, 2H), 3.82, 3.79 (2s, 3H), 3.53, 3.42 (2d, J = 14.6, 1H), 3.29, 3.22 (2s, 3H), 2.47-1.99 (m, 2H), 1.94-1.92 (m, 2H), 1.56-1.46 (m, 2H), 1.20-1.10 (bm, 6H), 1.06-1.02 (m, 6H), 0.50, 0.41 (2d, J = 6.5, 3H), MS (ESI) m/z 657 (M^+ + H).

Compound 246**(4S,5R)-5-(3.5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-4-methyl-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0353] Compound 246 (0.13 g, 69.1%) as colorless oil was obtained according to the same method as the synthesis of compound 206.

[0354] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture: δ 7.86 (s, 1H), 7.76 (d, J = 8.0, 1H), 7.73 (d, J = 7.3, 2H), 6.72 (d, J = 10.5, 1H), 5.60 (dd, J = 38.2, 8.1, 1H), 3.97 (m, 2H), 3.87, 3.83 (2s, 3H), 3.55, 3.34 (2d, J = 14.9, 1H), 2.64, 2.63 (2s, 3H), 2.40-1.92 (m, 4H), 1.50 (m, 2H), 1.05, 1.04, 1.01 (3s, 6H), 0.47, 0.45, 0.44, 0.43 (4s, 3H), MS (ESI) m/z 601 (M^+ + H).

Compound 247**(4S,5R)-3-((2-(5-amino-2-methoxy-4-methylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3.5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one**

[0355] Compound 247 (76.6 mg, 73%) as colorless oil was obtained according to the same method as the synthesis of compound 195.

[0356] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1H), 7.73 (s, 2H), 6.60, 6.54 (2s, 1H), 6.33, 6.31 (2s, 1H), 5.59, 5.57 (2d, J = 8.0, 1H), 4.05-3.84 (m, 2H), 3.67-3.50 (m, 4H), 3.33 (brs, 2H), 2.49-1.90 (m, 7H), 1.50-1.41 (m, 2H), 1.03, 1.01, 0.99 (3s, 6H), 0.47, 0.31 (2d, J = 6.6, 6.5, 3H). MS (ESI) m/z 571 (M^+ + H).

Compound 248**N-(5-(2-(((4S,5R)-5-(3.5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)acetamide**

[0357] Compound 248 (28.8 mg, 67.1 %) as colorless oil was obtained according to the same method as the synthesis of compound 110.

[0358] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.83-7.79 (m, 3H), 7.40, 7.21 (2s, 1H), 6.82, 6.76 (2s, 1H), 6.68, 6.65 (2s, 1H), 5.59, 5.46 (2d, J = 8.0, 1H), 4.07 (m, 1H), 3.94 (m, 1H), 3.74, 3.73 (2s, 3H), 3.61, 3.39 (2d, J = 14.7, 1H), 2.23-1.91 (m, 10H), 1.45 (m, 2H), 1.01, 1.00, 0.98 (3s, 6H), 0.44, 0.31 (2d, J = 6.5, 3H). MS (ESI) m/z 613 (M^+ + H).

Compound 249

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamide

[0359] Compound 249 (9.2 mg, 45.8%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0360] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (s, 2H), 6.77-6.70 (m, 2H), 5.61 (m, 1H), 4.03-3.91 (m, 2H), 3.78, 3.75, 3.74 (3s, 3H), 3.55-3.27 (m, 1H), 3.15, 3.14, 3.03 (3s, 3H), 2.50-1.45 (m, 12H), 1.13-0.96 (m, 6H), 0.48-0.31 (m, 3H). MS (ESI) m/z 627 (M^+ + H).

Compound 250

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoromethanesulfonamide

[0361] Compound 250 (24.2 mg, 57.3%) as colorless oil was obtained according to the same method as the synthesis of compound 110.

[0362] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (d, J = 4.0, 1H), 7.72 (d, J = 6.9, 2H), 7.01, 6.94 (2s, 1H), 6.72, 6.70 (2s, 1H), 5.60, 5.53 (2d, J = 8.0, 1H), 3.93 (m, 2H), 3.77, 3.76 (2s, 3H), 3.57, 3.34 (2d, J = 14.7, 1H), 2.43-1.91 (m, 7H), 1.47 (m, 2H), 1.02, 0.99, 0.98 (3s, 6H), 0.36, 0.29 (2d, J = 6.5, 3H). MS (ESI) m/z 703 (M^+ + H).

Compound 251

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-methylphenyl)trifluoro-N-methylmethanesulfonamide

[0363] Compound 251 (9.5 mg, 42.8%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0364] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.786, 7.84 (2s, 1H), 7.74, 7.71 (2s, 2H), 6.90-6.73 (m, 2H), 5.58-5.46 (m, 1H), 4.02-3.25 (m, 9H), 2.41-1.95 (m, 7H), 1.49 (m, 2H), 1.03, 1.01, 1.00 (3s, 6H), 0.44-0.32 (m, 3H). MS (ESI) m/z 717 (M^+ + H).

Compound 259

N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-

4-methoxyphenyl)-N-methylethane thioamide

[0365] Compound 112 (35 mg, 0.057 mmol) was dissolved in toluene (1.3 mL). Lawesson's reagent (23 mg, 0.06 mmol) was added dropwise to the solution, and then stirred at 80°C overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (10-20% hexane/ EtOAc), thus obtaining Compound 259 (28 mg, 78%) as solid.

[0366] ¹H NMR (400 MHz, CDCl₃): atropisomer mixture; δ 7.86 (s, 1 H), 7.73 (d, 2 H, *J* = 4.6 Hz), 7.06 - 7.03 (m, 1 H), 6.91 - 6.86 (m, 1 H), 6.83 (q, 1 H, *J* = 2.7 Hz), 5.62 (dd, 1 H, *J* = 4.1, 8.4 Hz), 4.05 - 3.91 (m, 2 H), 3.81, 3.78 (2s, 3 H), 3.70, 3.64 (2s, 3 H), 3.49, 3.39 (2d, 1 H, *J* = 14.5 Hz), 2.49 - 2.43 (m, 1 H), 2.38, 2.34 (2s, 3 H), 2.29 - 2.00 (m, 2 H), 1.93 - 1.85 (m, 2 H), 1.53 - 1.43 (m, 2 H), 1.05 - 1.01 (m, 6 H), 0.47, 0.36 (2d, 3 H, *J* = 6.6 Hz); MS (ESI) *m/z* 629.0 (*M*⁺+H).

Compound 271**N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-thioxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylacetamide**

[0367] Compound 112 (60 mg, 0.098 mmol) was dissolved in 2-propanol (0.6 mL). The solution of potassium hydroxide (28 mg) in water (0.1 mL) was added dropwise to the obtained solution at room temperature, and stirred at 80°C overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature, and concentrated under reduced pressure to remove the solvent. Ethyl acetate was added dropwise to the residue. The obtained mixture was washed with water and brine, and concentrated under reduced pressure. The obtained residue was separated by MPLC (SiO₂, 10%-70% Hexane/ EtOAc), thus obtaining an amino alcohol compound (26 mg, 45%) as colorless oil. The obtained amino alcohol compound was dissolved in methylene chloride (1.5 mL). Thiophosgene (2 μL, 0.02 mmol) and diisopropylamine (0.05 mL, 0.27 mmol) were added dropwise to the obtained solution, and then stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with methylene, and washed with water and brine. The organic layer was dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO₂ 30% -90% hexane/ EtOAc), thus obtaining Compound 271 (12 mg, 43%) as yellow solid.

[0368] ¹H NMR (400 MHz, CDCl₃): atropisomer mixture; δ 7.88 (s, 1H), 7.75 (s, 2 H), 7.06 (dt, 1 H, *J* = 2.4, 8.6 Hz), 6.90 - 6.81 (m, 2 H), 5.77 - 5.74 (m, 1 H), 4.66 - 4.63 (m, 1 H), 4.25 - 4.09 (m, 1 H), 3.83, 3.79 (2s, 3 H), 3.72, 3.66 (2d, 1 H, *J* = 14.8 Hz), 3.22, 3.14 (2s, 3 H), 2.53 - 1.89 (m, 4 H), 1.84, 1.79 (2s, 3 H), 1.53 - 1.44 (m, 2 H), 1.05 - 1.02 (m, 6 H), 0.51, 0.37 (2d, 1 H, *J* = 6.7 Hz); MS (ESI) *m/z* 628.8 (*M*⁺).

Compound 272**methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoate**

[0369] Compound 272 (0.12 g, 95.9%) as white solid foam was obtained according to the same method as the synthesis of compound 133.

[0370] ¹H NMR (400 MHz, CDCl₃): atropisomer mixture; δ 7.85 (s, 1 H), 7.75 (m, 2 H), 7.27 (2d, 1H, *J* = 2.12, 2.08 Hz), 6.83 (m, 2H), 5.60 (m, 1 H), 4.05-3.41 (m, 9 H), 2.89 (m, 2 H), 2.6 (m, 2 H), 2.50-2.00 (m, 2 H), 1.89 (m, 2 H), 1.50 (m, 2 H), 1.05 (m, 6 H), 0.40 (m, 3H).

Compound 273

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoic acid

[0371] Compound 273 (2 mg, 1.9%) as colorless oil was obtained according to the same method as the synthesis of compound 134.

[0372] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 (s, 2H), 7.05 - 7.07 (m, 1 H), 6.74 - 6.85 (m, 2 H), 5.56 - 5.61 (m, 1 H), 3.72 - 3.89 (m, 3 H), 3.42 - 3.58 (m, 1 H), 2.83 - 2.90 (m, 2 H), 2.61 - 2.66 (m, 2 H), 2.26 - 2.59 (m, 2 H), 1.87 - 1.93 (m, 2 H), 1.44 - 1.53 (m, 2 H), 1.01 - 1.05 (m, 6 H), 0.30, 0.45 (2d, 3 H, *J* = 4.86, 4.92 Hz); MS (ESI) *m/z* 614.2 (M⁺ + H).

Compound 274**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one**

[0373] Compound 274 (0.12 g, 76.5%) as white solid was obtained according to the same method as the synthesis of compound 18.

[0374] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1 H), 7.72 (d, *J* = 0.4 Hz, 2 H), 6.84, 6.80 (2d, *J* = 8.7 Hz, 1 H), 6.56, 6.52 (2d, *J* = 12.2 Hz, 1 H), 5.59 (t, *J* = 8.4 Hz, 1 H), 4.01-3.88 (m, 2 H), 3.73, 3.71 (2s, 3 H), 3.59, 3.46 (2d, *J* = 14.6 Hz, 1 H), 3.13 (m, 1 H), 2.44-1.13 (m, 16 H), 0.44-0.34 (m, 7H); MS (ESI): 600 (M⁺ + H).

Compound 275**tert-butyl 6-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-5-methoxyindoline-1-carboxylate**

[0375] tert-Butyl 5-methoxy-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)indoline-1-carboxylate was synthesized using 4-methoxyindoline as a starting material, and then Compound 275 (0.24 g, 72.1 %) as white solid foam was obtained according to the similar method to the synthesis of compound 133.

[0376] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84, 7.77, 7.73 (3s, 3 H), 7.53-7.05 (brs, 1 H), 6.70, 6.66 (2s, 1 H), 5.65-5.58 (m, 1 H), 4.10-3.88 (m, 4 H), 3.71-3.39 (m, 4 H), 3.07-3.02 (m, 2 H), 2.45-1.85 (m, 4 H), 1.51-1.18 (m, 16 H), 1.02-0.94 (m, 6 H), 0.85 (m, 3 H), 0.43, 0.37 (2d, 3 H, *J* = 6.5, 6.3 Hz); MS (ESI): 683 (M⁺ + H).

Compound 276**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0377] Compound 276 (0.13 g, 63.5%) as colorless oil was obtained according to the same method as the synthesis of compound 267.

[0378] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1 H), 7.73 (s, 2 H), 6.74, 6.67 (2s, 1 H), 6.31, 6.29 (2s, 1 H), 5.59, 5.58 (2s, 1 H), 4.05-3.87 (m, 2 H), 3.67-3.63 (m, 4 H), 3.55-2.48 (m, 3 H), 3.01-2.97 (m, 2 H), 2.45-1.86 (m, 4 H), 1.45 (m, 2

H), 1.03, 1.01, 0.99 (3s, 6 H), 0.48, 0.33 (2d, 3 H, $J = 6.5$ Hz); MS (ESI): 583 ($M^+ + H$).

Compound 277

(4S,5R)-3-((2-(1-acetyl-5-methoxyindolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0379] Compound 277 (18 mg, 64.6%) as colorless oil was obtained according to the same method as the synthesis of compound 261.

[0380] ^1H NMR (400 MHz, CDCl_3): atropisomer mixture; δ 7.91-7.74 (m, 4 H), 6.71 (d, 1 H, $J = 12.7$ Hz), 6.54, 5.50 (2d, 1 H, $J = 8.08, 8.04$ Hz), 4.12-3.91 (m, 4 H), 3.73, 3.72 (2s, 3 H), 3.59, 3.37 (2d, 1 H, $J = 14.7$ Hz), 3.17 (m, 2 H), 2.37-1.91 (m, 6 H), 1.46 (m, 2 H), 1.02, 1.00, 0.99 (3s, 6 H), 0.41, 0.38 (2d, 3 H, $J = 6.5$ Hz); MS (ESI): 625 ($M^+ + H$).

Compound 278

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(2,2,2-trifluoroethyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0381] Compound 278 (4 mg, 11.3%) as colorless oil was obtained according to the same method as the synthesis of compound 261.

[0382] ^1H NMR (400 MHz, CDCl_3): atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2 H), 6.74, 6.68 (2s, 1 H), 6.12 (s, 1 H), 5.58, 5.56 (2d, 1 H, $J = 4.2$ Hz), 4.03-3.85 (m, 2 H), 3.69, 3.67 (2s, 3 H), 3.63-3.38 (m, 5 H), 3.02-2.98 (m, 2 H), 2.47-1.87 (m, 6 H), 1.47 (m, 2 H), 1.25 (m, 6 H), 0.37, 0.35 (2d, 3 H, $J = 6.5$ Hz); MS (ESI): 665 ($M^+ + H$).

Compound 280

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-methoxy-1-(methylsulfonyl)indolin-6-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0383] Compound 280 (19 mg, 64.4%) as colorless oil was obtained according to the same method as the synthesis of compound 261.

[0384] ^1H NMR (400 MHz, CDCl_3): atropisomer mixture; δ 7.85 (s, 1 H), 7.74 (s, 2 H), 7.06 (d, 1 H, $J = 16.2$ Hz), 6.75 (d, 1 H, $J = 13.6$ Hz), 5.59 (2d, 1 H, $J = 8.2$ Hz), 3.99-3.87 (m, 4 H), 3.75-3.72 (2s, 3 H), 3.52, 3.33 (2d, 1 H, $J = 14.9, 14.6$ Hz), 3.14-3.09 (m, 2 H), 2.84, 2.79 (2s, 3 H), 2.38-1.91 (m, 4 H), 1.45 (m, 2 H), 1.03, 1.01, 1.00 (2d, 3 H, $J = 6.5$ Hz); MS (ESI): 661, 683 ($M^+ + H$).

Compound 285

methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoate

[0385] As shown in reaction scheme 6, Compound 22, an intermediate compound, was synthesized, and then subjected to reductive amination using Compound 4, which is an amino alcohol compound, to synthesize Compound 23. The obtained

Compound 23 (0.21 g, 0.34 mmol) was dissolved in methylene chloride (3 mL). Diisopropylamine (0.36 mL) and triphosgene (0.15 g) were added dropwise in sequence to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (12 g silica, 3:1 = n-hexane : EtOAc), thus obtaining Compound 285 (0.1 g, 45%) as white solid foam.

[0386] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (d, 1 H, J = 9.4 Hz), 6.92- 6.95 (m, 1 H), 6.67 - 6.77 (m, 2 H), 5.58 - 5.61 (m, 1 H), 3.87 - 4.01 (m, 2 H), 3.71, 3.73 (2s, 3 H), 3.63, 3.64 (2s, 3 H), 3.50, 3.59 (2d, 1 H, J = 11.25, 10.86 Hz), 2.73 - 2.77 (m, 2 H), 2.15 - 2.50 (m, 2 H), 1.90 - 2.05 (m, 2 H), 1.45 - 1.50 (m, 2 H), 1.12 - 1.15 (m, 6 H), 0.90 - 1.04 (m, 6 H), 0.28, 0.41 (2d, 3 H, J = 4.86, 4.92 Hz); MS (ESI) m/z 656 (M^+ + H).

Compound 286

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoic acid

[0387] Compound 286 (27 mg, 42.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0388] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 - 7.75 (m, 2 H), 6.99 - 7.02 (m, 1 H), 6.72 - 6.81 (m, 2 H), 5.61 (d, 1 H, J = 8.1 Hz), 3.88 - 4.02 (m, 2 H), 3.71 - 3.74 (m, 3 H), 3.52, 3.58 (2d, 1 H, J = 14.96, 14.52 Hz), 2.72 - 2.87 (m, 2 H), 2.00 - 2.50 (m, 2 H), 1.93 (m, 2 H), 1.14 - 1.17 (m, 6 H), 0.99 - 1.04 (m, 6 H), 0.28, 0.44 (d, 3 H, J = 6.52, 6.56 Hz); MS (ESI) m/z 656, 547 (M^+ + H).

Compound 291

(R)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide

[0389] Compound 291 (53 mg, 76%) as white solid foam was obtained according to the same method as the synthesis of compound 110.

[0390] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.55, 8.53 (2s, 1H), 7.87-6.81 (m, 11H, ArH), 5.60 (d, 0.5H, J = 8.2), 5.53 (d, 0.5H, J = 8.1), 4.08-3.93 (m, 2H), 3.77, 3.76 (2s, 3H), 3.52-3.56 (m, 4H), 2.48-2.08 (m, 3H), 1.92 (broad signal, 2H), 1.55-1.39 (m, 2H), 1.04, 1.01 (2s, 6H), 0.40 (d, 1.5H, J = 6.5), 0.36 (d, 1.5H, J = 6.5); MS (ESI) m/z 773.2 (M^+ + H).

Compound 292

(S)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide

[0391] Compound 292 (54 mg, 78%) as white solid foam was obtained according to the same method as the synthesis of compound 110.

[0392] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.54, 8.50 (2s, 1H), 7.87-6.80 (m, 11H, ArH), 5.59 (d, 0.5H, J = 8.1), 5.55 (d, 0.5H, J = 8.1), 4.06-3.94 (m, 2H), 3.77, 3.76 (2s, 3H), 3.55-3.37 (m, 4H), 2.48-2.06 (m, 3H), 1.91 (broad signal, 2H), 1.54-1.40 (m, 2H), 1.04, 1.03, 1.01 (3s, 6H), 0.39 (d, 1.5H, J = 6.5), 0.33 (d, 1.5H, J = 6.5); MS (ESI) m/z 773.2 (M^+ + H).

Compound 293**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one**

[0393] Compound 293 (0.73 g, 71 %) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0394] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1 H), 7.72 (s, 2 H), 7.25-7.20 (m, 1 H), 7.04-6.83 (m, 3 H), 5.58 (t, 1 H, $J = 8.5$ Hz), 4.03-3.90 (m, 2 H), 3.75, 3.74 (2s, 3 H), 3.59, 3.48 (2d, 1 H, $J = 15.0$, 14.6 Hz), 2.47-1.21 (m, 10H), 0.44-0.31 (m, 7H); MS (ESI): 542 ($\text{M}^+ + \text{H}$).

Compound 294**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(2-methoxy-5-nitrophenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one**

[0395] Compound 294 (0.73 g, 71%) as white solid foam was obtained according to the same method as the synthesis of compound 52.

[0396] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.18-8.14 (m, 1 H), 7.94 (dd, 1 H, $J = 9.8$, 2.8 Hz), 7.85 (s, 1 H), 7.71 (d, 2 H, $J = 4.7$ Hz), 6.95 (t, 1 H, $J = 9.4$ Hz), 5.63, 5.58 (2d, 1 H, $J = 8.1$ Hz), 4.01-3.94 (m, 2 H), 3.91, 3.88 (2s, 3 H), 3.53, 3.36 (2d, 1 H, $J = 15.0$ Hz), 2.39-1.31 (m, 7H), 0.46-0.35 (m, 7H); MS (ESI) m/z 585 ($\text{M}^+ + \text{H}$).

Compound 295**(4S,5R)-3-((6-(5-amino-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one**

[0397] Compound 294 (0.21 g, 0.36 mmol) was dissolved in methanol (3 mL). Raney-nickel (3 mL) was added dropwise to the obtained solution at room temperature, and stirred under hydrogen gas overnight. After the completion of the reaction, the reaction mixture was filtered with celite, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (25%-60% n-hexane / EtOAc), thus obtaining Compound 295 (0.12 g, 60%) as colorless oil.

[0398] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.71 (d, 2 H, $J = 4.1$ Hz), 6.73-6.46 (m, 2 H), 5.59, 5.53 (2d, 1 H, $J = 8.0$ Hz), 4.09-3.89 (m, 2 H), 3.74, 3.70 (2s, 3 H), 3.70-3.49 (m, 1 H), 2.47-1.23 (m, 7H), 0.50-0.35 (m, 7H); MS (ESI) m/z 555 ($\text{M}^+ + \text{H}$).

Compound 296**(R)-N-3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide**

[0399] Compound 296 (15 mg, 15%) as white solid was obtained according to the same method as the synthesis of compound 110.

[0400] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.56 (s, 1 H), 7.97-7.94 (m, 1 H), 7.85-7.69 (m, 3 H), 7.51 (m, 2 H), 7.44-7.34 (m, 4 H), 6.84 (t, 1 H, $J = 8.6$ Hz), 5.56, 5.52 (2d, 1 H, $J = 8.2$ Hz), 4.11-3.89 (m, 3 H), 3.77, 3.76 (2s, 3 H), 3.56-3.34 (m, 4 H), 2.44-1.24 (m, 11 H), 0.46-0.29 (m, 9H); MS (ESI) m/z 771 ($\text{M}^+ + \text{H}$).

Compound 297

(S)-N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-2-phenylpropanamide

[0401] Compound 297 (17 mg, 21 %) as white solid was obtained according to the same method as the synthesis of compound 110.

[0402] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.55, 8.53 (2s, 1 H), 7.84 (s, 1 H), 7.72-7.65 (m, 3 H), 7.56 (m, 1 H), 7.43-7.40 (m, 3 H), 7.33-7.17 (m, 3 H), 6.84, 6.81 (2d, 1 H, $J = 8.9$ Hz), 5.54 (d, 1 H, $J = 8.1$ Hz), 4.04-3.89 (m, 3 H), 3.77, 3.76 (2s, 3 H), 3.57-3.39 (m, 4 H), 2.45-1.23 (m, 9H), 0.46-0.34 (m, 8H); MS (ESI) m/z 771 ($\text{M}^+ + \text{H}$).

Compound 298

(R)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluoro-2-methoxy-N-methyl-2-phenylpropanamide

[0403] Compound 298 (30 mg, 82%) as white solid was obtained according to the same method as the synthesis of compound 112.

[0404] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (m, 1 H), 7.72 - 7.78 (m, 2 H), 7.59 - 7.60 (m, 1 H), 7.41 - 7.45 (m, 2 H), 7.30 - 7.36 (m, 2 H), 7.01 - 7.04 (m, 1 H), 6.84 - 6.90 (m, 2 H), 5.57 - 5.59 (m, 1 H), 3.90 - 4.10 (m, 2 H), 3.82 - 3.85 (m, 3 H), 3.47 - 3.65 (m, 3 H), 3.47 - 3.65 (m, 3 H), 2.91 - 3.29 (m, 3 H), 2.10 - 2.50 (m, 2 H), 1.80 - 2.00 (m, 2 H), 1.46 - 1.50 (m, 2 H), 0.94 - 1.04 (m, 6 H), 0.29 - 0.50 (m, 3 H); MS (ESI) m/z 787 ($\text{M}^+ + \text{H}$).

Compound 299

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanamide

[0405] Compound 273 (0.48 g, 0.78 mmol) was dissolved in methylene chloride (5 mL). Thionyl chloride (0.1 mL) and dimethylformamide (1 drop) were added dropwise to the obtained solution, and stirred for 5 hours. After the completion of the reaction, the reaction mixture was cooled down to room temperature, and concentrated under reduced pressure to remove the solvent. The residue was dissolved in tetrahydropuran (10 mL). Ammonia water (2 mL) was added dropwise to the obtained solution, and stirred for 1 hour at room temperature. Ethyl acetate was added dropwise to the reaction mixture. And then, the obtained reaction mixture was washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO_2 , 4:1 hexane/ EtOAc), thus obtaining Compound 299 (0.39 g, 84%) as colorless oil.

[0406] ^1H NMR (400 MHz, $\text{DMSO}-d_6$); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, 1 H, $J = 4.6$ Hz), 7.04 - 7.08 (m, 1 H), 6.73 - 6.87 (m, 2 H), 5.47 - 5.62 (in, 3 H), 3.93 - 3.97 (m, 2 H), 3.71, 3.77 (2s, 3 H), 3.38, 3.55 (2d, 1 H, $J = 11.25, 10.89$ Hz), 2.85 - 2.91 (m, 2 H), 2.44 - 2.51 (m, 2 H), 1.90 - 2.30 (m, 4 H), 1.45 - 1.48 (m, 2H), 1.01 - 1.05 (m, 6 H), 0.33, 0.47 (2d, 3 H, $J = 4.89, 4.92$ Hz);

MS (ESI) m/z 613.2 ($M^+ + H$).

Compound 300

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanenitrile

[0407] Compound 299 (0.19 g, 0.32 mmol) was dissolved in pyridine (5 mL). Phosphoryl chloride (0.12 mL) and imidazole (40 mg) were added dropwise to the obtained solution, and stirred at - 20°C for 1 hour. The reaction was quenched with 1M HCl (hydrochloride) solution. The reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO_2 , 4:1 hexane/EtOAc), thus obtaining Compound 300 (0.14 g, 74%) as white oil.

[0408] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.85 (s, 1 H), 7.74 (s, 2 H), 7.06 - 7.12 (m, 1 H), 6.79 - 6.93 (m, 2 H), 5.58, 5.61 (2d, 1 H, J = 6.18, 6.09 Hz), 3.89 - 4.00 (m, 2 H), 3.74, 3.77 (2s, 3 H), 3.46, 3.60 (2d, 1 H, J = 11.28, 10.98 Hz), 2.82- 2.90 (m, 2 H), 2.60 - 2.62 (m, 2 H), 2.20 - 2.59 (m, 2 H), 1.94 (m, 2 H), 1.47 - 1.51 (m, 2 H), 1.01 - 1.05 (m, 6 H), 0.35, 0.42 (2d, 3 H, J = 4.86, 4.92 Hz); MS (ESI) m/z 595.2 ($M^+ + H$).

Compound 301

(4S,5R)-3-((2-(5-(2-(2H-tetrazol-5-yl)ethyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one

[0409] Compound 300 (0.1 g, 0.16 mmol) was dissolved in dimethylformamide (5 mL). Sodium azide (0.04 g) and ammonium chloride (0.04 g, 0.82 mmol) were added dropwise to the obtained solution, and stirred at 120 °C overnight. After the reaction was quenched with 1M HCl (hydrochloride) solution, the reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO_2 , 20:1 DCM/MeOH), thus obtaining Compound 301 (11 mg, 11%) as white oil.

[0410] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.88 (s, 1 H), 7.69 - 7.77 (m, 2 H), 6.73 - 6.83 (m, 2 H), 6.60 - 6.67 (m, 1 H), 5.41, 5.74 (2d, 1 H, J = 6.42, 5.97 Hz), 4.49 - 4.95 (m, 1 H), 4.15 - 4.33 (m, 1 H), 3.70, 3.84 (2s, 3 H), 2.90 - 3.36 (m, 4 H), 1.98 - 2.50 (m, 2 H), 1.90 - 1.98 (m, 2 H), 1.46 - 1.50 (m, 2 H), 1.00 - 1.05 (m, 6 H), 0.60 - 0.70 (2d, 3 H, J = 4.92, 4.98 Hz); MS (ESI) m/z 638.2 ($M^+ + H$).

Compound 302

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0411] Compound 302 (0.12 g, 88.4%) as white solid foam was obtained according to the same method as the synthesis of compounds 18.

[0412] ^1H NMR (400 MHz, $CDCl_3$); atropisomer mixture; δ 7.86 (s, 1H), 7.73 (d, 1 H, J = 3.6 Hz), 6.86, 6.83 (2d, 1 H, J = 8.7 Hz), 6.53, 6.49 (2d, 1 H, J = 12.2 Hz), 5.60 (t, 1 H, J = 7.5 Hz), 3.99-3.89 (m, 2 H), 3.72, 3.68 (2s, 3H), 3.51, 3.39 (2d, 1 H, J = 14.6 Hz), 2.42-1.89 (m, 4 H), 1.45 (m, 2 H), 1.29-1.23 (m, 6 H), 1.03-0.85 (m, 8 H), 0.73-0.60 (m, 4 H), 0.38, 0.31 (2d, 3 H, J = 6.5 Hz); MS (ESI): 614 ($M^+ + H$).

Compound 303

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((6-(4-fluoro-2-methoxy-5-(1-methylcyclopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-one

[0413] Compound 303 (80 mg, 54.7%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0414] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.72 (s, 2 H), 6.92, 6.88 (2d, 1 H, *J* = 8.8, 8.7 Hz), 6.55, 6.51 (2d, 1 H, *J* = 12.2, 12.1 Hz), 5.59 (t, 1 H, *J* = 7.8 Hz), 4.00-3.95 (m, 2 H), 3.73, 3.70 (2s, 3H), 3.54, 3.44 (2d, 1 H, *J* = 14.9, 14.6 Hz), 2.42-1.24 (m, 10 H), 0.74-0.61 (m, 4 H), 0.44-0.37 (m, 7 H); MS (ESI): 612 (M⁺ + H).

Compound 304

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3',5'-difluoro-4'-methoxy-4'-(methoxymethoxy)biphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0415] 3'-(2-(Bromomethyl)-4,4-dicyclohex-1-enyl)-3,5-difluoro-4'-methoxy-4'-(methoxy methoxy)biphenyl, which is an intermediate compound, was dissolved in dimethylformamide (DMF). (4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-oxazolidin-2-one and sodium hydride were added dropwise to the obtained solution at room temperature. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO₂, 5:1 n-hexane : EtOAc), thus obtaining Compound 304 (60 mg, 46%) as white oil.

[0416] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.86 (s, 1 H), 7.79 (s, 2 H), 7.36 - 7.39 (m, 1 H), 6.88 - 6.95 (m, 3 H), 5.57 - 5.62 (m, 1 H), 5.17 (d, 1 H, *J* = 9.9 Hz), 3.96 - 4.04 (m, 2 H), 3.79 - 3.82 (2s, 3 H), 3.58 - 3.62 (m, 3 H), 3.44 - 3.58 (m, 1 H), 2.00 - 2.50 (m, 2 H), 1.93 - 1.95 (m, 2 H), 1.50 - 1.55 (m, 2 H), 1.02 - 1.07 (m, 6 H), 0.37, 0.43 (2d, 3 H, *J* = 6.6, 6.5 Hz); MS (ESI) *m/z* 714 (M⁺ + H).

Compound 305

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(3',5'-difluoro-4'-hydroxy-4-methoxybiphenyl-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0417] Compound 304 (0.03 g, 0.04 mmol), a starting material, was dissolved in methanol (2 mL). The solution (0.5 mL) of hydrogen chloride in methanol was added dropwise to the obtained solution, and stirred at room temperature for 3 hours. After the completion of the reaction, the reaction mixture was extracted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO₂, 5:1 n-hexane : EtOAc), thus obtaining Compound 305 (20 mg, 71%) as white solid.

[0418] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.86 (s, 1 H), 7.72 (s, 2 H), 7.34 - 7.37 (m, 1 H), 6.99 - 7.12 (m, 3 H), 6.89, 6.94 (2d, 1 H, *J* = 8.60, 8.60 Hz), 5.95 (br s, 1 H), 5.61 (t, 1 H, *J* = 7.8 Hz), 3.93 - 4.05 (m, 2 H), 3.78, 3.81 (2s, 3 H), 3.49, 3.63 (2d, 1 H, *J* = 15.04, 14.64 Hz), 2.10 - 2.54 (m, 2 H), 1.95 (m, 2 H), 1.47 - 1.55 (m, 2 H), 1.02 - 1.06 (m, 6 H), 0.37, 0.43 (2d, 3 H, *J* = 6.48, 6.56 Hz); MS (ESI) *m/z* 670 (M⁺ + H).

Compound 306

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanamide

[0419] Compound 306 (42 mg, 56%) as white solid foam was obtained according to the same method as the synthesis of compound 299.

[0420] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 - 7.74 (m, 2 H), 7.00 - 7.03 (m, 1 H), 6.70 - 6.81 (m, 1 H), 5.52 - 5.60 (m, 3 H), 3.88 - 4.03 (m, 2 H), 3.71, 3.75 (2s, 3 H), 3.39, 3.58 (2d, 1 H, J = 14.84, 14.48 Hz), 2.65 - 2.82 (m, 2 H), 2.00 - 2.50 (m, 2 H), 1.92 (m, 2 H), 1.45 - 1.50 (m, 2 H), 1.14 - 1.18 (m, 6 H), 1.01 - 1.64 (m, 6 H), 0.29, 0.46 (2d, 3 H, J = 6.48, 6.56 Hz); MS (ESI) m/z 641 (M⁺ + H).

Compound 307**3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanenitrile**

[0421] Compound 307 (12 mg, 48%) as white solid foam was obtained according to the same method as the synthesis of compound 300.

[0422] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.73 - 7.93 (m, 3 H), 6.82 - 7.16 (m, 3 H), 5.58 - 5.60 (m, 1 H), 3.89 - 4.02 (m, 2 H), 3.75 - 3.77 (m, 3 H), 3.43 - 3.67 (m, 1 H), 2.57 - 2.86 (m, 2 H), 1.85 - 2.47 (m, 4 H), 1.94 (m, 2 H), 1.21 - 1.78 (m, 6 H), 0.85 - 0.89 (m, 6 H), 0.30 - 0.40 (m, 3 H); MS (ESI) m/z 623.3 (M⁺ + H).

Compound 308**methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoate**

[0423] Methyl 3-(4-methoxyphenyl)-3-methylbutanoate, an intermediate compound, was synthesized, and then Compound 308 (0.9 g, 66.5%) as white solid foam was obtained according to the same method as the synthesis of compound 285.

[0424] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (s, 2 H), 7.18 - 7.21 (m, 1 H), 6.92 - 6.96 (m, 1 H), 6.74 - 6.81 (m, 1 H), 5.58 - 5.61 (m, 1 H), 3.87 - 4.00 (m, 2 H), 3.73, 3.74 (2s, 3 H), 3.47, 3.60 (2d, 1 H, J = 11.22 10.89 Hz), 3.49, 3.50 (2s, 3 H), 2.54 - 2.59 (m, 2 H), 2.00 - 2.30 (m, 2 H), 1.93 - 1.94 (m, 2 H), 1.46 - 1.48 (m, 2 H), 1.38 - 1.41 (m, 6 H), 1.01 - 1.05 (m, 6 H), 0.28, 0.41 (2d, 3 H, J = 4.89, 4.92 Hz); MS (ESI) m/z 656.3 (M⁺ + H).

Compound 309**3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoic acid**

[0425] Compound 309 (0.24 g, 32.7%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0426] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (s, 2 H), 7.20 - 7.23 (m, 1 H), 6.94 - 6.98 (m, 1 H), 6.75 - 6.82 (m, 1 H), 5.57 - 5.60 (m, 1 H), 3.85 - 4.01 (m, 2 H), 3.73, 3.75 (2s, 3 H), 3.49, 3.58 (2d, 1 H, J = 10.98, 10.83 Hz),

2.55- 2.64 (m, 2 H), 2.05 - 2.08 (m, 2 H), 1.92 - 1.94 (m, 2 H), 1.47 - 1.51 (m, 2 H), 1.43 - 1.44 (m, 6 H), 1.00 - 1.05 (m, 6 H), 0.26, 0.43 (2d, 3 H, $J = 4.95, 4.86$ Hz); MS (ESI) m/z 642.2 ($M^+ + H$).

Compound 310

methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoate

[0427] Compound 310 (0.7 g, 96.1 %) as white solid foam was obtained according to the same method as the synthesis of compound 285.

[0428] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 - 7.75 (m, 2 H), 6.99 - 7.02 (m, 1 H), 6.71 - 6.79 (m, 2 H), 5.59 - 5.62 (m, 1 H), 3.91 - 4.02 (m, 2 H), 3.71, 3.74 (2s, 3 H), 3.63, 3.68 (2s, 3 H), 3.47, 3.59 (2d, 1 H, $J = 11.10, 10.95$ Hz), 2.40 - 2.47 (m, 2 H), 2.00 - 2.38 (m, 2 H), 1.91 - 1.93 (m, 2 H), 1.76 - 1.80 (m, 2 H), 1.46 - 1.49 (m, 2 H), 1.24 - 1.28 (m, 6 H), 1.19 (d, 1 H, $J = 3.4$ Hz), 1.01- 1.05 (m, 6 H), 0.31, 0.43 (2d, 3 H, $J = 4.86, 4.95$ Hz); MS (ESI) m/z 670.2 ($M^+ + H$).

Compound 311

4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoic acid

[0429] Compound 311 (0.11 g, 20%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0430] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 - 7.75 (m, 2 H), 7.70 - 7.04 (m, 1 H), 6.72 - 6.76 (m, 2 H), 5.59 - 5.61 (m, 1 H), 3.95 - 4.00 (m, 2 H), 3.71 - 3.80 (m, 3 H), 3.40 - 3.59 (m, 1 H), 2.46 - 2.54 (m, 2 H), 2.00 - 2.15 (m, 4 H), 1.84 - 1.93 (m, 2 H), 1.70 - 1.84 (m, 2 H), 1.46 - 1.49 (m, 2 H), 1.22 - 1.24 (m, 6 H), 0.31, 0.44 (2d, 3 H, $J = 5.01, 4.83$ Hz); MS (ESI) m/z 656.3 ($M^+ + H$).

Compound 312

ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylate

[0431] Compound 312 (0.38 g, 85%) as white solid foam was obtained according to the same method as the synthesis of compound 285.

[0432] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84, 7.77, 7.73 (3 brs, 3 H), 7.70-6.95 (m, 1 H), 6.76-6.69 (m, 2 H), 5.58 (t, 1 H, $J = 8.0$ Hz), 4.13-4.05 (m, 2 H), 3.99-3.85 (m, 2 H), 3.72, 3.70 (2s, 3 H), 3.56, 3.45 (2d, 1 H, $J = 14.9, 14.5$ Hz), 2.99-2.94 (m, 2 H), 2.37-1.97 (m, 11 H), 1.46 (m, 2 H), 1.27-1.18 (m, 5 H), 1.03-0.86 (m, 6 H), 0.34, 0.25 (2d, 3 H, $J = 6.5$ Hz); MS (ESI): 726 ($M^+ + H$).

Compound 313

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxylic acid

[0433] Compound 313 (0.15 g, 47.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0434] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84, 7.75, 7.72 (3s, 3 H), 7.04-7.01 (m, 1 H), 6.82-6.70 (m, 2 H), 5.58 (d, 1 H, $J = 8.1$ Hz), 3.99-3.86 (m, 2 H), 3.72, 3.70 (2s, 3 H), 3.56, 3.46 (2d, 1 H, $J = 14.9, 14.6$ Hz), 3.04-2.96 (m, 2H), 2.47-1.81 (m, 12 H), 1.46 (m, 2 H), 1.03-0.98 (m, 6 H), 0.38, 0.25 (2d, 3 H, $J = 6.5$ Hz); MS (ESI): 654 ($\text{M}^+ + \text{H}$).

Compound 314

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutanecarboxamide

[0435] Compound 314 (0.04 g, 59.5%) as colorless oil was obtained according to the same method as the synthesis of compound 299.

[0436] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (s, 2 H), 7.06, 7.03 (2d, 1 H, $J = 7.06, 7.04$ Hz), 6.84, 6.79 (2d, 1 H, $J = 6.84, 6.79$ Hz), 6.77, 6.72 (2d, 1 H, $J = 8.4$ Hz), 5.58, 5.50 (2d, 1 H, $J = 8.1, 8.0$ Hz), 5.34-5.26 (brs, 2H), 4.12-3.85 (m, 2 H), 3.77, 3.70 (2s, 3 H), 3.54, 3.30 (2d, 1 H, $J = 14.8, 14.5$ Hz), 2.96 (d, 2 H, $J = 10.6$ Hz), 2.75-1.79 (m, 11 H), 1.46 (m, 2 H), 1.02-1.00 (m, 3 H); MS (ESI): 697 ($\text{M}^+ + \text{H}$).

Compound 315

methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoate

[0437] Methyl 2-(4-methoxyphenyl)-2-methylpropanoate, an intermediate compound, was synthesized, and then Compound 315 (0.16 g, 76.8%) as colorless oil was obtained according to the same method as the synthesis of compound 285.

[0438] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (d, 2 H, $J = 4.4$ Hz), 7.19, 7.17 (2t, 1 H, $J = 2.7$ Hz), 6.94, 6.90 (2d, 1 H, $J = 2.5$ Hz), 6.81, 6.76 (2d, 1 H, $J = 8.7$ Hz), 5.59, 5.55 (2d, 1 H, $J = 8.2$ Hz), 3.96-3.88 (m, 2 H), 3.75, 3.73 (2s, 3 H), 3.63, 3.55 (2s, 3 H), 3.54, 3.40 (2d, 1 H, $J = 14.8, 13.3$ Hz), 2.52-1.93 (m, 5 H), 1.55-1.44 (m, 10 H), 1.04, 1.02, 1.00 (3s, 6 H), 0.35, 0.27 (2d, 3 H, $J = 6.7, 6.5$ Hz); MS (ESI): 642 ($\text{M}^+ + \text{H}$).

Compound 316

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethyl)pyridin-3-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0439] Compound 316 (0.08 g, 30.6%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0440] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.37 (m, 1 H), 7.88 (s, 1 H), 7.74 (s, 2H), 7.49 (m, 1H), 5.64 (m, 1 H), 4.02-3.94 (m, 5 H), 3.47-3.36 (m, 1 H), 2.60-2.00 (m, 2 H), 1.94 (s, 2 H), 1.55 (m, 2 H), 1.10 (m, 6 H), 0.40 (m, 3 H); MS (ESI): 611.2 ($\text{M}+\text{H}$) $^+$.

Compound 317

methyl-2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetate

[0441] Compound 317 (0.2 g, 77%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0442] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1 H), 7.76 (s, 2 H), 6.67 (m, 1H), 6.50 (m, 1H), 5.95 (2d, 2H, J = 1.04, 1.32 Hz), 5.57 (m, 1 H), 4.09 (m, 1 H), 3.95 (m, 1 H), 3.64 (m, 4 H), 3.50 (s, 2 H), 2.40-2.20 (m, 2 H), 1.95 (s, 2 H), 1.51 (m, 2 H), 1.03 (m, 6 H), 0.41 (m, 3 H); MS (ESI): 628.1 (M+H)⁺.

Compound 318

2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetic acid

[0443] Compound 318 (0.09 g, 76.7%) as colorless oil was obtained according to the same method as the synthesis of compound 134.

[0444] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (s, 2 H), 6.65 (m, 1H), 6.46 (m, 1H), 5.93 (m, 2H), 5.59 (m, 1 H), 4.09-3.91 (m, 2 H), 3.66 (m, 1 H), 3.49 (s, 2 H), 2.40-2.18 (m, 2 H), 1.93 (s, 2 H), 1.50 (m, 2 H), 1.03 (m, 6 H), 0.42 (m, 3 H); MS (ESI): 614.1 (M+H)⁺.

Compound 319

2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)benzo[d][1,3]dioxol-5-yl)-N-methylacetamide

[0445] Compound 318 (0.06 g, 0.1 mmol) was dissolved in methylene chloride (10 mL). Methylamine (0.02 g), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.04 g) and hydroxybenzotriazole (0.03 g) were added to the obtained solution at room temperature, and stirred at room temperature overnight. After the completion of the reaction, ethyl acetate was added dropwise to the reaction mixture. The obtained reaction mixture was washed with saturated sodium hydrogen carbonate solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO₂, 4:1 hexane/ EtOAc), thus obtaining Compound 319 (0.03 g, 49%) as white solid.

[0446] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1 H), 7.75 (s, 2 H), 6.64 (m, 1H), 6.49 (m, 1H), 5.96 (2d, 2H, J = 1.16, 1.28 Hz), 5.69 (br s, 1 H), 5.56 (m, 1 H), 4.17 (m, 1 H), 4.03 (m, 1 H), 3.53 (m, 1 H), 3.34 (s, 2 H), 2.74 (m, 3 H), 2.40-2.20 (m, 2 H), 1.94 (s, 2 H), 1.51 (m, 2 H), 1.02 (m, 6 H), 0.49 (m, 3 H).

Compound 320

2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoic acid

[0447] Compound 320 (0.05 g, 31.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0448] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.71 (d, 2 H, $J = 4.6$ Hz), 7.24-7.21 (m, 1 H), 6.97, 6.96 (2d, 1 H, $J = 2.6$ Hz), 6.82, 6.77 (2d, 1 H, $J = 8.7$ Hz), 5.55 (t, 2 H, $J = 7.9$ Hz), 3.98-3.85 (m, 2 H), 3.75, 3.73 (2s, 3H), 3.54, 3.39 (2d, 1 H, $J = 15.0, 14.6$ Hz), 2.56-1.92 (m, 5 H), 1.54-1.44 (m, 8 H), 1.04, 1.01, 1.00 (3s, 6 H), 0.38, 0.28 (2d, 3 H, $J = 6.6, 6.5$ Hz); MS (ESI): 628 ($\text{M}^+ + \text{H}$).

Compound 321

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamide

[0449] Compound 321 (78 mg, 76.4%) as white solid foam was obtained according to the same method as the synthesis of compound 319.

[0450] ^1H NMR (400 MHz, $\text{DMSO}-d_6$); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 - 7.75 (m, 2 H), 6.94 - 6.98 (m, 1 H), 6.71 - 6.76 (m, 2 H), 5.31 - 5.60 (m, 2 H), 3.88 - 4.06 (m, 2 H), 3.71, 3.76 (2s, 3 H), 3.37, 3.56 (2d, 1 H, $J = 14.92, 14.40$ Hz), 2.47 - 2.84 (m, 2 H), 2.67 - 2.76 (m, 3 H), 2.00 - 2.50 (m, 2 H), 1.93 (m, 2 H), 1.44 - 1.57 (m, 6 H), 1.11 - 1.14 (m, 6 H), 1.01 - 1.05 (m, 6 H), 0.29, 0.46 (2d, 3 H, $J = 6.48, 6.56$ Hz); MS (ESI) m/z 655 ($\text{M}^+ + \text{H}$).

Compound 323

methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylate

[0451] Compound 323 (81 mg, 51%) as white solid foam was obtained according to the same method as the synthesis of compound 285.

[0452] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.77, 7.72 (2s, 2 H), 6.94 - 6.90 (m, 1 H), 6.74 - 6.66 (m, 2 H), 5.59 (t, 1 H, $J = 8.0$ Hz), 3.99 - 3.84 (m, 2 H), 3.75, 3.70 (2s, 3 H), 3.63, 3.59 (2s, 3 H), 3.57, 3.46 (2d, 1 H, $J = 14.5$ Hz), 2.85, 2.81 (2d, 1 H, $J = 3.7$ Hz), 2.53 - 2.42 (m, 1 H), 2.24 - 2.16 (m, 1 H), 2.02 - 1.93 (m, 5 H), 1.64 - 1.44 (m, 7 H), 1.03 - 0.99 (m, 6 H), 0.38, 0.26 (2d, 3 H, $J = 6.6$ Hz); MS (ESI) m/z 682.2, 704.1 ($\text{M}^+ + \text{H}$, $\text{M}^+ + \text{Na}$).

Compound 324

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclopentanecarboxylic acid

[0453] Compound 324 (6 mg, 9.4%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0454] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.73 (s, 2 H), 7.03 - 6.99 (m, 1 H), 6.84 (dd, 1 H, $J = 9.9, 2.2$ Hz), 6.73 (dd, 1 H, $J = 16.4, 8.4$ Hz), 5.62 - 5.58 (m, 1 H), 3.99 - 3.89 (m, 2 H), 3.73, 3.70 (2s, 3 H), 3.54 - 3.50 (m, 1 H), 2.99 - 2.77 (m, 2 H), 2.17 - 1.88 (m, 7 H), 1.66 - 1.32 (m, 7 H), 1.03 - 0.98 (m, 6 H), 0.47, 0.32 (2d, 3 H, $J = 6.6$ Hz); MS (ESI) m/z 668.1, 690.1 ($\text{M}^+ + \text{H}$, $\text{M}^+ + \text{Na}$).

Compound 325

3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoic acid

[0455] Compound 325 (1.07 g, 90%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0456] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.74 (d, 2 H, *J* = 7.0 Hz), 6.92 (t, 0 H, *J* = 58.5 Hz), 6.57 - 6.51 (m, 1 H), 5.62 (dd, 1 H, *J* = 8.2, 2.3 Hz), 4.00 - 3.81 (m, 2 H), 3.73, 3.70 (2s, 3 H), 3.51 - 3.47 (m, 1 H), 2.88 - 2.79 (m, 2 H), 2.49 - 2.41 (m, 1 H), 2.14 - 2.11 (m, 1 H), 1.90 - 1.88 (m, 2 H), 1.49 - 1.40 (m, 2 H), 1.29 - 1.10 (m, 6 H), 1.02 - 0.95 (m, 6 H), 0.46 (2d, 3 H, *J* = 6.6 Hz); MS (ESI) *m/z* 660.2 (M⁺+H).

Compound 326

methyl 7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate

[0457] Methyl 6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate, which is an intermediate compound, was synthesized, and then Compound 326 (0.21 g, 65%) as white solid foam was obtained according to the same method as the synthesis of compound 285.

[0458] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (d, 1 H, *J* = 5.0 Hz), 7.73 (d, 2 H, *J* = 4.5 Hz), 6.67-6.50 (m, 2 H), 5.62-5.58 (m, 1 H), 4.02-3.90 (m, 2 H), 3.72-3.41 (m, 7 H), 2.90-1.78 (m, 10 H), 1.46 (m, 2 H), 1.28 (m, 5 H), 1.03-0.96 (m, 6 H), 0.45 (t, 1.3 H, *J* = 5.9 Hz), 0.33 (d, 1.7 H, *J* = 6.5 Hz); MS(ESI): 654 (M⁺ + H).

Compound 327

7-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid

[0459] Compound 327 (0.07 g, 38.7%) as white solid foam was obtained according to the same method as the synthesis of compound 134.

[0460] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (d, 2 H, *J* = 4.3 Hz), 6.67, 6.66 (2d, 1 H, *J* = 2.2, 1.6 Hz), 6.56, 6.51, 6.50 (3s, 1 H), 5.60 (t, 1 H, *J* = 6.6 Hz), 4.02-3.90 (m, 2 H), 3.71, 3.69, 3.68 (3s, 3 H), 3.62-3.43 (m, 3 H), 2.52-1.81 (m, 4 H), 1.46 (m, 2 H), 1.04, 1.03, 0.99 (3s, 6 H), 0.48-0.33 (m, 3 H); MS(ESI): 640 (M⁺ + H).

Compound 328

methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanoate

[0461] Compound 328 (1.52 g, 98%) as white solid foam was obtained according to the same method as the synthesis of compound 285.

[0462] ^1H NMR (400 MHz, CDCl_3) atropisomer mixture; δ 7.85 (s, 1 H), 7.76, 7.72 (2s, 2 H), 6.67 (dd, 1 H, J = 16.1, 8.6 Hz), 6.53 (dd, 1 H, J = 14.7, 11.7 Hz), 5.60 (t, 1 H, J = 7.4 Hz), 3.98 - 3.84 (m, 2 H), 3.72, 3.70 (2s, 3 H), 3.64 (s, 3 H), 3.54, 3.44 (2d, 1 H, J = 14.4 Hz), 2.85 - 2.72 (m, 2 H), 2.47 - 2.41 (m, 1 H), 2.23 - 2.14 (m, 1 H), 2.00 - 1.91 (m, 2 H), 1.52 - 1.41 (m, 2 H), 1.18 - 1.12 (m, 6 H), 1.05 - 0.98 (m, 6 H), 0.41, 0.31 (2d, 3 H, J = 6.6 Hz); MS (ESI) m/z 674 ($\text{M}^+ + \text{H}$).

Compound 329

3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluoro-4-methoxyphenyl)-2,2-dimethylpropanamide

[0463] Compound 329 (23 mg, 23%) as white solid was obtained according to the same method as the synthesis of compound 299.

[0464] ^1H NMR (400 MHz, CDCl_3) atropisomer mixture; δ 7.84 (s, 1 H), 7.73 (d, 1 H, J = 7.2 Hz), 6.82 (dd, 1 H, J = 17.7, 8.6 Hz), 6.54 (dd, 1 H, J = 15.4, 11.6 Hz), 5.68 (brs, 0.47 H), 5.59 (dd, 1 H, J = 8.1, 3.0 Hz), 5.55 (brs, 0.13 H), 5.41 (brs, 0.4 H), 4.00 - 3.86 (m, 2 H), 3.73, 3.69 (2s, 3 H), 3.53, 3.32 (2d, 1 H, J = 14.6 Hz), 2.88 - 2.72 (m, 2 H), 2.45 - 1.97 (m, 2 H), 1.89 (brs, 2 H), 1.50 - 1.39 (m, 2 H), 1.17 (t, 6 H, J = 9.9 Hz), 1.00 (dd, 6 H, J = 5.3, 12.1 Hz), 0.44, 0.31 (2d, 3 H, J = 6.6 Hz); MS (ESI) m/z 659.1 ($\text{M}^+ + \text{H}$).

Compound 330

ethyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutane carboxylate

[0465] Compound 330 (0.03 g, 72.2%) as white solid was obtained according to the same method as the synthesis of compound 285.

[0466] ^1H NMR (400 MHz, CDCl_3) atropisomer mixture; δ 7.86 (s, 1 H), 7.74 (s, 2 H), 7.03 (m, 1H), 6.79 (m, 2H), 5.62 (m, 1H), 4.20-3.90 (m, 4 H), 3.75 (m, 3 H), 3.60 (m, 1 H), 2.50-1.83 (m, 13 H), 1.50 (m, 2 H), 1.30 (m, 5 H), 1.05 (m, 6 H), 0.44 (2d, 3H, J = 6.56, 6.52 Hz).

Compound 331

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenethyl)cyclobutanecarboxylic acid

[0467] Compound 331 (3 mg, 10.4%) as white solid was obtained according to the same method as the synthesis of compound 286.

[0468] ^1H NMR (400 MHz, CDCl_3) atropisomer mixture; δ 7.85 (s, 1 H), 7.74 (s, 2 H), 7.05 (m, 1H), 6.80 (m, 2H), 5.62 (m, 1H), 4.04-3.90 (m, 2 H), 3.76 (m, 3 H), 3.60 (m, 1 H), 2.50-1.83 (m, 13 H), 1.50 (m, 2 H), 1.30 (m, 5 H), 1.05 (m, 6 H), 0.46 (m, 3H).

Compound 332

3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzonitrile

[0469] Compound 332 (0.2 g, 56.1%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0470] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.88 (s, 1 H), 7.75 (m, 2 H), 7.59 (m, 1H), 7.29 (m, 1H), 6.95 (m, 1H), 5.66, 5.60 (2d, 1H, J = 8.20, 8.08 Hz), 4.01-4.90 (m, 2H), 3.85 (m, 3H), 3.52-3.30 (m, 1 H), 2.20-2.04 (m, 2 H), 1.52-1.47 (m, 2 H), 1.05-0.98 (m, 6 H), 1.47 (m, 3H); MS (ESI): 610.1 ($\text{M}+\text{H}$) $^+$.

Compound 333

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0471] Compound 333 (0.01 g, 18.6%) as white solid foam was obtained according to the same method as the synthesis of compound 301.

[0472] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.13 (m, 1 H), 7.92-7.72 (m, 4 H), 7.03-6.99 (m, 1H), 5.77, 5.62 (2d, 1H, J = 8.00, 8.24 Hz), 4.20-4.03 (m, 2H), 3.86 (m, 3H), 3.12 (m, 1 H), 2.60-2.04 (m, 2 H), 1.54-1.41 (m, 2 H), 1.05-0.98 (m, 6 H), 1.52, 0.46 (2d, 3H, J = 6.56, 6.52 Hz); MS (ESI): 610.1 ($\text{M}+\text{H}$) $^+$.

Compound 334

(4R,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0473] Referring to the published article "Cameron J. Smith et al., J. Med. Chem. 2011 54 4880", (1R,2R)-2-amino-1-(3,5-bis(trifluoromethyl)phenyl)propane-ol was synthesized, and then Compound 334 (0.11 g, 61.1%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0474] ^1H NMR (400 MHz, $\text{DMSO}-d_6$); atropisomer mixture; δ 7.91 (s, 1 H), 7.79 (s, 2 H), 6.74 - 6.78 (m, 2 H), 6.54 - 6.58 (m, 2 H), 5.00 (t, 1 H, J = 5.7 Hz), 3.85 - 3.94 (m, 1 H), 3.66 - 3.73 (2s, 3 H), 3.44 - 3.60 (m, 1 H), 3.34 - 3.50 (m, 1 H), 3.12 - 3.19 (m, 1 H), 2.12 - 2.40 (m, 2 H), 1.85 - 2.07 (m, 2 H), 1.15 - 1.45 (m, 2 H), 1.20 - 1.38 (m, 6 H), 0.95 - 1.19 (m, 3 H), 0.60 - 1.00 (m, 6 H); MS (ESI) m/z 602 ($\text{M}^+ + \text{H}$).

Compound 335

(4S,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0475] Referring to the published article "Cameron J. Smith et al., J. Med. Chem. 2011 54 4880", (1S,2S)-2-amino-1-(3,5-bis(trifluoromethyl)phenyl)propane-ol was synthesized, and then Compound 335 (0.16 g, 86%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0476] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.89 (s, 1 H), 7.78 (s, 2 H), 6.75 (dd, 1 H, J = 5.6, 8.6 Hz), 6.55 (dd, 1 H, J = 12.2, 3.2 Hz), 4.99 (t, 0 H, J = 5.6 Hz), 3.93 - 3.84 (m, 1 H), 3.73, 3.65 (2s, 3 H), 3.59 - 3.32 (m, 2 H), 3.16 - 3.11 (m, 1 H),

2.34 - 2.11 (m, 2 H), 1.94 - 1.84 (m, 2 H), 1.44 - 1.25 (m, 2 H), 1.22 - 1.16 (m, 6 H), 1.09, 0.98 (2d, 3 H, $J = 6.2$ Hz), 0.94 (s, 1.3 H), 0.90 (s, 1.7 H), 0.77 (s, 1.3 H), 0.59 (s, 1.7 H); MS (ESI) m/z 602.1 ($M^+ + H$). (ratio = 1 : 1.25).

Compound 336

(4R,5S)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(4-fluoro-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0477] Referring to the published article "Cameron J. Smith et al., J. Med. Chem. 2011 54 4880", (1S,2R)-2-amino-1-(3,5-bis(trifluoromethyl)phenyl)propane-ol was synthesized, and then Compound 336 (0.09 g, 57%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0478] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (s, 2 H), 6.81 (2d, 1H, $J = 12.64$, 12.68 Hz), 6.56 (2d, 1H, $J = 12.24$, 12.12 Hz), 5.63 (m, 1H), 4.01-3.90 (m, 2H), 3.72 (m, 3 H), 3.56 (m, 1 H), 3.14 (m, 1 H), 2.50-2.00 (m, 2 H), 1.92 (m, 2H), 1.51-1.47 (m, 2H), 1.20 (m, 6H), 1.04 (m, 6H), 0.40 (m, 3H).

Compound 337

7-2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalene-2-carboxamide

[0479] Compound 337 (0.03 g, 79.5%) as white solid foam was obtained according to the same method as the synthesis of compound 299.

[0480] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (d, 2 H, $J = 4.3$ Hz), 6.67, 6.66 (2d, 1 H, $J = 2.2$, 1.6 Hz), 6.56, 6.51, 6.50 (3s, 1 H), 5.60 (t, 1 H, $J = 6.6$ Hz), 4.02-3.90 (m, 2 H), 3.71, 3.69, 3.68 (3s, 3 H), 3.62-3.43 (m, 3 H), 2.52-1.81 (m, 4 H), 1.46 (m, 2 H), 1.04, 1.03 (m, 6H).

Compound 338

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0481] Compound 333 (0.03 g, 0.048 mmol) was dissolved in acetonitrile (10 mL). Potassium carbonate (7 mg) and iodomethane (7 mg) were added to the obtained solution, and then stirred at 100°C overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was PTLC (SiO_2 , $\text{Hex:EA} = 1:1$, thus obtaining Compound 338 (0.01 g, 39.1%) as colorless oil.

[0482] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 8.04 (m, 1 H), 7.85-7.71 (m, 4 H), 6.99-6.94 (m, 1H), 5.66, 5.54 (2d, 1H, $J = 8.04$, 8.04 Hz), 4.40 (m, 3H), 4.03 (m, 2H), 3.83 (m, 3 H), 3.62-3.40 (m, 1 H), 2.53-2.05 (m, 2 H), 1.95 (m, 2 H), 1.50 (m, 2H), 1.06 (m, 6H), 0.38 (m, 3H); MS (ESI): 624.1 ($M + H$) $^+$.

Compound 339

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1-methyl-1H-tetrazol-5-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0483] Compound 339 (0.01 g, 39.1%) as colorless oil was obtained according to the same method as the synthesis of compound 338.

[0484] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.75 (m, 2 H), 7.65-7.48 (m, 2H), 7.06-7.02 (m, 1H), 5.63, 5.57 (2d, 1H, *J* = 8.24, 8.04 Hz), 4.21 (m, 3H), 4.10-3.95 (m, 2 H), 3.90-3.82 (m, 3 H), 3.58-3.35 (m, 1 H), 2.53-2.05 (m, 2 H), 1.95 (m, 2 H), 1.50 (m, 2H), 1.06 (m, 6H), 0.48, 0.44 (2d, 1H, *J* = 6.60, 6.62 Hz); MS (ESI): 624.1 (M+H)⁺.

Compound 340

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0485] Compound 340 (0.04 g, 26.7%) as white solid foam was obtained according to the same method as the synthesis of compound 301.

[0486] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 8.00 (s, 1 H), 7.86, 7.84 (2s, 1 H), 7.73, 7.71 (2s, 1 H), 6.72-6.33 (m, 2 H), 5.62, 5.50 (2d, 1 H, *J* = 8.0 Hz), 4.37-4.04 (m, 2 H), 3.80, 3.66 (2s, 3 H), 3.10, 2.83 (2d, 1 H, *J* = 15, 8.4 Hz), 2.38-1.89 (m, 4 H), 1.60-1.31 (m, 8 H), 1.03-0.97 (m, 6 H), 0.64, 0.38 (2d, 3 H, *J* = 6.6 Hz); MS (ESI): 666 (M⁺ + H).

Compound 341

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0487] Compound 341 (6 mg, 32.6%) as white solid foam was obtained according to the same method as the synthesis of compound 338.

[0488] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.76, 7.72 (2s, 2 H), 6.82-6.79 (m, 1 H), 6.68, 6.64 (2d, 1 H, *J* = 8.4 Hz), 6.43, 6.41 (2d, 1 H, *J* = 2.2 Hz), 5.60, 5.56 (2d, 1 H, *J* = 8.2 Hz), 4.27, 4.26 (2s, 3 H), 3.93-3.73 (m, 2 H), 3.70, 3.68 (2s, 3 H), 3.42, 3.35 (2d, 1 H, *J* = 14.9 Hz), 3.03-2.85 (m, 2 H), 2.48-1.64 (m, 6H), 1.46-1.20 (m, 8 H), 1.06-0.98 (m, 6 H), 0.38, 0.21 (2d, 3 H, *J* = 6.5 Hz); MS (ESI): 680 (M⁺ + H).

Compound 342

tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxoxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)acetate

[0489] Compound 37 (0.1 g, 0.17 mmol) was dissolved in methylene chloride (3 mL). tert-Butyl 2-aminoacetate·HCl (37 mg, 0.22 mmol), diisopropylethylamine (0.09 mL, 0.51 mmol) and hydroxybenzotriazole (46 mg, 0.34 mmol) were added dropwise to the obtained solution, and stirred at room temperature 10 minutes. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide (66 mg, 0.34 mmol) was added dropwise to the reaction mixture, and then stirred at room temperature for 1 hour. After the completion of the reaction, the reaction mixture was diluted with methylene chloride, and washed with water and brine. The organic layers were collected, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was separated by MPLC (SiO₂, 20%-30% Hexane/ EtOAc), thus obtaining Compound 342 (0.1 g, 87%) as white solid.

[0490] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.82 (d, 1 H, $J = 4.7$ Hz), 7.73 - 7.70 (m, 2.5 H), 7.65 (dd, 0.5 H, $J = 8.6, 2.3$ Hz), 7.53, 7.47 (2d, 1 H, $J = 2.4$ Hz), 6.86 (t, 1 H, $J = 8.6$ Hz), 6.67 - 6.60 (m, 1 H), 5.56 (dd, 1 H, $J = 16.3, 8.1$ Hz), 4.12 - 4.03 (m, 2 H), 3.99 - 3.92 (m, 2 H), 3.80, 3.77 (2s, 3 H), 3.47, 3.32 (2d, 1 H, $J = 14.8$ Hz), 2.45 - 2.00 (m, 2 H), 1.90 (brs, 2 H), 1.48 - 1.44 (m, 11 H), 1.00 (dd, 6 H, $J = 11.0, 2.3$ Hz), 0.41, 0.34 (2d, 3 H, $J = 6.5$ Hz); MS (ESI) m/z 699.1 ($\text{M}^+ + \text{H}$).

Compound 343

tert-butyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetate

[0491] Compound 343 (21 mg, 21 %) as white solid was obtained according to the same method as the synthesis of compound 112.

[0492] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.74 (s, 2 H), 7.41 - 7.34 (m, 1 H), 7.20 - 7.12 (m, 1 H), 6.86 - 6.83 (m, 1 H), 5.62, 6.83 (2d, 1 H, $J = 8.1$ Hz), 4.13 - 3.82 (m, 4 H), 3.79, 3.77 (2s, 3 H), 3.52 - 3.34 (m, 1 H), 3.05 - 3.02 (m, 3 H), 2.39 - 2.04 (m, 2 H), 1.92 (brs, 2 H), 1.51 - 1.45 (m, 11 H), 1.03 - 1.00 (m, 6 H), 0.43, 0.37 (d, 3 H, $J = 6.6$ Hz); MS (ESI) m/z 713.1 ($\text{M}^+ + \text{H}$).

Compound 344

(R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoate

[0493] Compound 344 (96 mg, 81 %) as white solid was obtained according to the same method as the synthesis of compound 342.

[0494] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.73 (s, 2 H), 7.71 (dd, 0.5 H, $J = 8.6, 2.4$ Hz), 7.65 (dd, 0.5 H, $J = 8.6, 2.4$ Hz), 7.53, 7.48 (2d, 1 H, $J = 2.3$ Hz), 6.89 (t, 1 H, $J = 8.8$ Hz), 6.58 - 6.54 (m, 1 H), 5.55 (dd, 1 H, $J = 19.5, 8.0$ Hz), 4.76 - 4.69 (m, 1 H), 4.01 - 3.93 (m, 2 H), 3.83, 3.80 (2s, 3 H), 3.77, 3.74 (2s, 3 H), 3.50, 3.33 (2d, 1 H, $J = 15.0$ Hz), 2.45 - 2.21 (m, 2 H), 1.93 (brs, 2 H), 1.52 - 1.46 (m, 2 H), 1.04 - 0.89 (m, 12 H), 0.41 (t, 3 H, $J = 6.7$ Hz); MS (ESI) m/z 699.1 ($\text{M}^+ + \text{H}$).

Compound 345

(R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)-3-methylbutanoate

[0495] Compound 345 (50 mg, 55%) as white solid was obtained according to the same method as the synthesis of compound 112.

[0496] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.74 (d, 2 H, $J = 8.5$ Hz), 7.32 (dd, 1 H, $J = 8.5, 2.2$ Hz), 7.12 (dd, 1 H, $J = 10.5, 2.2$ Hz), 6.88 - 6.53 (m, 1 H), 5.61 (d, 0.5 H, $J = 8.4$ Hz), 5.46 (d, 0.5 H, $J = 7.2$ Hz), 4.08 - 3.90 (m, 3 H), 3.82 - 3.73 (m, 6 H), 3.68 - 3.36 (m, 2 H), 3.01 - 2.96 (m, 3 H), 2.44 - 2.19 (m, 2 H), 1.96 - 1.87 (m, 2 H), 1.53 - 1.41 (m, 2 H), 1.03 - 0.75 (m, 12 H), 0.41, 0.36 (2d, 3 H, $J = 6.5$ Hz); MS (ESI) m/z 713.2 ($\text{M}^+ + \text{H}$).

Compound 346

(R)-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoic acid

[0497] Compound 346 (21 mg, 48%) as white solid was obtained according to the same method as the synthesis of compound 134.

[0498] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (s, 2 H), 7.43 - 7.37 (m, 1 H), 7.22 - 7.09 (m, 1 H), 6.90 - 6.86 (m, 1 H), 5.63 - 5.48 (m, 1 H), 4.23 - 3.95 (m, 4 H), 3.82, 3.80 (2s, 3 H), 3.51 - 3.32 (m, 1 H), 3.06 (brs, 3 H), 2.56 - 2.17 (m, 2 H), 1.92 - 1.87 (m, 2 H), 1.49 - 1.41 (m, 2 H), 1.10 - 0.84 (m, 12 H), 0.43, 0.38 (2d, 3 H, *J* = 6.0 Hz); MS (ESI) *m/z* 699.1 (M⁺+H).

Compound 347**methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)cyclobutane carboxylate**

[0499] Compound 313 (0.03g, 0.046 mmol) was dissolved in dimethylformamide (3 mL). Potassium carbonate (8.2 mg) and iodomethane (4.0 μL) were added dropwise to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with ethyl acetate, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (SiO₂, 5%-20% n-hexane / EtOAc), thus obtaining Compound 347 (0.02 g, 75.1%) as white solid foam.

[0500] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1 H), 7.77, 7.73 (2s, 2 H), 6.96-6.93 (m, 1 H), 6.76-6.69 (m, 2 H), 5.58 (t, 1 H, *J* = 8.2 Hz), 3.98-3.84 (m, 2 H), 3.72, 3.70 (2s, 3 H), 3.63, 3.61 (2s, 3 H), 3.55, 3.46 (2d, 1 H, *J* = 14.5 Hz), 3.00-2.94 (m, 2 H), 2.39-1.81 (m, 11 H), 1.46 (m, 2 H), 1.03-0.99 (m, 6 H), 0.35, 0.25 (2d, 3 H, *J* = 6.5 Hz); 668 (M⁺ + H).

Compound 348**2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-N-methylbenzamido)acetic acid**

[0501] Compound 348 (1.4 mg, 8%) as white solid was obtained according to the same method as the synthesis of compound 134.

[0502] MS (ESI) *m/z* 657.1 (M⁺+H).

Compound 349**Methyl 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoate**

[0503] As shown in reaction scheme 7, Compound 31, an intermediate compound, was synthesized, and then Compound 349 (0.28 g, 69.5%) as white solid foam was obtained according to the similar method to the synthesis of compound 285.

[0504] ¹H NMR (400 MHz, DMSO-d₆); atropisomers mixture; δ 7.86 (m, 1 H), 7.81, 7.83 (2d, 1 H, *J* = 1.77, 1.83 Hz), 7.74 - 7.75 (m, 2 H), 7.02, 7.05 (2d, 1 H, *J* = 1.77, 1.77 Hz), 5.60, 5.63 (2d, 1 H, *J* = 5.94, 6.00 Hz), 3.91 - 4.03 (m, 2 H), 3.85, 3.88 (2d, 3 H),

3.64, 3.65 (2s, 3 H), 3.46- 3.52 (m, 1 H), 2.73 - 2.80 (m, 2 H), 1.90 - 1.95 (m, 2 H), 1.43 - 1.48 (m, 2 H), 1.16 - 1.20 (m, 6 H), 1.01 - 1.09 (m, 6 H), 0.28, 0.49 (2d, 3 H, $J = 4.89, 4.89$ Hz); MS (ESI) m/z 657.2 ($M^+ + H$).

Compound 350

3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoic acid

[0505] Compound 350 (75 mg, 54%) as white solid was obtained according to the same method as the synthesis of compound 134.

[0506] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.90, 7.90 (2d, 1 H, $J = 2.36, 2.36$ Hz), 7.85 - 7.86 (m, 1 H), 7.73 - 7.74 (2s, 2 H), 7.13, 7.15 (2d, 1 H, $J = 2.40, 2.36$ Hz), 5.60, 5.64 (2d, 1 H, $J = 8.16, 8.00$ Hz), 3.91 - 4.02 (m, 2 H), 3.85 - 3.88 (2s, 3 H), 3.50, 3.55 (2d, 1 H, $J = 14.64, 15.16$ Hz), 2.71 - 2.86 (m, 2 H), 2.00 - 2.53 (m, 2H), 1.86 - 1.95 (m, 2 H), 1.46 - 1.49 (m, 2 H), 1.12 - 1.18 (m, 6 H), 1.00 - 1.04 (m, 6 H), 0.30, 0.52 (2d, 3 H, $J = 6.52, 6.60$ Hz); MS (ESI) m/z 643.2 ($M^+ + H$).

Compound 353

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-chloro-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one

[0507] Compound 353 (1.2 g, 62.6%) as white solid foam was obtained according to the same method as the synthesis of compound 18.

[0508] ^1H NMR (400 MHz, $CDCl_3$); atropisomer mixture; δ 7.87 (s, 1 H), 7.75 (m, 2 H), 7.20-7.17 (m, 1H), 6.96 (m, 1H), 6.81, 6.77 (2d, 1H, $J = 8.80, 8.80$ Hz), 5.65, 5.59 (2d, 1H, $J = 8.16, 8.24$ Hz), 4.01-3.90 (m, 2H), 3.76(m, 3 H), 3.58-3.38 (m, 1 H), 2.50-2.00 (m, 2 H), 1.92 (m, 2H), 1.50-1.40 (m, 2H), 1.04 (m, 6H), 0.40 (m, 3H); MS (ESI): 576.0 ($M+H$) $^+$.

Compound 354

tert-butyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate

[0509] Compound 353 (0.1 g, 0.174 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate (0.05 g, 0.17 mmol), sodium carbonate (0.06 g) and palladium (0.01 g) were dissolved in dimethoxyethane/ water (0.8 mL, v/v 3:1). The obtained solution in microwave-reactor was stirred at 120°C for 30 minutes. After the completion of the reaction, the reaction mixture was cooled down to room temperature, diluted with EtOAc, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (SiO_2 , 10:1 hexane/EtOAc), thus obtaining Compound 354 (10 mg, 8%) as colorless oil.

[0510] ^1H NMR (400 MHz, DMSO- d_6); atropisomer mixture; δ 7.85 (s, 1H), 7.73 (s, 2 H), 7.24 (m, 1 H), 7.00 (m, 1H), 6.85, 6.80 (2d, 1H, $J = 8.68, 8.68$ Hz), 5.90 (m, 1H), 5.59 (m, 1H), 4.10-3.85 (m, 4 H), 3.74 (m, 3 H), 3.60-3.40 (m, 3 H), 2.60-2.03 (m, 5H), 1.92 (m, 2H), 1.44 (m, 9H), 1.03-1.00 (m, 6H), 0.40 (m, 3H).

Compound 355

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-

1-enyl)methyl)-4-methyloxazolidin-2-one

[0511] Compound 355 (30 mg, 27.7%) as white solid foam was obtained according to the same method as the synthesis of compound 354.

[0512] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 (s, 2 H), 7.25 (m, 1 H), 7.02 (m, 1H), 6.85, 6.81 (2d, 1H, J = 8.60, 8.64 Hz), 6.04-5.96 (m, 1H), 5.61 (m, 1H), 4.32-4.26 (m, 1 H), 4.00-3.48 (m, 8 H), 2.48 (m, 2 H), 2.40-2.03 (m, 2H), 1.94 (m, 2H), 1.50 (m, 2H), 1.03-1.00 (m, 6H), 0.40, 0.33 (2d, 3H, J= 6.56, 6.52 Hz).

Compound 356**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-5-(hydroxymethyl)-2-methoxyphenyl)-5-5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0513] According to the same method as the synthesis of Compound 79, the aldehyde compound was synthesized. The obtained aldehyde compound (0.03 g, 0.05 mmol) and (s)-3-fluoropyrrolidine (5 mg) were dissolved in methylene chloride (10 mL). Acetic acid (30 µL) was added dropwise to the obtained solution, and stirred for 1 hour at room temperature. Sodium cyanoborohydride (4 mg) was added dropwise to the reaction mixture. The reaction mixture was stirred overnight, diluted with methylene chloride, washed with saturated sodium hydrogen carbonate solution, water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by PTLC (SiO₂, H₂O:EA = 1:1, thus obtaining "by-product" Compound 356 (0.01 g, 33.2%) as white solid foam.

[0514] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (s, 1 H), 7.73 (m, 2 H), 7.24 (m, 1 H), 7.06-6.98 (m, 1 H), 6.87, 6.82 (2d, 1 H, J= 8.44, 8.40 Hz), 5.59, 5.51 (2d, 1 H, J= 7.96, 8.16 Hz), 4.62-4.53 (m, 2 H), 4.07-3.92 (m, 2 H), 3.79-3.74 (m, 3 H), 3.56-3.37 (m, 1 H), 2.51-2.05 (m, 2 H), 1.93 (m, 2 H), 1.53 (m, 2 H), 1.05-1.02 (m, 6 H), 0.45, 0.34 (2d, 3 H, J= 6.60, 6.52 Hz).

Compound 357**methyl 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,2,4-oxadiazole-5-carboxylate**

[0515] Compound 332 (0.03 g, 0.053 mmol) was dissolved in ethanol (20 mL). Sodium carbonate (22 mg) and hydroxylamine (11 mg) were added dropwise to the obtained solution at room temperature, and stirred at 90°C overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature, and concentrated under reduced pressure to remove the solvent. The residue was dissolved in pyridine (5 mL). Methyl 2-chloro-2-oxoacetate (20 mg) was added dropwise to the obtained solution at room temperature, and stirred at 40°C overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with EtOAc, washed with saturated ammonium solution and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (SiO₂, H₂O:EA = 4:1, thus obtaining Compound 357 (5 mg, 45%) as white solid foam.

[0516] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 8.07 (m, 1 H), 7.87 (m, 2 H), 7.74 (m, 2 H), 7.00, 6.97 (2d, 1 H, J = 8.64, 8.68 Hz), 5.66, 5.56 (2d, 1 H, J = 8.12, 8.24 Hz), 4.12 (m, 3 H), 4.03 (m, 2 H), 3.86 (m, 3 H), 3.58-3.36 (m, 1 H), 2.45-2.03 (m, 2 H), 1.95 (m, 2 H), 1.55-1.46 (m, 2 H), 1.06-1.01 (m, 6 H), 0.39 (m, 3 H).

Compound 358**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0517] Compound 354 (0.03 g, 0.042 mmol) was dissolved in methanol/HCl solution. The obtained solution was stirred at room temperature overnight. After the completion of the reaction, the reaction mixture was concentrated under reduced pressure. The residue was separated by column chromatography, thus obtaining Compound 358 (0.02 g, 77%) as yellow solid.

[0518] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.99 (m, 1 H), 7.92 (m, 2 H), 7.40 (m, 1 H), 7.20-6.98 (m, 2 H), 6.10-6.00 (m, 1 H), 5.90-5.80 (m, 1 H), 4.20 (m, 1 H), 3.82-3.78 (m, 5 H), 3.60-3.40 (m, 3 H), 2.80 (m, 2 H), 2.45-1.85 (m, 4 H), 1.55-1.46 (m, 2 H), 1.09-1.01 (m, 6 H), 0.48, 0.38 (2d, 1 H, J = 5.64, 6.40 Hz).

Compound 359

methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridine-1(2H)-carboxylate

[0519] Compound 359 (20 mg, 62.5%) as white solid was obtained according to the same method as the synthesis of compound 110.

[0520] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 (s, 2 H), 7.24 (m, 1 H), 7.00 (m, 1 H), 6.85, 6.80 (2d, 1 H, J = 8.68, 8.64 Hz), 6.00-6.84 (m, 1 H), 5.61 (m, 1 H), 4.11-3.90 (m, 4 H), 3.80-3.44 (m, 9 H), 2.52-1.91 (m, 6 H), 1.52-1.45 (m, 2 H), 1.06-1.01 (m, 6 H), 0.39 (2d, 3 H); MS (ESI): 681.1 (M^+H^+).

Compound 360

(S)-methyl 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)pyrrolidine-2-carboxylate

[0521] Compound 360 (65 mg, 54%) as colorless oil was obtained according to the same method as the synthesis of compound 356.

[0522] MS (ESI) m/z 683.2 (M^+H^+).

Compound 361

(R)-methyl 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzylamino)-3-methylbutanoate

[0523] Compound 361 (68 mg, 57%) as yellow oil was obtained according to the same method as the synthesis of compound 356.

[0524] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.84 (s, 1 H), 7.72 (s, 2 H), 7.16 (dd, 1 H, J = 8.4, 2.2 Hz), 6.92 (dd, 1 H, J = 7.4, 2.2 Hz), 6.81 - 6.74 (m, 1 H), 5.60 (dd, 1 H, J = 3.6, 8.1 Hz), 4.03 - 3.86 (m, 2.5 H), 3.75 - 3.68 (m, 7 H), 3.65 - 3.41 (m, 2.5 H), 3.00 - 2.94 (m, 1 H), 2.45 - 2.05 (m, 2 H), 1.91 - 1.81 (m, 2 H), 1.51 - 1.42 (m, 2 H), 1.03 - 1.00 (m, 6 H), 0.94 - 0.83 (m, 6 H), 0.42, 0.30 (2d, 3 H, J = 6.6 Hz); MS (ESI) m/z 685.2 (M^+H^+).

Compound 362

4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclohex-3-enecarboxylic acid

[0525] According to the same method as the synthesis of Compound 354, the obtained methyl 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl) phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyclohex-3-enecarboxylate was dissolved in dioxan/water (5 mL, v/v 2:1). Lithium hydroxide (10 mg) was added dropwise to the obtained solution at room temperature, and stirred at room temperature for 5 hours. After the completion of the reaction, the reaction mixture was acidified with 2 M HCl solution. The reaction mixture was diluted with EtOAc, was washed with water and brine. The organic layers were collected, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (3:1 hexane:EtOAc), thus obtaining Compound 362 (30 mg, 24%) as white solid foam.

[0526] ¹H NMR (400 MHz, DMSO-d₆); atropisomer mixture; δ 7.86 (s, 1 H), 7.73 (s, 2 H), 7.21 - 7.25 (m, 1 H), 6.99 - 7.00 (m, 1 H), 6.78, 6.83 (2d, 1 H, J = 8.68, 8.68 Hz), 5.94 - 6.03 (m, 1 H), 5.58, 5.61 (2d, 1 H, J = 8.04, 8.20 Hz), 3.91 - 4.01 (m, 2 H), 3.72 - 3.78 (m, 3 H), 3.49, 3.61 (2d, 1 H, J = 15.08, 14.68 Hz), 2.10 - 2.70 (m, 8 H), 1.90 - 1.93 (m, 2 H), 1.43 - 1.53 (m, 2 H), 1.01 - 1.05 (m, 6 H), 0.32 - 0.43 (2d, 3 H, J = 6.48, 5.76 Hz); MS (ESI) m/z 666 (M⁺ + H).

Compound 363**(R)-methyl 2-((3-(2-(((4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxybenzyl)(methyl)amino)-3-methylbutanoate**

[0527] Compound 363 (13 mg, 21%) as colorless oil was obtained according to the same method as the synthesis of compound 112.

[0528] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.85 (d, 1 H, J = 4.9 Hz), 7.72 (s, 2 H), 7.16 (d, 1 H, J = 8.4 Hz), 6.90 (d, 1 H, J = 2.0 Hz), 6.78 (dd, 1 H, J = 18.2, 8.4 Hz), 5.61 - 5.57 (m, 1 H), 4.03 - 3.88 (m, 2 H), 3.74 - 3.69 (m, 6 H), 3.65 - 3.30 (m, 3 H), 2.79 (dd, 1 H, J = 7.0, 10.7 Hz), 2.52 - 2.18 (m, 3 H), 2.10 - 2.01 (m, 3 H), 1.92 - 1.90 (m, 2 H), 1.51 - 1.44 (m, 2 H), 1.04 - 0.95 (m, 9 H), 0.87 - 0.81 (m, 3 H), 0.40, 0.27 (2d, 3 H, J = 6.6 Hz); MS (ESI) m/z 699.2 (M⁺+H).

Compound 364**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(2-methoxy-5-(((R)-2-(trifluoromethyl)pyrrolidin-1-yl)methyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0529] Compound 364 (22 mg, 36%) as colorless oil was obtained according to the same method as the synthesis of compound 356.

[0530] ¹H NMR (400 MHz, CDCl₃); atropisomer mixture; δ 7.84 (s, 1 H), 7.73 (d, 1 H, J = 4.2 Hz), 7.18 (dd, 0.5 H, J = 8.4, 2.1 Hz), 7.10 (dd, 0.5 H, J = 8.3, 2.0 Hz), 6.94, 6.88 (2d, 1 H, J = 2.0 Hz), 6.77 (d, 1 H, J = 8.4 Hz), 5.60 (dd, 1 H, J = 14.2, 8.1 Hz), 4.08 - 3.88 (m, 3 H), 3.74, 3.72 (2s, 3 H), 3.58, 3.50 (2d, 1 H, J = 14.8 Hz), 3.42 - 3.36 (m, 1 H), 3.23 - 3.18 (m, 1 H), 2.92 - 2.70 (m, 1 H), 2.47 - 2.05 (m, 3 H), 2.07 - 1.76 (m, 6 H), 1.53 - 1.43 (m, 2 H), 1.03 (d, 6 H, J = 12.1 Hz), 0.37, 0.29 (2d, 3 H, J = 6.6 Hz); MS (ESI) m/z 693.1 (M⁺+H).

Compound 366**(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one**

[0531] As shown in reaction scheme 8, 2-bromopyridin-3-ol, as a starting material, was subjected to the several processes, to synthesize 2-(2-(ethoxycarbonyl)-4,4-dimethylcyclohex-1-enyl)-6-diisopropyl-3-methoxypyridin-1-oxide. The synthesized compound was reacted with diisobutylaluminum hydride (DIBAL-H) and Dess-Martin periodinane (DMP) reagent, thus synthesizing an aldehyde compound. The obtained aldehyde compound was subjected to reductive amination using amino alcohol, thereby an amino alcohol compound was synthesized. 2-(2-(ethoxycarbonyl)-4,4-dimethylcyclohex-1-enyl)-6-diisopropyl-3-methoxypyridin-1-oxide (62 mg, 0.11 mmol), a starting compound, was dissolved in methylene chloride (5 mL). Diisopropylamine (0.11 mL) and triphosgene (0.05 g, 0.16 mmol) were added dropwise to the obtained solution at room temperature, and stirred at room temperature for 2 hours. After the completion of the reaction, the reaction mixture was diluted with EtOAc, washed with water and brine, dried with anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (12 g silica, 3:1 = n-hexane : EtOAc, thus obtaining Compound 43 (32 mg, 48.4%) as colorless oil. Compound 43 (32 mg, 0.05 mmol) was dissolved in ethanol (5 mL). Indium (7 mg) and saturated ammonium solution (4 mL) were added dropwise to the obtained solution, and stirred at 80°C overnight. After the completion of the reaction, the reaction mixture was cooled down to room temperature. The reaction mixture was diluted with EtOAc, washed with water and brine, dried with sodium sulfate anhydrous, filtered, and concentrated under reduced pressure to remove the solvent. The residue was separated by MPLC (4 g silica, 1:1 = n-hexane : EtOAc, thus obtaining Compound 366 (5 mg, 16.1 %) as colorless oil.

[0532] ^1H NMR (400 MHz, DMSO- d_6); δ 7.85 (s, 1 H), 7.73 (s, 2 H), 7.10 (d, 1 H, J = 8.6 Hz), 7.02 (d, 1 H, J = 8.5 Hz), 5.54 (d, 1 H, J = 7.6 Hz), 3.97 - 4.05 (m, 2 H), 3.77 (m, 3 H), 3.40 (d, 1 H, J = 15.0 Hz), 2.94 - 3.01 (m, 1 H), 2.18 - 2.48 (m, 2 H), 1.95 (m, 2 H), 1.41 - 1.55 (m, 2 H), 1.20 - 1.25 (m, 6 H), 0.33 (d, 3 H, J = 6.5 Hz); MS (ESI) m/z 585 ($M^+ + \text{H}$).

Compound 367

(4S,5R)-5-(3,5-bis(trifluoromethyl)phenyl)-3-((2-(5-(((S)-3-fluoropyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-one





[0533] Compound 367 (10 mg, 30%) as white solid foam was obtained according to the same method as the synthesis of compound 356.

[0534] ^1H NMR (400 MHz, CDCl_3); atropisomer mixture; δ 7.85 (s, 1 H), 7.74 (m, 2 H), 7.21-6.95 (m, 2 H), 6.82 (2d, 1 H, J = 8.52, 8.36 Hz), 5.62 (m, 1 H), 5.30-5.03 (m, 1 H), 4.04-3.91 (m, 2 H), 3.76 (m, 3 H), 3.70-3.42 (m, 3 H), 2.82-2.40 (m, 3 H), 2.30-1.98 (m, 4 H), 1.94 (m, 2 H), 1.53-1.44 (m, 2 H), 1.05-1.01 (m, 6 H), 0.40 (2d, 1 H, J = 6.56, 6.52 Hz); MS (ESI): 643.1 ($M+\text{H}$) $^+$.





[0535] The chemical structures of compounds 15 to 367 as described above are shown in Tables 1 to 45 below.

[Table 1]

Compound	Structure	Compound	Structure
15		16	

Compound	Structure	Compound	Structure
17		18	
19		25	

[Table 2]

Compound	Structure	Compound	Structure
26		27	
28		29	







Compound	Structure	Compound	Structure
		31	

[Table 3]



Compound	Structure	Compound	Structure
32		34	
36		37	
41		42	




[Table 4]

Compound	Structure	Compound	Structure







Compound	Structure	Compound	Structure
43		44	
46		47	
48		49	

[Table 5]

Compound	Structure	Compound	Structure
50		51	

Compound	Structure	Compound	Structure
52			
56		57	

[Table 6]





Compound	Structure	Compound	Structure
58		59	
60		61	
62		63	

[Table 7]





Compound	Structure	Compound	Structure
64		65	
66		67	
68		69	

[Table 8]

Compound	Structure	Compound	Structure
70		71	

Compound	Structure	Compound	Structure
72		76	
79		80	

[Table 9]

Compound	Structure	Compound	Structure
81		82	
83		84	

Compound	Structure	Compound	Structure
85		86	

[Table 10]

Compound	Structure	Compound	Structure
87		96	
97		101	
103		104	

[Table 11]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
107		108	
109		110	
111		112	

[Table 12]

Compound	Structure	Compound	Structure
113		114	
115		116	

Compound	Structure	Compound	Structure
117		118	

[Table 13]

Compound	Structure	Compound	Structure
120		121	
122		123	
124		128	

[Table 14]







Compound	Structure	Compound	Structure
130		132	

Compound	Structure	Compound	Structure
133		134	
136		137	





[Table 15]



Compound	Structure	Compound	Structure
138		140	
141		142	
143		144	

[Table 16]







Compound	Structure	Compound	Structure
145		146	
147		148	
149		151	

[Table 17]

Compound	Structure	Compound	Structure
153		156	
157		159	

Compound	Structure	Compound	Structure
160		161	

[Table 18]

Compound	Structure	Compound	Structure
162		163	
166		167	
168		170	

[Table 19]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
171		172	
173		174	
177		178	

[Table 20]

Compound	Structure	Compound	Structure
179		180	
181		182	







Compound	Structure	Compound	Structure
183		184	

[Table 21]





Compound	Structure	Compound	Structure
185		187	
188		189	
190		191	

[Table 22]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
192		193	
194		195	
196		197	

[Table 23]

Compound	Structure	Compound	Structure
204		206	
207		209	

Compound	Structure	Compound	Structure
210		212	

[Table 24]

Compound	Structure	Compound	Structure
213		215	
216		217	
218			

[Table 25]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
222		223	
224		225	
226		227	

[Table 26]

Compound	Structure	Compound	Structure
228		229	
230			





Compound	Structure	Compound	Structure
232		233	

[Table 27]




Compound	Structure	Compound	Structure
234		235	
237		240	
241		243	

[Table 28]

Compound	Structure	Compound	Structure
244			

Compound	Structure	Compound	Structure
246		247	
248		249	

[Table 29]

Compound	Structure	Compound	Structure
250		251	
259			

[Table 30]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
271		272	

[Table 31]

Compound	Structure	Compound	Structure
273		274	
275		276	
277		278	

[Table 32]

Compound	Structure	Compound	Structure
280			





Compound	Structure	Compound	Structure
		285	

[Table 33]







Compound	Structure	Compound	Structure
286		291	
292		293	
294		295	

[Table 34]

Compound	Structure	Compound	Structure
296		297	

Compound	Structure	Compound	Structure
298		299	
300		301	

[Table 35]

Compound	Structure	Compound	Structure
302		303	
304		305	
306		307	



[Table 36]

Compound	Structure	Compound	Structure







Compound	Structure	Compound	Structure
308		309	
310		311	
312		313	

[Table 37]



Compound	Structure	Compound	Structure
314		315	
316		317	





Compound	Structure	Compound	Structure
318		319	

[Table 38]







Compound	Structure	Compound	Structure
320		321	
323		324	
325		326	

[Table 39]

Compound	Structure	Compound	Structure
327		328	







Compound	Structure	Compound	Structure
329		330	
331		332	

[Table 40]





Compound	Structure	Compound	Structure
333		334	
335		336	
337		338	



[Table 41]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
339		340	
341		342	
343		344	

[Table 42]

Compound	Structure	Compound	Structure
345		346	
347		348	

Compound	Structure	Compound	Structure
349		350	

[Table 43]

Compound	Structure	Compound	Structure
345		346	
347		348	
349		350	

[Table 44]

Compound	Structure	Compound	Structure

Compound	Structure	Compound	Structure
359		360	
361		362	
363		364	

[Table 45]

Compound	Structure	Compound	Structure
366		367	

Measurement of activities of the compounds of the present invention - experimental protocols

[0536] In order to test the effects of the compounds of formula I of the present invention on the prevention and treatment of arteriosclerosis and hyperlipidemia and the safety thereof, comparative tests were carried out using an existing material as a control.

Experimental Example 1: *In vitro* test for the ability to inhibit cholesteryl ester transfer

1. Preparation of cholesteryl ester donor

[0537] In order to prepare a cholesteryl ester donor to be used in the test, a radiolabeled recombinant HDL containing [^3H]-cholesteryl oleate (GE healthcare, TRK886, 3.5 $\mu\text{Ci}/\text{mg}$ of apoA-1) and apoA-1 was synthesized. Then, rHDL-agarose obtained by immobilizing the recombinant HDL with CNBr-activated Sepharose 4B resin (Amersham Biosciences, Sweden) was used in the test.

2. Cholesteryl ester transfer test

[0538] As a source of cholesteryl ester transfer protein, plasma from healthy humans was used, and as cholesteryl ester receptor, LDL from healthy humans was used. Each of test compounds was added to be final concentrations of 16, 80, 400, 2000 and 10000 nM and tested in duplicate. In order to test cholesteryl ester transfer, 20 μl of plasma, 50 μl of LDL (0.25 mg/ml) and 50 μl of rHDL-agarose (0.25 mg/ml) were mixed with each other, and a solution of each test compound was added thereto and reacted thereto at 37 °C. Then, the reaction solution was centrifuged at 4 °C for 3 minutes, thereby the reaction was stopped, 150 μl of the supernatant was transferred into a 96-well plate for radioactivity measurement, and the radioactivity thereof was measured with a beta-ray detector.

3. Statistical processing

[0539] The ratio of [^3H]-cholesteryl oleate transferred from HDL to LDL was determined, and based on the determined ratio, the IC_{50} value of each compound was determined using GraphPad Prism 5.0. The results are shown in Table 46 below.

Table 46. Results of cholesteryl ester transfer test

Compound	IC_{50} (μM)	Compound	IC_{50} (μM)
15	0.60	196	0.49
17	0.51	209	0.01
18	1.36	210	0.008
19	0.002	212	0.08
25	0.20	215	0.02
26	0.92	222	0.04
27	0.24	223	0.1
28	0.39	227	0.14
36	1.09		
44	0.43	234	0.02
48	0.005	237	0.009
79	0.89	241	0.39
80	0.10	243	0.009
82	0.08	244	0.02
86	0.11		
97	0.02	249	0.001
101	0.07	251	0.69
103	0.03		
104	0.18		
107	0.004		
108	0.02	272	0.222
109	0.02	273	0.217
110	0.23	274	0.014
112	0.008	285	0.033

Compound	IC ₅₀ (μM)	Compound	IC ₅₀ (μM)
115	0.01	286	0.012
117	0.08	300	0.001
123	0.02	302	0.006
124	0.02	303	0.005
128	0.06	308	0.007
130	0.02	313	0.020
132	0.05	316	0.030
137	0.08	317	0.054
181	0.05	321	0.104
182	0.05	323	0.058
184	0.02	324	0.097
185	0.18	329	0.009
188	0.12	338	0.035
189	0.02	340	0.008
190	0.01	341	0.013
191	0.09	350	0.051
192	0.06	353	0.030
193	0.04	366	0.006
194	0.1	367	0.083
195	0.84		

Experimental Example 2: *In vitro* test for anti-hyperlipidemia activity in hamsters

1. Experimental animals

[0540] As test animals, 8-week-old male golden syrian hamsters were purchased and used in the experimental. The animal facility was kept at constant temperature and constant humidity with a 12-hr dark/12-hr light cycle, and the animals were allowed to access food and water *ad libitum*.

2. Experimental for anti-hyperlipidemia activity in hamsters

[0541] The test animals were used in the test after an acclimation of 1 week. The test animals were divided according to body weight into several groups, each consisting of 5-8 animals. 3 mg/kg of each test compound (CETP inhibitor) was administered orally to the animals. Each test compounds was suspended in a solvent vehicle that is a solution of 5% ethanol, 10% solutol and 85% deionized water (DW), to be used. Each of test compounds suspended in a solvent vehicle was administered orally to the mice for 5 days. To the control group, a solvent vehicle itself was administered. And then, after 4 hours from the last administration, blood was collected through the cardiac puncture. The collected blood was centrifuged at 3000 rpm for 15 minutes, and the concentration of HDL-cholesterol (Biosystem) in the separated serum was measured using a biochemical analyzer (ILab 300 plus, Instrumentation Laboratory).

3. Statistical processing

[0542] All the results were expressed as mean ± SEM, and each test group and the control group were compared using one-way ANOVA test (Dunnett's test, $p < 0.001$) in order to determine the effect of each test group. The results are shown in Table 47

below.

Table 47. Results of measurement of increase in blood HDL-c levels in hamsters

Compound	HDL-c Increase (%)	Compound	HDL-c Increase (%)
019	35	112	43
025	33	113	17
036	11	115	29
048	41	132	33
073	17	205	8
093	17	106	17
097	22	274	21
099	16	286	42
108	23	287	22
102	25	289	53
106	26	302	38

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [WO2008085A \[0004\]](#)
- [WO2006014357A \[0004\]](#)
- [WO9835937A \[0004\]](#)
- [WO2007081569A2 \[0006\]](#)
- [WO2006014357A1 \[0014\] \[0017\] \[0018\] \[0021\]](#)
- [US20100081673A1 \[0026\]](#)
- [US5829094A1 \[0026\]](#)

Non-patent literature cited in the description

- **GOLDBOURT et al.** Arterioscler Thromb Vase Biol, 1997, vol. 17, 107-113 [0002]
- **TAILOR et al.** Circulation, 2004, vol. 110, 3512-3517 [0002]
- **BARTER et al.** Arterioscler Thromb Vase Biol., 2003, vol. 23, 160-167 [0003]
- **FERREST et al.** British Journal of Pharmacology, 2008, vol. 154, 1465-1473 [0005]
- **HISASHI SHINKAI** Expert Opinion on Therapeutic Patents, 2009, vol. 19, 91229-1237 [0005]
- **NIESOR et al.** Journal of lipid Research, 2010, vol. 51, 3443-3453 [0005]
- **MORRIS, G. A. et al.** Tetrahedron Lett., 2001, vol. 42, 2093- [0017] [0022] [0023] [0024] [0025] [0027]
- **MARTIN G. BANWELL et al.** Org. Lett., 2004, vol. 6, 2741- [0017] [0297]
- **ERIN F. DIMAURO et al.** J. Med. Chem., 2006, vol. 49, 5671- [0017]
- **JINGJUN YIN et al.** J. Org. Chem., 2006, 840- [0018] [0021]
- **AKIO BABA et al.** Tetrahedron, 2009, vol. 65, 5462- [0025] [0026]
- **CAMERON J. SMITH et al.** J. Med. Chem., 2011, vol. 54, 4880- [0473] [0475] [0477]

PATENTKRAV


1. Cykloalkenylaryl-derivater ifølge formel 1, racemat, racemiske blandinger, enantiomere, diastereomere blandinger, diastereomere, atropisomere og blandinger af atropisomere deraf, pharmaceutisk accepterbare salte deraf, hydrater deraf eller opløsninger deraf:

[Formel 1]

10

15

20




hvor

B^1 og B^2 hver uafhængigt er N eller C, med den angivelse, at både B^1 og B^2 ikke samtidigt kan være N, og såfremt en af B^1 og B^2 er N, R^2 eller R^6 ikke tilstede;

- 25 R^1 og R^2 er hver uafhængigt H, -F, -OH, -NH₂, -C(=O)H, -CH₂OH, -OC₁-C₆alkyl, -SC₁-C₆alkyl, -CH₂OC₁-C₆alkyl, -NH(C₁-C₆alkyl), -NH(C=O)(C₁-C₆alkyl), -N(C₁-C₆alkyl)₂, eller

30




- R^1 og R^2 kan sammen med carbonatomerne, hvortil de er knyttet, danne en 5- eller 6-leddet heterocyklisk aromatisk eller ikke-aromatisk ringforbindelse med 1 til 3 heteroatomer uafhængigt udvalgt fra gruppen omfattende N, O, S og C(=O), hvor den heterocykliske aromatiske eller ikke-aromatiske ringforbindelse som option kan være substitueret med R^8 ,
- 35

R^3 er -H, -F, -OH, -C₁-C₆-alkyl;

R^4 er -H, halogen, -CN, -NO₂, -C₁-C₆-alkenyl, -C₁-C₆-cykloalkyl,

5




-OR⁷, -CH₂O⁷, -CH₂NR⁷R⁸, -SR⁷-C(=O)R⁷, -CO₂R⁷, -CHR⁷CO₂R⁸, -C(=O)NR⁷R⁸,

10




15




-NR⁷R⁸, -NR⁷C(=O)R⁸,


20



25



30



35

$-\text{NR}^7\text{C}(=\text{O})\text{NR}^8\text{R}^9$, $-\text{NR}^7\text{C}(=\text{S})\text{NR}^8\text{R}^9$, Ar eller Het;

R^3 og R^4 kan sammen med carbonatomerne, hvortil de er knyttet, danne en 5- eller 6-leddet cykloalkyl eller heterocyklisk ringsammensætning med 0 til 3 heteroatomer uafhængigt udvalgt fra gruppen omfattende N, O, S og $\text{C}(=\text{O})$, hvor den cykloalkyle eller heterocykliske ringsammensætning kan som option være substitueret med R^8 ;

Ar er en C_6 -monocyklisk aromatisk sammensætning, som er usubstitueret eller som option er substitueret med en eller flere udvalgt fra gruppen omfattende halogen, $-\text{OH}$, $-\text{NH}_2$, $-\text{C}_1\text{-C}_5\text{-alkyl}$ og $-\text{OC}_1\text{-C}_6\text{-alkyl}$;

Het er en 5- eller 6-leddet heterocyklisk ringforbindelse omfattende 0 til 2 dobbeltbindinger og med 1 til 4 heteroatomer uafhængigt udvalgt fra gruppen omfattende N, O, S, $\text{C}(=\text{O})$ og $\text{C}(=\text{S})$, og kan være usubstitueret eller som option kan være substitueret med R^8 ;


R^5 er $-\text{H}$, $-\text{F}$, $-\text{OH}$, $-\text{CF}_3$, $-\text{C}_1\text{-C}_6\text{-alkyl}$ eller $-\text{OC}_1\text{-C}_6\text{-alkyl}$;

R^6 er $-\text{H}$ eller $-\text{C}_1\text{-C}_6\text{-alkyl}$;


R^7 er $-\text{H}$, halogen, $-\text{C}(=\text{O})(\text{C}_1\text{-C}_3\text{-Alkyl})$, $-\text{C}_1\text{-C}_6\text{-alkyl}$, $-\text{OC}_1\text{-C}_6\text{-alkyl}$, $-\text{C}_3\text{-C}_6\text{-cykloalkyl}$ eller $-\text{OC}(=\text{O})(\text{C}_1\text{-C}_3\text{-alkyl})$;

R^8 er $-\text{H}$, halogen, $-\text{OH}$, $-\text{CN}$, $-\text{NH}_2$, $-\text{NH}(\text{C}_1\text{-C}_3\text{-Alkyl})$, $-\text{C}(=\text{O})\text{NH}_2$, $-\text{CO}_2\text{H}$,

20




25



$-\text{C}_1\text{-C}_6\text{-alkyl}$, $-\text{OC}_1\text{-C}_6\text{-alkyl}$, $-\text{C}_3\text{-C}_6\text{-cykloalkyl}$, $-\text{Ph}$ eller

30




R^9 er $-\text{H}$, $-\text{CN}$, $-\text{C}_1\text{-C}_6\text{-alkyl}$, $-\text{OC}_1\text{-C}_6\text{-alkyl}$ eller $-\text{C}(=\text{O})(\text{C}_1\text{-C}_3\text{-alkyl})$;


R^{10} er $-\text{NH}(\text{C}_1\text{-C}_3\text{-alkyl})$, $-\text{N}(\text{C}_1\text{-C}_3\text{-alkyl})_2$ eller $-\text{S}(\text{C}_1\text{-C}_3\text{-alkyl})$;

35

Z er $-\text{CH}_2-$,



eller




- 5 R^a er -H, -Cl eller $-CF_3$
 p er et heltal i området 0 til 2;
 A^1 og A^2 er hver uafhængigt $-(CR^{11}R^{12})-$, hvor R^{11} og R^{12} hver uafhængigt er -H, -F eller $-C_1-C_6$ -alkyl, eller R^{11} og R^{12} danner sammen en 3- eller 4-leddet spirocyklisk ikke-aromatisk ringsammensætning;
- 10 A^3 er $-(CH_2)_n-$;
 X er S eller O;
 m er et heltal i området 0 til 3;
 n er et heltal i området 0 til 2;
 q er et heltal i området 1 til 3;
- 15 hvor nævnte $-C_1-C_3$ -alkyl, $-C_3-C_6$ -cykloalkyl, $-C_1-C_6$ -alkyl eller C_2-C_6 -alkenyl er unsubstitueret eller substitueret med en eller flere udvalgt fra gruppen omfattende halogen,
 $-OH$, $-CF_3$, $-CN$, $-CO_2H$, $-C(=O)CH_3$, $-OC(=O)CH_3$, $-C_1-C_3$ -alkyl, $-OC_1-C_3$ -alkyl og
- 20 $-Ph$.
2. Cykloalkenyl-aryl-derivater ifølge krav 1, racemater racemiske blandinger, enantiomere, diastomeriske blandinger, diastomere, atropisomere og blandinger af atropisomere deraf, pharmaceutisk accepterbare salte deraf, hydrater deraf eller opløsninger deraf,
- 25

i hvilke


B^1 og B^2 hver uafhængigt er N eller C, med den betingelse, at både B^1 og B^2 ikke samtidigt kan være N, og såfremt en hvilken som helst af B^1 og B^2 er N, er R^2 eller R^5 fraværende;

- 5 R^1 er -F, -OH, -NH₂, -C(=O)H, -CH₂OH, -OCH₃, -OCF₃, -SCH₃, -CH₂OCH₃, -NHCH₃,



10

-N(CH₃)₂, eller




15

R^2 er -H;

- R^1 og R^2 kan sammen med carbonatomerne, hvortil de er knyttet, danne en 5- eller 6-leddet heterocyklusk aromatisk eller ikke-aromatisk ringsammensætning med 1 til 3
20 heteroatomer uafhængigt udvalgt fra gruppen omfattende N, O, S og C(=O), hvor den heterocykliske aromatiske eller ikke-aromatiske ringsammensætning som option kan være substitueret med R^8 ;

R^3 er -H, -F, -OH, -CH₃, -CF₃, -CH₂CH₃, eller -OCH₃;

- R^4 er -H, -F, -Cl, -CN, -NO₂, -CH₃, -CH₂CH₃, -CH(CH₃)₂, -C(CH₃)₃, -CF₃, -CH(CF₃)₂,
25 -CH(CH₃)(CF₃), -C(OCH₃)(CF₃)₂, -CH(OH)CH₃, -C(OH)(CH₃)₂, -C(OH)(CF₃)₂,
-C(=CF₂)CF₃, -cyklopropyl,



30

-OCH₃, -OCH₂CH₃, -OCH(CH₃)₂, -OC(CH₃)₃, -OCF₃, -OCH₂CF₃, -CH₂OH, -CH₂OCH₃,
-CH₂NR⁷R⁸, -SCH₃, -C(=O)R⁷, -CO₂R⁷, -CHR⁷CO₂R⁸, -C(=O)NR⁷R⁸,

35







5

$-\text{NR}^7\text{R}^8$, $-\text{NR}^7\text{C}(=\text{O})\text{R}^8$, $-\text{NR}^7\text{CO}_2\text{R}^8$,


10



15



20



$-\text{NR}^7\text{C}(=\text{O})\text{NR}^8\text{R}^9$, $-\text{NR}^7\text{C}(=\text{S})\text{NR}^8\text{R}^9$,

Ar eller Het;


R^3 og R^4 kan sammen med carbonatomerne, hvortil de er knyttet, danne en 5- eller 6-
 25 leddet cykloalkyl eller heterocyklisk ringsammensætning med 0 til 3 heteroatomer
 uafhængigt udvalgt fra gruppen omfattende N, O, S og C(=O), hvor den cykloalkyle
 eller heterocykliske ringsammensætning kan som option være substitueret med R^8 ;


Ar er en C6-monocyklisk aromatisk sammensætning, som er usubstitueret eller som
 option er substitueret med en eller flere udvalgt fra gruppen omfattende -F, -Cl, -OH,

30 - NH_2 , - CH_3 og - OCH_3 ;


Het er udvalgt blandt

35







5




10

15 R^5 er -H; R^6 er -H eller -CH₃; R^7 er -H, halogen, -C(=O)(C₁-C₃-Alkyl), -C₁-C₆-alkyl, -OC₁-C₆-alkyl, -C₃-C₆-cykloalkyl eller -OC(=O)(C₁-C₃-alkyl); R^8 er -H, halogen, -OH, -CN, -NH₂, -NH(C₁-C₃-Alkyl), -C(=O)NH₂, -CO₂H,


20




25


-alkyl, -C₃-C₆-cykloalkyl, -Ph eller

30

 R^9 er -H, -CN, -C₁-C₆-alkyl, -OC₁-C₆-alkyl eller -C(=O)(C₁-C₃-alkyl);35 R^{10} er -NH(C₁-C₃-alkyl), -N(C₁-C₃-alkyl)₂ eller -S(C₁-C₃-alkyl);Z er -CH₂-,



eller



R^a er -H, -Cl eller -CF₃

5 p er et heltal i området 0 til 2;

A^1 er -CH₂- eller -C(CH₃)₂-;

A^2 er -(CR¹¹R¹²)-, hvor R¹¹ og R¹² hver uafhængigt er -H, -F, -CH₃, -CF₃, -CH₂CH₃, -CH(CH₃)₂ eller -C(CH₃)C₃, eller R¹¹ og R¹² danner sammen en 3- eller 4-leddet spiro-cyklisk ikke-aromatisk ringsammensætning;

10 A^3 er -(CH₂)_n-;

X er S eller O;

m er et heltal i området 0 til 3;

n er et heltal i området 0 til 2;

q er et heltal i området 1 til 3;

15

hvor nævnte -C₁-C₃-alkyl, -C₃-C₆-cykloalkyl, -C₁-C₆-alkyl eller -C₂-C₆-alkenyl er usubstitueret eller substitueret med en eller flere udvalgt fra gruppen omfattende -F, -Cl, -Br, -OH, -CF₃, -CN, -CO₂H, -C(=O)CH₃, -OC(=O)CH₃, -C₁-C₃-alkyl, -OC₁-C₃-alkyl og -Ph.

20

3. Cykloalkenylaryl-derivater, racemater, racemiske blandinger, enantiomere, diastereomere blandinger, diastereomere, atropisomere og blandinger af atropisomere deraf, farmaceutisk accepterbare salte deraf, hydrater deraf eller solvater deraf ifølge krav 1, hvor cykloalkenylaryl-derivatet er udvalgt fra gruppen omfattende følgende

25 forbindelser:

(4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;

(4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 5 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5-methylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5-methylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
 15 (4S,5R,Z)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohept-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklopent-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-cyklopent-1-enyl)methyl)-4-methyloxazolidin-2-on;
 20 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyklohex-1-enyl)-4-methoxybenzoesyre;
 methyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyklohex-1-enyl)-4-methoxybenzoat;
 25 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzoesyre;
 methyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzoat;
 (4S,5R,Z)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-cyklohept-1-enyl)methyl)-4-methyloxazolidin-2-on;
 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((5-ethyl-2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 35 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(methoxymethyl)-phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxy-phenyl)-5-(trifluormethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 5 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(3'-chlor-4,6'-dimethoxybiphenyl-3-yl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-chlor-2-methoxyphenyl)-cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-3-((2-(1H-indol-4-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(tri-
10 fluormethyl)phenyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(dimethylamino)-2-methoxy-phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 15 2-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyclohex-1-enyl)-5-methoxybenzaldehyd;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-(hydroxymethyl)-4-methoxy-phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-methoxy-2-(methoxymethyl)-phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-3-((2-(chinolin-8-yl)cyclohex-1-enyl)methyl)oxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-3-((2-(1-methyl-1H-indazol-4-yl)cyclohex-1-enyl)methyl)oxazolidin-2-on;
- 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(3-isopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-hydroxy-5-isopropyl-phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-hydroxy-5-isopropyl-phenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-hydroxy-5-isopropyl-phenyl)-5-(trifluormethyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-morpholino-phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 35 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxy-N-methylbenzamid;

- 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyclohex-1-enyl)-N-ethyl-4-methoxybenzamid;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyclohex-1-enyl)-4-methoxy-N-(2,2,2-trifluorethyl)benzamid;
- 5 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxybenzamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)isobutyramid;
- 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(3-cyklopropyl-1,2,4-oxadiazol-5-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyclohex-1-enyl)-4-methoxybenzaldehyd;
- 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-3-((2-(5-acetyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-3-((2-(2-(trifluormethoxy)-phenyl)cyclohex-1-enyl)methyl)oxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-fluor-5-(trifluormethyl)phenyl)-cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 25 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)ethylacetat;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyclohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramid;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)cyclohex-1-enyl)-N-isopropyl-4-methoxy-N-methylbenzamid;
- 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)-phenyl)-5-methylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)-phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 35 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((5-tert-butyl-2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 5 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 10 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)acetamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)isobutyramid;
- 15 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-methylacetamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramid;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-(methoxymethyl)-4-(trifluoromethyl)-phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)-N-(2,2,2-trifluoroethyl)acetamid;
- 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluoromethoxy)-phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- N-acetyl-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-acetamid;
- 30 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluor-N-ethylacetamid;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopyrrolidin-1-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 35 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxopiperidin-1-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((5,5-difluor-2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- methyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(methyl)carbamat;
- 5 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylmethansulfonamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluor-N-methylpropanamid;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(1,1,1-trifluoropropan-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 10 methyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)acetat;
- 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)eddikesyre;
- 15 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)cyklopropansulfonamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-ethoxyphenyl)trifluormethansulfonamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-N-methylcyklopropansulfonamid;
- 20 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-3-methylthiourea;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)trifluor-N-methylmethansulfonamid;
- 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxoimidazolidin-1-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-oxooxazolidin-3-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-3-((2-(2-amino-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
- 30 N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)-N-methylacetamid;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,1-dimethylurea;
- 35 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(methylthio)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

(4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((5,5-dimethyl-2-(2-(methylthio)-5-(trifluormethoxy)phenyl)cyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (Z)-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,1-dimethylguanidin;
 5 (E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-3-methylguanidin;
 (E)-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-cyano-1,3,3-trimethylguanidin;
 (Z)-methyl-N-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl-N'-methylcarbamidimidothioat;
 10 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-1,3,3-trimethylurea;
 methyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)propanoat;
 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(1,1,1-trifluorpropan-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(1,1,1-trifluorpropan-2-yl)-amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2,2,2-trifluoracetamid;
 20 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl)-2-bromacetamid;
 N-(2-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-isopropylphenyl)acetamid;
 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-(methylamino)-phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-(dimethylamino)-5-isopropylphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluoracetyl)-phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(perfluorprop-1-en-2-yl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluorpropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 35 tert-butyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxyphenyl(isopropyl)carbamit;

tert-butyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl(ethyl)carbamat;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-ethylacetamid;
 5 (4S,5R,Z)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2,2,2-trifluor-1-(methoxyimino)ethyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-(2-hydroxy-2-methylpropyl)acetamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(3,3-difluorazetidin-1-carbonyl)-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluor-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-3-((2-(5-acetyl-4-fluor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(3-hydroxyazetidin-1-carbonyl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 25 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)cyklopropanecarbonitril;
 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)cyklopropanecarboxamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(2,2,2-trifluoracetyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(cyklopropanecarbonyl)-4-fluor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)phenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 35 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

(4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluormethyl)cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluormethyl)cyclohex-1-enyl)-4-methoxyphenyl)acetamid;
 5 methyl-5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluor-4-methoxybenzoat;
 5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluor-4-methoxybenzosyre;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-nitro-4-(trifluormethyl)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 10 (4S,5R)-3-((2-(5-amino-2-methoxy-4-(trifluormethyl)phenyl)-5,5-dimethyl-cyclohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethyl-cyclohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)trifluor-N-methylmethansulfonamid;
 15 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-N-methylacetamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluormethyl)thiazol-2-yl)amino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(4-(trifluormethyl)thiazol-2-ylamino)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 20 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluor-4-methoxyphenyl)-N-methylacetamid;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-2-fluor-4-methoxyphenyl)acetamid;
 25 (4S,5R)-3-((2-(5-amino-4-fluor-2-methoxyphenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-nitrophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyclohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-N-methylisobutyramid;
 35 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyclohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-N-methylpropionamid;

- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-N-ethylmethansulfonamid;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-2,2,2-trifluor-N-ethylacetamid;
 5 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)trifluormethansulfonamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2,4-dimethoxy-5-nitrophenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-2,4-dimethoxyphenyl)-N-methylacetamid;
 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-hydroxy-2-methoxy-5-nitrophenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(methylamino)-4-(trifluormethyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 15 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-((2-hydroxy-2-methylpropyl)(methyl)amino)-2-methoxy-4-(trifluormethyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-cyklopropyl-4-fluor-2-methoxy-phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 20 1-((5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl-acetat;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropoxy-2-methoxy-phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 25 1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetat;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-4-methyl-5-nitrophenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 30 (4S,5R)-3-((2-(5-amino-2-methoxy-4-methylphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-methylphenyl)acetamid;
 35 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamid;

N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-methylphenyl)trifluormethansulfonamid;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-methylphenyl)trifluor-N-methylmethansulfonamid;
 5 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-methylethanthioamid;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-thiooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-methylacetamid;
 methyl-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)propanoat;
 10 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)propansyre;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((6-(4-fluor-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-on;
 15 tert-butyl-6-(2-(((4S,SR)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-5-methoxyindolin-1-carboxylat;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-methoxyindolin-6-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-3-((2-(1-acetyl-5-methoxyindolin-6-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-methoxy-1-(2,2,2-trifluorethyl)-indolin-6-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-methoxy-1-(methylsulfonyl)indolin-6-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 25 methyl-3-(3-(2-(((4S,SR)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoat;
 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropansyre;
 (R)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluor-2-methoxy-2-phenylpropanamid;
 30 (S)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluor-2-methoxy-2-phenylpropanamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((6-(2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-on;
 35 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((6-(2-methoxy-5-nitrophenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-on;

(4S,5R)-3-((6-(5-amino-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;

(R)-N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluor-2-methoxy-2-phenylpropanamid;

5 (S)-N-(3-(5-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-spiro[2.5]oct-5-en-6-yl)-4-methoxyphenyl)-3,3,3-trifluor-2-methoxy-2-phenylpropanamid;

(R)-N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluor-2-methoxy-N-methyl-2-phenylpropanamid;

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)propanamid;

10 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)propannitril;

(4S,5R)-3-((2-(5-(2-(2H-Tetrazol-5-yl)ethyl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;

15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(1-methylcyklopropyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

(4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((6-(4-fluor-2-methoxy-5-(1-methylcyklopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-on;

(4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(3',5'-difluor-4-methoxy-4'-(methoxy-methoxy)biphenyl-3-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(3',5'-difluor-4'-hydroxy-4-methoxybiphenyl-3-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanamid;

25 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropannitril;

methyl-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoat;

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3-methylbutansyre;

30 methyl-4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutanoat;

4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylbutansyre;

35 ethyl-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklobutancarboxylat;

1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklobutancarbonylsyre;
 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklobutancarboxamid;
 5 methyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoat;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)-pyridin-3-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 methyl-2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetat;
 10 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)benzo[d][1,3]dioxol-5-yl)eddikesyre;
 2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)benzo[d][1,3]dioxol-5-yl)-N-methylacetamid;
 15 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2-methylpropanoylsyre;
 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamid;
 methyl-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklopentancarboxylat;
 20 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklopentancarbonylsyre;
 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-2-fluor-4-methoxyphenyl)-2,2-dimethylpropanoylsyre;
 25 methyl-7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalin-2-carboxylat;
 7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalin-2-carbonylsyre;
 methyl-3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-2-fluor-4-methoxyphenyl)-2,2-dimethylpropanoat;
 30 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-2-fluor-4-methoxyphenyl)-2,2-dimethylpropanamid;
 ethyl-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenethyl)cyklobutancarboxylat;
 35 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenethyl)cyklobutancarbonylsyre;

- 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzonitril;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 5 (4R,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5S)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4R,5S)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 10 7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-6-methoxy-1,2,3,4-tetrahydronaphthalin-2-carboxamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(1-methyl-1H-tetrazol-5-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-ethyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 20 tert-butyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzamido)acetat;
 tert-butyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-N-methylbenzamido)acetat;
 25 (R)-methyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzamido)-3-methylbutanoat;
 (R)-methyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-N-methylbenzamido)-3-methylbutanoat;
 (R)-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzamido)-3-ethylbutansyre;
 30 methyl-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklobutancarboxylat;
 2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-N-ethylbenzamido)eddikesyre;
 35 methyl-3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropanoat;

3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropansyre;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-chlor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 5 tert-butyl-4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridin-1(2H)-carboxylat;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(3,6-dihydro-2H-pyran-4-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(hydroxymethyl)-2-methoxy-phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 10 methyl-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-1,2,4-oxadiazol-5-carboxylat;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-one ;
 15 methyl-4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-5,6-dihydropyridin-1(2H)-carboxylat;
 (S)-methyl-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)pyrrolidin-2-carboxylat;
 (R)-methyl-2-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzylamino)-3-methylbutanoat;
 20 4-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)cyklohex-3-encarbonsyre;
 (R)-methyl-2-((3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)(methyl)amino)-3-methylbutanoat;
 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(((R)-2-(trifluormethyl)pyrrolidin-1-yl)methyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on; og
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(((S)-3-fluorpyrrolidin-1-yl)-methyl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-ethyloxazolidin-2-on.
 30

4. Cykloalkenylaryl-derivater, racemater, racemiske blandinger, enantiomere, diastereomere blandinger, diastereomere, atropisomere og blandinger af atropisomere deraf, farmaceutisk accepterbare salte deraf, hydrater deraf eller solvater deraf ifølge krav 3, hvor cykloalkenylaryl-derivaterne er udvalgt fra gruppen omfattende følgende sammensætninger:

35

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
- 5 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5-methylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5-methylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-thion;
- methyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyklohex-1-enyl)-4-methoxybenzoat;
- 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyklohex-1-enyl)-4-methoxybenzaldehyd;
- 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 30 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)cyklohex-1-enyl)-4-methoxyphenyl)-N-methylisobutyramid;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((5-tert-butyl-2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 35

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1-hydroxyethyl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 5 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-isopropyl-2-methoxyphenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropyl-2-methoxyphenyl)-4,4-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 10 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)acetamid;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-methylacetamid;
- 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-tert-butyl-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethoxy)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((5,5-difluor-2-(4-fluor-5-isopropyl-2-methoxyphenyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 20 methyl-3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl(methyl)carbamat;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N-methylmethansulfonamid;
- 25 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3,3,3-trifluor-N-methylpropanamid;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(1,1,1-trifluorpropan-2-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)trifluormethansulfonamid;
- 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluor-2-hydroxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(1,1,1,3,3,3-hexafluor-2-methoxypropan-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 35 (4S,5R)-3-((2-(5-acetyl-4-fluor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;

(4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-((R)-4-isopropyl-4,5-dihydrooxazol-2-yl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 5 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)cyklopropancarbnitril;
 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)cyklopropancarboxamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(2,2,2-trifluoracetyl)-phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(cyklopropancarbnonyl)-4-fluor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)-phenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 15 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-nitrophenyl)-5-(trifluormethyl)cyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-3-((2-(5-amino-2-methoxyphenyl)-5-(trifluormethyl)cyklohex-1-enyl)-methyl)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyloxazolidin-2-on;
 N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4-(trifluormethyl)cyklohex-1-enyl)-4-methoxyphenyl)acetamid;
 20 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-trifluormethyl)phenyl)trifluor-N-methylmethansulfonamid;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-N-methylacetamid;
 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(methyl(4-(trifluormethyl)-thiazol-2-yl)amino)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-2-fluor-4-methoxyphenyl)-N-methylacetamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 30 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(6-methoxybenzo[d][1,3]dioxol-5-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-(trifluormethyl)phenyl)-2,2,2-trifluor-N-methylacetamid;
 35 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-2-ethyl-4-methoxyphenyl)-N-methylacetamid;

- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-cyklopropyl-4-fluor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-5-isopropoxy-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 5 1-((3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)(methyl)amino)-2-methyl-1-oxopropan-2-yl acetat;
- N-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2-hydroxy-N,2-dimethylpropanamid;
- N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-methylphenyl)-N-methylacetamid;
- 10 N-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxy-2-methylphenyl)trifluor-N-methylmethansulfonamid;
- methyl-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-ethoxyphenyl)propanoat;
- 15 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)propansyre;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((6-(4-fluor-5-isopropyl-2-methoxyphenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-on;
- methyl-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropanoat;
- 20 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-2,2-dimethylpropansyre;
- 3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)propannitril;
- 25 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(4-fluor-2-methoxy-5-(1-methylcyklopropyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((6-(4-fluor-2-methoxy-5-(1-methylcyklopropyl)phenyl)spiro[2.5]oct-5-en-5-yl)methyl)-4-methyloxazolidin-2-on;
- methyl-3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-3-methylbutanoat;
- 30 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklobutancarbonsyre;
- (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(trifluormethyl)pyridin-3-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
- 35 methyl-2-(7-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)benzo[d][1,3]dioxol-5-yl)acetat;

3-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)-methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxyphenyl)-N,2,2-trimethylpropanamid;
 methyl-1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklopentancarboxylat;
 5 1-(3-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-4-methoxybenzyl)cyklopentancarbonylsyre;
 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-2-fluor-4-methoxyphenyl)-2,2-dimethylpropanamid;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2H-tetrazol-5-yl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 10 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2H-tetrazol-5-yl)-propyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(2-methoxy-5-(2-methyl-2-(2-methyl-2H-tetrazol-5-yl)propyl)phenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on;
 15 3-(5-(2-(((4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-4-methyl-2-oxooxazolidin-3-yl)methyl)-4,4-dimethylcyklohex-1-enyl)-6-methoxypyridin-3-yl)-2,2-dimethylpropansyre;
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-chlor-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on; og
 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(6-isopropyl-3-methoxypyridin-2-yl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on,
 20 (4S,5R)-5-(3,5-bis(trifluormethyl)phenyl)-3-((2-(5-(((S)-3-fluorpyrrolidin-1-yl)methyl)-2-methoxyphenyl)-5,5-dimethylcyklohex-1-enyl)methyl)-4-methyloxazolidin-2-on.

5. Pharmaceutiske sammensætninger omfattende cykloalkenylaryl-derivater ifølge
 25 formel 1, racemater, racemiske blandinger, enantiomere, diastereomere blandinger, diastereomere, atropisomere og blandinger af atropisomere deraf, farmaceutisk accepterbare salte deraf, hydrater deraf eller solvater deraf ifølge et hvilket som helst af kravene 1 til 3 sammen med farmaceutisk accepterbare bæremidler.

30 6. Pharmaceutiske sammensætninger ifølge krav 5 til anvendelse ved prævention eller behandling af dyslipidæmi og med dyslipidæmi associeret arteriosklerosis ved forøgelse af høj-densitets-lipoprotein-cholesterol (HDL-C) og forringelse af lav-densitets-lipoprotein-cholesterol (LDL-C) ved inhibering af CETP-aktiviteten.


35 7. Fremgangsmåde til fremstilling af cykloalkenylaryl-derivater ifølge formel 1, hvor fremgangsmåden omfatter følgende fremgangsmådetrin:

en sammensætning ifølgende følgende formel 2 gøres til genstand for en Vilsmeier-reaktion til fremstilling af en sammensætning ifølgende formel 3;


den opnåede sammensætning ifølgende formel 3 gøres til genstand for en Suzuki-reaktion med en sammensætning ifølgende følgende formel 4 under tilstedeværelse af palladium til fremstilling af en sammensætning ifølgende følgende formel 5; og

den opnåede sammensætning ifølgende formel 5 og en sammensætning ifølgende følgende formel 6 gøres til genstand for reduktion til fremstilling af en sammensætning ifølgende følgende formel 7, og hvorpå den opnåede sammensætning ifølgende formel 7 gøres til genstand for dannelse af en ring:


[Formel 1]




[Formel 2]




[Formel 3]




[Formel 4]




[Formel 5]



[Formel 6]



[Formel 7]



hvor A^1 , A^2 , A^3 , B^1 , B^2 , R^1 , R^2 , R^3 , R^4 , R^5 , R^a , p og X er de samme som defineret ifølge krav 1; Y er Cl eller Br; og Q er $B(OH)_2$ eller



8. Fremgangsmåde til fremstilling af cykloalkenylaryl-derivater ifølge formel 1, hvor fremgangsmåden omfatter følgende fremgangsmådetrin:

25


sammensætningen ifølge formel 3 og en sammensætning ifølge formel 6 gøres til genstand for reduktion til fremstilling af en sammensætning ifølge følgende formel 8 og derpå gøres sammensætningen ifølge formel 8 til genstand for dannelse af en ring; og

30


den opnåede sammensætning ifølge formel 9 gøres til genstand for en Suzuki-reaktion med en sammensætning ifølge følgende formel 4 under tilstedeværelse af palladium til fremstilling af en sammensætning ifølge følgende formel 1:

35


[Formel 1]




[Formel 3]




[Formel 4]




[Formel 6]



[Formel 8]



[Formel 9]



15 hvor A^1 , A^2 , A^3 , B^1 , B^2 , R^1 , R^2 , R^3 , R^4 , R^5 , R^a , p og X er de samme som defineret i krav 1; Y er Cl eller Br; og Q er $-B(OH)_2$ eller

